# Laboratory Evaluations for Integrative and Functional Medicine
## Chapter 4: Amino Acids

Richard S. Lord and J. Alexander Bralley

Fasting Plasma Amino Acids................................................................................................................182
Differences in Amino Acid Status Between Individuals...................................................................182
Inherited Metabolic Diseases Effects. .........................................................................................182
Life-Cycle Effects. .......................................................................................................................183
Dietary Protein Intake.................................................................................................................183
Protein Digestion and Amino Acid Absorption ..............................................................................184
Diseases.......................................................................................................................................184
Exercise and Injury.....................................................................................................................185
Amino Acid Transport.................................................................................................................185

Amino Acid Profiling in Clinical Practice.............................................................................................185
Identifying Candidates for Amino Acid Profiling.............................................................................185
Selecting a Test: Fasting Plasma, Whole Blood, or Urine. ...............................................................186
Anabolic/Catabolic Responses and Tissue pH Regulation...............................................................188
A Class of Their Own for the Most Versatile Amino Acids.........................................................188
Glutamate (Glu) and Glutamine (Gln)........................................................................................188
Ureagenesis and pH Modulation.................................................................................................189
Brain Regulation..........................................................................................................................190
Gluconeogenesis. ........................................................................................................................192
Dietary Protein Influences...........................................................................................................194
Clinical Relevance and Treatment...............................................................................................194
The Urea Cycle and Nitrogen Management. ....................................................................................197
Arginine (Arg).............................................................................................................................198
Asymmetric dimethylarginine (ADMA)......................................................................................201
Citrulline (Cit)............................................................................................................................202
Ornithine (Orn)...........................................................................................................................203
Aspartic Acid (Asp).....................................................................................................................204
Asparagine (Asn).........................................................................................................................204
Essential Amino Acids for Proteins and Energy...............................................................................205
The Branched-Chain Amino Acids (BCAA): . .............................................................................205
Valine (Val), Leucine (Leu) and Isoleucine (Ile). ........................................................................205
Threonine (Thr)..........................................................................................................................208
Histidine (His). ...........................................................................................................................209
Lysine (Lys), alpha-Aminoadipic Acid (α-AAA) and Pipecolic Acid...........................................212
Neurotransmitter Precursors. ..........................................................................................................215
Phenylalanine (Phe) and Tyrosine (Tyr)......................................................................................215
Tryptophan (Trp). .......................................................................................................................220
α-Amino-N-butyric Acid (AANB)................................................................................................221
γ-Aminobutyric Acid (GABA)......................................................................................................222
Sulfur-Containing Amino Acids for Methylation and Glutathione Synthesis..................................222
Methionine (Met)........................................................................................................................222
Cysteine (Cys) and Cystine (Cyss); (tCys).................................................................................225
Homocysteine, Homocystine (HCys) and Cystathionine............................................................227
Taurine (Tau). .............................................................................................................................229
Precursors of Heme, Nucleotides and Cell Membranes...................................................................230
Glycine (Gly) and Serine (Ser)....................................................................................................230

Sarcosine (N-Methylglycine).......................................................................................................234
Alanine (Ala)...............................................................................................................................235
Ethanolamine (EtN), Phosphoethanolamine (PE) and Phosphoserine (PS)................................236
Bone Collagen-Specific Amino Acids...............................................................................................238
Proline (Pro)................................................................................................................................238
Hydroxyproline (HPro). ..............................................................................................................238
Hydroxylysine (HLys). ................................................................................................................238
β-Amino Acids .................................................................................................................................239
β-Alanine.....................................................................................................................................239
β-Aminoisobutyric Acid. .............................................................................................................240
Carnosine and Anserine..............................................................................................................241
The Methylhistidines.......................................................................................................................242
1-Methylhistidine (1-MHis).........................................................................................................242
3-Methylhistidine (3MHis)..........................................................................................................242
The Polyamines................................................................................................................................242
Putrescene...................................................................................................................................243
Spermine.....................................................................................................................................243
Cadaverine. .................................................................................................................................244

Free-Form Amino Acid Supplement Formulas.....................................................................................244

Correction of Abnormal Amino Acid Levels. .......................................................................................245
Free-Form Amino Acid Supplementation. .......................................................................................245
Cofactors..........................................................................................................................................247

Case Illustrations. ................................................................................................................................248
4.1 — Metabolic Fragility from Insufficient Glu & Gln. .................................................................248
4.2 — High Glu/Gln Ratio in a Patient with Autism........................................................................248
4.3 — Apparent Ornithine Transcarbamylase Deficiency................................................................249
4.4 — Plasma Histidine in Major Cognitive Failure........................................................................251
4.5 — Indication of Impaired SN1-SN2 Transporter.......................................................................251
4.6 — Essential Amino Acid Support in Schizophrenia. .................................................................252
4.7 — Anxiety Correction by Lysine................................................................................................252
4.8 — Tyrosine Utilization Cofactors in Bronchospasms. ...............................................................253
4.9 — Apparent Diet-Induced Taurine deficiency with Cardiovascular Consequences. .................254

References. ...........................................................................................................................................255
Notes:

Table 4.1 — Summary of Nutrient-Related Amino Acid Abnormalities

Amino Acid

Low Result

High Result

## Anabolic/Catabolic Responses and Tissue pH Regulation
α-KG, 600 mg TID

Glutamic Acid (Glu)
Glutamine (Gln)

a-KG, 600 mg BID; B6, 100 mg

*

The Urea Cycle and Nitrogen Management
## Arginine (Arg)

* (Arg, 500 mg)

Mn, 15 mg, Excessive L-lysine supplementation

Asymmetric dimethylarginine

Arg, 3–6 g

Citrulline

Mg, 200 mg BID; a-KG, 600 mg BID

## Ornithine (Orn)

Mg, 200 mg BID; a-KG, 600 mg BID,
Excessive L-lysine supplementation
a-KG, 600 mg TID

Mg, 200 mg BID; Zn, 25 mg

## Asparagine (Asn)

Mg, 200 mg BID

a-KG, 600 mg BID; B6, 100 mg

## Aspartic Acid (Asp)

## Essential Amino Acids for Proteins and Energy
*

B6, 100 mg; Check for insulin insensitivity

Leucine (Leu)

Isoleucine (Ile)
Valine (Val)
*

B6, 100 mg

Histidine (His)

Folate, 800 µg; His, 500 mg TID

Lysine (Lys)

Carnitine, 1–2 g
Associated with increased stress response
Check for excessive Arg intake

α-Aminoadipic acid

*

Tyrosine (Tyr)
Tryptophan (Trp)

Vitamin C, 1 g BID; niacin, 50 mg;
B6, 100 mg; Fe, 15 mg (confirm with ferritin).
Supplementation tends to decrease arginine.
Excessive lysine can contribute to kidney pathology
B6, 100 mg; α-KG, 300 mg TID
Fe, 30 mg; Tetrahydrobiopterin; Vit. C, 300 mg/d;
Low-Phe diet

Fe, 30 mg, Tyr, 500 mg TID

Cu, 3 mg; Fe, 30 mg; Vitamin C, 1 g TID

5-HTP, 50 mg TID

Niacin, 50 mg; B6, 100 mg BID
B6, 100 mg; Fe, 30 mg; Cu, 3 mg

α-KG, 300 mg TID; B6, 100 mg

α-Amino-N-butyric acid

Phenylalanine (Phe)

Neurotransmitters and Precursors

B6, 100 mg

## Threonine (Thr)

γ-Aminobutyric acid (GABA)

α-KG, 600 mg BID; B6, 50 mg

Sulfur-Containing Amino Acids for Methylation and Glutathione Synthesis
Methionine (Met)

*

Cystine (Cys)

NAC, 500 mg BID

B6, 200 mg; a-KG, 600 mg BID

Homocystine (HCys)

B6, 100 mg; Folate, 800 µg; B12, 1,000 µg;
Betaine, 1,000 mg

Cystathionine

B6, 100 mg

Taurine (Tau)

B6, 100 mg

**

Precursors of Heme, Nucleotides and Cell Membranes
Glycine (Gly)

Gly , 1,000 mg TID

Folate, 800 µg; B6, 100 mg; B2, 50 mg;
B5, 500 mg

Serine (Ser)

* B6, 100 mg; Folate, 800 µg, Mn, 15 mg

Thr, 500 mg BID; BCAAs, 2 g TID

Sarcosine

B2, 50 mg
Table 4.1 continued on following page...

Table 4.1 continued from previous page...
Amino Acid

Low Result

High Result

Precursors of Heme, Nucleotides and Cell Membranes (continued)
Alanine (Ala)

*

B6, 100 mg

Ethanolamine

Mg, 200 mg BID

Phosphoethanolamine

S-Adenosylmethionine, 200 mg BID

Phosphoserine

Mg, 200 mg BID

Bone Collagen-Specific Amino Acids
a-KG, 600 mg BID; His, 300 mg

Proline (Pro)

Vitamin C, 1,000 mg TID; Niacin, 50 mg

Hydroxyproline (HPro)

Vitamin C, 1,000 mg TID; Fe, 15 mg

Hydroxylysine (HLys)

Vitamin C, 1,000 mg TID; Fe, 15 mg

β-Amino Acids
Lactobacillus and Bifidobacteria sp.; B6, 100 mg
B6, 50 mg; B12, 100 mg

Anserine

Zn, 30 mg

Carnosine

Zn, 30 mg

β-Alanine
β-Aminoisobutyric acid

The Methylhistidines
1-Methylhistidine

Vitamin E, 400 IU
BCAA,**6–9 g (if evident muscle wasting)

3-Methylhistidine

* Low levels are generally best normalized with balanced or custom mixtures of essential amino acids
** Multiple antioxidants: vitamin E, 800 IU; vitamin C, 1 g TID; β-carotene, 25,000 IU; coenzyme Q10, 100 mg; lipoic acid, 300 mg

Table 4.2 — Salient Features of Amino Acid Metabolism

Unique Metabolic Feature

Glutamine

SN1-SN2 transporter modulated by pH
Major gluconeogenic precursor
Major amine group supplier

Principal tissue pH buffering system
Principal amino acid blood supply of carbon for gluconeogenesis
Principal blood supply of nitrogen

BCAA

Branched-chain ketoacid dehydrogenase
complex (BCKDC)

Regulates rate of BCAA degradation

Glycine

Glycine Clearing System
– Major metabolic fate of glycine
– Stimulated by glucagon
– cAMP mediated

Conditions such as fasting and low-carbohydrate
diets that call for glucagon-stimulated glucose
mobilization can cause high plasma glycine
Defects of transporter system proteins will
produce elevated plasma histidine

Histidine

Transported via SN1 and SN2 membrane
system shared by glutamic and aspartic acids
Dietary deficiency has blunted effect on levels
in plasma and urine due to release from
hemoglobin and sarcosine
Binds zinc and copper
Not catabolized by initial transamination
Stimulates cholesterol biosynthesis

High plasma lysine and glycine and low arginine and BCAAs
are associated with hypercholesterolemia
Explains favorable effect of lysine supplementation on stressinduced diarrhea and IBS

Lysine

Amino Acid

Blocks 5-HT4 serotonin receptors

Physiological Effects

Anemia from increased hemoglobin degradation
Excessive intake causes low metallothionein
and loss of zinc and copper

α-AAA

Product of lysine via pipecolic acid

Elevation reflects B6 deficiency or hepatic
peroxisome insufficiency

Tryptophan

Plasma level related to serotonin synthesis

Proposed as cause of fibromyalgia

Tyrosine

Phenylalanine hydroxylase
– not produced in PKU
– dependent on iron (vitamin C),
tetrahydrobiopterin and NAD

Low – hypothyroidism, catecholamine deficit
Low – need for iron, folic acid, vitamin B3
Watch for high Phe/Tyr ratio indicating milder forms of PKU,
some of which respond to tetrahydrobiopterin

Amino acids are central to virtually every function
of the human body. Of the 20 amino acids required for
synthesis of proteins, nine must be derived from dietary
protein because they cannot be produced in human tissues. The elaborate gene expression mechanisms of all
cells result in the assembling of amino acids into thousands of specific proteins that make up the structures
and catalyze the metabolic reactions necessary for life.
In addition to protein synthesis, individual amino acids
flow into pathways that produce hormones and neurotransmitters, detoxify thousands of chemicals, supply
antioxidant protection and build bile acids for digestion.
In spite of their universal demand for life functions,
free amino acids are present in very low amounts per
total body content, most occurring in the circulating
blood. When demand for amino acids increases, they
must be supplied by dietary sources or from turnover
of body proteins. This situation means that the pool of
amino acids is highly dynamic, changing moment by
moment by shifting the flow though dozens of metabolic pathways in response to multiple physiological
signals. In perfused liver, removal of amino acids from
the perfusate causes dramatic and almost instantaneous
increase of proteolysis.1 Because so many processes are
affected by amino acids, knowing when and how to
implement amino acid therapies has great clinical value.2
The full clinical potential of nutritional, hormonal and
detoxifying therapies can be achieved only when amino
acid supply for tissue restoration is assured.
The assessment of amino acid status is particularly
challenging when the object is to identify restrictions
that might contribute to suboptimal function and the

loss of organ reserve in chronic diseases. This chapter
presents considerable detail about each of the amino
acids commonly measured by laboratory testing of body
fluids. The overall outlook is that patterns observed by
measurements of amino acids in whole blood, plasma,
or urine may be used to identify patients who are candidates for amino acid therapy. The information about
individual amino acids may then be used to adjust the
therapeutic emphasis and to explain clinical responses
to therapy. A patient who cannot sustain normal levels
of essential amino acids in fasting plasma or whole
blood may be a candidate for individualized amino acid
supplementation to assure optimization of total body
function. The question of how “normal” is defined in
this context must be addressed.
The initial clinical use of amino acid testing was
for detection of neonatal inborn errors of metabolism
(IEM) where only abnormally high levels are of interest.
Low limits frequently fall at (or even below) zero when
they were calculated as the mean minus two times the
standard deviation.3 To meet the need of identifying
patients who may not have frank metabolic diseases of
genetic origin, yet still have need for amino acid therapy,
it is useful to use the first quintile (lower 20% of reference population) as a cutoff point. In other words, when
80% of the reference population shows essential amino
acid levels higher than those in a patient with chronic
disease, then that patient may be considered a candidate
for essential amino acid enhancements.
Ingested dietary protein is digested to release amino
acids, which are absorbed into the bloodstream in the
small intestine. The efficiency of protein digestion depends on adequate residence time in the stomach where
food must be mixed with large amounts of hydrochloric
acid to initiate protein denaturation and to stimulate
pancreaticobiliary fluid flow. Partially digested chyme,
leaving the stomach in small portions, elicits bicarbonate-rich pancreatic secretion along with bile from the
gall bladder to assist protein unfolding and digestive
enzyme activation. Various classes of amino acids are absorbed most actively in discrete regions of the jejunum
and upper ileum by active transport, resulting in their
passage through enterocytes and into capillaries. Blood
drains from the small intestines into the portal circulation that delivers amino acids to the liver. The liver
possesses numerous enzyme systems for metabolism of
amino acids and during sleep the liver carries out net
synthesis of some amino acids to sustain blood (plasma)

in Human Health

Notes:

Protein synthesis requires a basic set of 20 amino
acids. Under conditions where all other essential nutrients are available, human adults can usually produce
the 11 NEAA at rates adequate to sustain growth and
reproduction. Arginine is essential during the first
several months after birth, because infants are unable to
produce sufficient amounts to sustain growth. Dietary or
supplemental arginine also is beneficial for adults under
a variety of conditions that create special demands. Amino acids that exhibit such clinical characteristics may be
called conditionally essential. Glycine, glutamine and
tyrosine are included in this category because they can
help overcome conditions where their biosynthesis is
inhibited or their physiological demands are increased.

levels for detoxification and biosynthetic processes active
at that time. The physiological stresses of digestion result
in significant daily losses of protein (digestive enzymes,
desquamated cells and mucin) and account for a major
part of dietary amino acid requirements.4
The main objective of this chapter is to explain
how laboratory testing can identify patients in need of
therapeutic supplementation of essential amino acid
mixtures, individual amino acids, or other therapies to
correct abnormal amino acid status. Abnormally low or
high amino acid levels in plasma or urine can be caused
by dietary deficiencies of protein or micronutrients,
variations in metabolic demands elicited by hormones,
or toxic factors that increase losses or decrease utilization rates. Insufficient amino acid status can result from
digestive impairments due to toxicants or lifestyle factors
or from pathologies of the stomach, pancreas, liver, or
small intestine.

Essential Amino Acids
Histidine

Amino Acids Classifications

Isoleucine

Leucine

Since only l-amino acids are utilized in human
metabolism, the stereoisomer is presumed to be l- and
the designation will be dropped for simplicity. Therefore, all undesignated references such as “alanine” refer
to “l-alanine.” The nine essential amino acids (EAA) are
sometimes referred to as indispensable amino acids because they must be obtained from food intake. Transfers
of amino groups to organic acids that are produced in
other metabolic pathways can form the other 11 amino
acids used for protein synthesis. These 11 are sometimes
called dispensable or non-essential amino acids (NEAA).
Because of limitations in the rates of their formation
some amino acids that are technically non-essential
become essential to maintain optimal wellness under
specific conditions of disease or genetic and environmental factors. These are called conditionally essential
amino acids (CEAA). Other amino acids, such as hydroxyproline, are formed by reactions that add chemical
groups after proteins are synthesized. Such amino acid
derivatives are released into body fluids at cell death or
during protein turnover in viable cells. Hydroxyproline
and hydroxylysine are also released from turnover of
the extracellular matrix that is largely composed of collagen. Biochemical transformations in detoxification or
neurotransmitter pathways lead to the formation of still
other amino acids and simple peptides. All of the amino
acids and derivatives listed in Figure 4.1 may be measured in profiles of amino acids in plasma or urine.

Lysine

Methionine

Phenylalanine
Threonine
Tryptophan
Valane

Conditionally Essential
Arginine
Glutamine
Glycine
Taurine

Non-Essential
Amino Acids of Proteins
Alanine
Asparagine
Aspartic acid
Cysteine
Glutamic acid
Proline

Amino Acid Derivatives
a-Alanine
a-Aminobutyrate
a-Aminoisobutyric acid
Asymmetric-dimethylarginine
Citrulline
Cystine
Cystathionine
Homocysteine
Homocystine
Hydroxyproline
Hydroxylysine
1-Methylhistidine
3-Methylhistidine
Methionine sulfoxide
Nitrotyrosine
Ornithine
Phophoethanolamine
Phosphoserine

Figure 4.1 — Amino Acids Classifications
In this categorization, amino acids that do not meet the
strict definition of nutritional essentiality, but may be
beneficial under special circumstances are grouped as
conditionally essential.

Amino Acid Requirements for
Protein and Polypeptide Synthesis

learned that prenatal amino acid deficiency produces
offspring with preference for energy-dense foodstuffs
and hyperphagia, along with tendencies for greater
insulin resistance, glucose intolerance, adiposity and
hypertension.5
Amino acid catabolism increases to support gluconeogenesis during starvation. Glucocorticoids and
glucagon up-regulate, while insulin down-regulates,
the gene expression of many amino acid-catabolizing
enzymes.6 The rate of catabolism of most amino acids
increases when dietary protein exceeds the body’s
requirements. Gene transcription rates are adjusted to
achieve regulation of the catabolic sequences. When
amino acids are catabolized in energy-yielding pathways

Protein and polypeptide synthesis produces the major flux of amino acids supplied by blood flow. The 20
peptide-forming essential and non-essential amino acids
are universally required for enzymes, structural and
transport proteins and cell-signaling polypeptides. This
flux of amino acids to load tRNA for protein synthesis is
the universal background for discussions of amino acid
status. In addition, the carbon skeletons from amino
acids flow into gluconeogenesis or fatty acid synthesis
as demands for energy dictate. Amino acid nitrogen
flows into pathways of nucleotide, neurotransmitter and
polyamine biosynthesis. From studies in rats, we have

Amino Acid In-flow

(Fasting)

Case Illustration 4.2 High Glu/Gln Ratio in an autistic

Case
Amin

Essent

Illust
Analys

is - 20

Essential Amino Acids
ial Am

Argin
in

e

ino Ac

ids

Histidi

ne

55 L

Leucin
e
Lysin
e

e
Phen
ylalan
ine
Threo
nine

Trypto

Valin

phan

itive

Inter
19 - 153

ce

303 - 626
53 - 10
val

37 - 98
73 - 16
109 235
15 - 32
80%

42 - 13
60%

95%
Reference
Interval

fail
35 L
40%

5th
r cogn

4th

43 - 81
67 - 16
34 - 70
134 -

e

20%

majo

383 H
ionin

3rd

1st
Meth

Glutamine
cine

2nd

ure
Method
Percen
ology:
tile Ra
ION Ex
nking
change
by Q
2nd
uintile
HPLC
3rd
20%
4th
40%
5th
95%
60%
80%
Refer
en

Results
umol/
L

Isoleu

Glutamic Acid

umol/L istidine in
Pl
asma

Percentile Ranking by Quintile

1st

ration Results
4.4 P
lasma
h

o Acid

Circulatory
System

Total body proteolysis
Hepatic amino acid
and apoptosis
synthesis
Methodology: ION Exchange
HPLC

Release from
skeletal muscle
Amino Acid Analysis - 20 Plasma

Amino Acid
Out-flow
Biosynthesis
Hemoglobin
Enzymes
DNA, RNA
Signaling molecules
Receptors
Cell identifiers

Neurotransmitters

Insulin
Growth hormone
Estrogen
Testosterone

Excretion

Glutathione

Renal losses
Skin
GI tract

Figure 4.2 — Sources and Destinations of Plasma Amino Acids
The amount of amino acids in the free form in plasma is very small compared with plasma protein concentrations. In
humans, biosynthesis cannot yield EAA and in the fasting state portal supply is absent. Concentrations of EAA measured in
fasting plasma, therefore, are determined by the flux into the blood from tissue protein degradation balanced with flux out
of the blood for protein synthesis, excretion, oxidation and formation of non-protein products.

Table 4.3 — Special Metabolic Functions of Amino Acids

Function >> >>

Glucose
Synthesis

Urea
Cycle

Glutathione
Synthesis

Neurotransmitters

Creatine

DNA & RNA

Amino Acid
Alanine

√√

Arginine

√

√

Aspartic acid

√

√

Asparagine

√

Cysteine

√

Glutamic acid

√

√

Glutamine

√

√√

Glycine

√√

Histidine

√

Methionine

√

√
√√
√√
√

√
√

√

√

√
√

√

Serine

√√

√

Threonine

√

Tryptophan

√

Tyrosine

√

Valine

√

Phenylalanine

√
√

√

√

The carbon skeletons of most amino acids are able to enter into the biosynthesis of glucose. Those with multiple check marks are most easily transformed into
glucogenic compounds and they play important roles in the maintenance of blood glucose during intervals of fasting. A smaller number of amino acids are
involved in each of the other special functions.

or in skeletal muscle during strenuous exertion, toxic
ammonia that is formed from their amino groups must
be removed. In the liver, amino acids are used to produce transport proteins such as albumin, prealbumin,
ferritin and transferrin. In the pituitary gland, all of the
releasing hormones are polypeptides requiring the 20
protein-forming amino acids.
Since the process of polypeptide biosynthesis is
relatively constant, it is the other amino acid-specific
pathways that generally control the concentrations of
individual amino acids measured in plasma or other
body fluids. Figure 4.2 presents a diagram of the amino
acid flux into the various pathways that determine
plasma concentrations of amino acids. Most can serve as
carbon sources for glucose synthesis and several serve
demanding roles in synthesis of critical molecules like
DNA, RNA and glutathione (Table 4.3). Neurons in the
central and peripheral nervous system depend on the
supply of amino acids for synthesis of neurotransmitters
and for control of neuronal activation.7,8 Intermediates
formed by catabolic breakdown regulate cell activity. For

example, arginine forms nitric oxide, the polyamines
form putrescence and spermine and tryptophan forms
quinolinic acid. Some of the symptoms that are frequently associated with impairment of various non-protein functions of individual amino acids are summarized
in Table 4.4.
Notes:

Table 4.4 — Symptoms Associated with Impairment of

Non-Protein Functions of Amino Acids

Symptoms of Insufficiency

Ammonia removal9

Lethargy, irritability, nausea10

Nitric oxide precursor

Hypertension11

Creatine precursor12

Weakness

Histidine

Histamine

Anemia,14 sleep disorders15,16

Methionine &
Cysteine

Glutathione, taurine, sulfate precursor17

Chemical sensivity

Glycine & Serine

Heme,18 creatine, bile acids, glutathione, nucleic acid
bases, methyl group metabolism, collagen precursor19

Anemia, depression,20,21 poor detoxification22

Lysine

Carnitine precursor

Hypoglycemia, fatigue, CVD23

Tryptophan

Serotonin, melatonin, nicotinic acid precursor

Depression,24 insomnia25

Phenylalanine &
Tyrosine

Catecholamines, thyroid hormones, melanin precursor

Hypothyroid, lassitude, mental/emotional
disorders,26,27 schizophrenia28

Arginine

Function

Amino Acid

The cells of the liver, intestines and kidneys deliver
amino acids to blood, supplemented by the release of
non-essential amino acids from skeletal muscle to supply
the demands of other tissues during the overnight fasting
state. In this state, the influence of dietary protein is reduced so the primary factors influencing amino acid concentrations in blood plasma are the output from muscle
and uptake for hepatic protein synthesis offset by hepatic
release of amino acids from proteolysis (Figure 4.2).
Utilization of amino acids is highly tissue and time
dependent. During sleep, the rate of brain melatonin
synthesis increases and many tissues are more actively
removing amino acids from the blood for tissue repair,
neuronal plasticity and detoxification. In the morning,
cortisol rises and amino acids are broken down from
skeletal muscle and oxidized for energy. The demand for
amino acids in individual tissues determines the rates
of uptake. For example, postprandial gastric mucosal
cells and mast cells during allergy seasons have a large
demand for histidine to supply the formation of histamine.29–31 Tryptophan demand by the cells in the small
intestines is increased during episodes of diarrhea and
serotonergic cells in the brain increase their utilization
of tryptophan when SSRI medications are being used.
The reason for the SSRI effect is the increased catabolism
of serotonin that is maintained in the synapse under the
influence of the drug.

Fasting Plasma
The amount of an essential amino acid in plasma
determines the rate of any dependent process in the
tissues. For example, low plasma tryptophan results in
reduced formation of serotonin in the brain.32 The gut
is an even larger consumer of tryptophan for serotonin
synthesis, though this GI mucosal process is diminished
in inflammation.33 Low histidine reduces the potential for
increasing flow of histamine. High plasma essential amino
acid levels show either increased release due to catabolic
states (see “The Methylhistidines” section later in this
chapter) or decreased utilization as is seen when hepatic
activity is inadequate to clear portal amino acid flow.34
Differences in Amino Acid
Status Between Individuals
Inherited Metabolic Diseases Effects
Amino acid testing is widely used for neonatal
screening and confirmation of genetic abnormalities in
amino acid metabolism. The United States public health
programs are estimated to screen 4.1 million infants
annually.35 Recently 14 aminoacidopathies were recommended for inclusion in all state screening programs:
phenylketonuria, maple syrup urine disease, homocystinuria, citrullinemia, argininosuccinic acidemia, tyrosinemia type I, benign hyperphenylalaninemia, tyrosinemia type II, defects of biopterin cofactor biosynthesis,
argininemia, tyrosinemia type III, defects of biopterin
cofactor regeneration, hypermethioninemia and citrullinemia type II.36 Phenotypes of genetic diseases produce
effects that range from severe to mild.37,38 The total

number of potential genetic polymorphisms that can
affect amino acid status is too large to estimate. When
phenotypic expression is mild, metabolic abnormalities
may go undetected since overt pathology may not appear until later in life. Quantitative data on amino acid
levels are therefore useful for early identification of mild
phenotypes. Simple nutritional interventions can be effective for reducing morbidity and mortality.

(0.35 g protein)/kg/d, whereas others required 150 mg
N (1.06 g protein)/kg/d.47,48
When dietary changes cause limitations of the
essential amino acid pool, enzyme activities change to
conserve tissue supply of individual amino acids.49 For
example, during nutritional stress, cell division rate
slows. The return to normal growth rate when amino acids become available is critically dependent on responses
such as expression of the CAT-1 (cationic amino acid
transport) gene for the utilization of arginine and lysine,
which is essential for cell survival.50 In experimental
animals when dietary protein was lowered from 21% to
6% of caloric intake, essential amino acids were reduced
by an average of 36% (Figure 4.3). The branched chain
amino acids correlated with dietary protein decline,
but the non-essential amino acids increased as protein
intake decreased because there was increased mobilization of amino acids from muscle to meet physiological
demands. When these investigators examined hormonal

3500

## Dietary Protein Intake

Estimates of average dietary protein intake required
to sustain amino acid status in healthy adult populations are of very limited usefulness in assessing the
amino acid need of individual patients. In part because
of new methods offered by research in proteomics and
nutrigenomics, the question of adequate levels of amino
acid intake has been the subject of numerous recent
reports. Not only can low levels of catabolic products
be measured in body fluids, but also individual differences in specific enzymes, such as the cytochrome
P450s, can predict individuals who may have difficulty
sustaining amino acid concentrations.42–46 Conclusions
regarding the amino acid needs for adults have been
based primarily on nitrogen balance studies. Needs for
infants and children are predicted from the smallest
amounts compatible with normal growth. Even within
a single study, widely ranging variability of individual
needs are found to cluster around the average adult
intake of 105 mg protein nitrogen (0.74 g protein)
per kg per day required to sustain nitrogen balance.
Some individuals were in nitrogen balance at 50 mg N

A

3000

(uM)

2500
2000

21% Protein

1500

6% Protein

1000
BCAA

Hormone Concentration

Total Concentration for Category

Effects of altered amino acid status may be seen very
early in life as alterations of cell differentiation in utero
that result in difficulties with blood pressure regulation
after birth.39 The plasma concentrations of some amino
acids have been shown to be age specific in healthy
children.3,40 Rapid decreases during the first year of life
are followed by gradually increasing concentrations
that stabilize at 14 to 16 years of age. The age-related
changes found for 18 amino acids are clustered within
15% of adult levels. Lysine and tryptophan concentrations, however, change approximately 30% from birth
to adolescence. Comparison of North American and Taiwan Chinese populations show that plasma amino acid
concentrations vary with age similarly in both groups,
independent of race and diet.41

Life-Cycle Effects
EAA

NEAA

B
Insulin
IGF-1
21% Protein

6% Protein

Figure 4.3 — Responses to Dietary

Protein Restriction

Although branched-chain and other essential amino
acids show the expected fall when dietary intake is
restricted, plasma levels of non-essential amino acids
tend to rise (A). Glutamine is the major contributor to
this rise, as periveinous hepatocytes increase output to
supply nitrogen to critical tissues for protein synthesis.
Chronic low intake of protein induces hormonal
responses (B). Insulin and especially insulin-like growth
factor-I (IGF-I) fall in order to decrease the flow of amino
acids into tissues so that plasma levels can be maintained
for critical functions.

responses, insulin and insulin-like growth factor-I
(IGF-I) were shown to fall dramatically with lowered
protein intake.51 By shifting signals to lower metabolic
demands, this response assures that plasma amino acid
levels do not drop so low as to prevent critical functions
like neurotransmitter formation in brain and cardiovascular tissues. When dietary protein that has been imbalanced by depleting histidine or threonine is fed to rats,
a single meal causes increased uptake of limiting amino
acids with concurrent decreases of plasma amino acid
concentrations.52 Such rapid transport response mechanisms serve to maintain constant tissue flux of amino
acids as intake patterns shift. They also have obvious
bearing on interpretation of plasma amino acid results
for patients on unbalanced diets.

malabsorption is a typical feature of the condition.61
Protein digestion inadequacy is commonly dealt with by
administration of betaine hydrochloride and pancreatic
enzymes at mealtime and daily use of zinc supplements
to restore body pools of the trace element.

## Diseases

## Protein Digestion and Amino Acid Absorption
The suppression of stomach acid can strongly inhibit digestion of dietary protein in the stomach and the
effects can extend to the small intestine by affecting pancreatic function.53–57 Impaired digestion and assimilation
account for some of the individual variability of protein
requirements because high digestive efficiency means
that lower protein intake levels can supply adequate
delivery of amino acids for tissue functions. If emotional
stress or use of antacid medications decrease stomach
acid below the level needed to initiate the digestive processes, then a larger fraction of dietary protein remains
undigested; amino acids are not released and the peptide
residues pass into the lower gut where growth rates of
bacterial populations are stimulated. During periods of
acute stress, protein breakdown increases by as much as
20% with concurrent increased amino acid demands.58
Lowered status of essential amino acids may result
from inadequate secretion of pancreatic protease enzyme
activity. Because zinc is required as a cofactor in several
pancreatic proteases, a deficiency of this element can
affect plasma amino acids.59,60 Lower serum levels of free
amino acids due to malabsorption are found in patients with spleen deficiency syndrome where intestinal

Infection increases immune system demand for
amino acids. The chronic viral infection of HIV-positive infants results in growth suppression. Uninfected
infants use 42% of their leucine intake to synthesize
new protein, but the HIV-infected group used only
19%.62 Infection by the virus elicits the same changes in
whole-body protein metabolism as do other conditions
of stress. Depletion of glutathione by HIV infection is
accompanied by 67%, 52% and 32% lowering of plasma
cystine, tryptophan and methionine, respectively.63 In
hepatic encephalopathy, plasma concentrations of the
aromatic amino acids are high (phenylalanine and tyrosine), whereas those of the branched-chain amino acids
(leucine, isoleucine and valine) are low.64
Although the main emphasis of this chapter is the
assessment of conditions that may respond favorably to
increased amino acid intake, excessive protein intake
as a risk factor for multiple diseases must be examined
as well. There is strong evidence that excessive protein
intake is a strong risk factor for many degenerative
diseases, including heart disease, cancer, diabetes and
Alzheimer’s disease.65 Multiple mechanisms have been
investigated that can account for high dietary protein induction of diseases. Xenobiotic hepatotoxicity has been
shown to be specifically increased by raising dietary
protein, associated with altered activities of xenobiotic
biotransformation in rats.66 High protein can increase
alflatoxin carcinogenesis by raising mixed function oxidase activities.67 Such evidence calls for increased focus
on use of biomarkers that signal excessive total protein
intake. Urinary total nitrogen (by Kjeldahl analysis) is a
simple, though laborious, measurement that is directly
related to protein intake.68 Urinary urea-nitrogen,

Notes:

ammonia, allantoin and uric acid also rise in direct
response to dietary protein intake.69 Quantitative evaluation of dietary records, of course, provides direct information about protein intake, but there are significant
drawbacks to this approach. Inaccurate patient recall
and data entry can produce large errors and the process
of evaluation can be quite laborious. Simple, routine
laboratory measures can provide direct, quantitative
evidence of excessive protein intake and prompt clinical attention. Adoption of a plant-based diet is an even
more simple prescription that is advocated for optimizing protein intake.65

Protein supplements are frequently used by individuals attempting body- and strength-building routines,
although studies in athletes have found insignificant
effects on nitrogen retention70 or optimal growth and
strength gain.71 However, essential amino acid intake has
an immediate effect of reducing muscle protein breakdown and release of muscle amino acids into plasma.72
Compared with controls given a placebo drink, intake of
100 g of carbohydrates 1 hour after resistance exercise
decreased release of amino acids into blood. The effect
extended for 3 hours after ingestion of the maltodextrin beverage, indicating an effect of insulin on muscle
metabolism.73 Because of the strongly fluctuating nature
of total-body protein dynamics following strenuous
exercise, specimens for analysis of amino acids should
be taken only after an overnight rest period.
Injury is characterized by a unique pattern of elevated plasma branched-chain and aromatic amino acids as
well as methionine.74 The non-essential amino acids in
muscle tend to decline with injury, glutamine having the
most marked change. Following elective surgical procedures, oral glutamine supplementation helps to correct
the drop of muscle glutamine and enhances net skeletal
muscle protein synthesis.75

## Exercise and Injury

The concentration of a given amino acid transporter
in cell membranes has been shown to be tissue specific,
that is, in the gut and kidney, effectively regulating small
intestinal absorption and renal resorption of amino
acids.76–78 The transporters are coded by single genes
or a number of separate genes.76 Defective amino acid
transporters have been implicated in genetic disease.79
Similarly, they can be up- or down-regulated in response
to exogenous signals such as nitric oxide or insulin,76,80,81
thereby affecting the influx of a given amino acid into
the cell.
The physiological substrates for the SN1 and SN2
amino acid transporters are Gln, Asn and His, whereas
SN2 also transports Ser, Ala and Gly.77 The amino acid
transporter for taurine and β-alanine is appropriately
named Taurine T (TAUT).76 Both of these transporter
systems will be discussed later in the chapter. Recent
research has revealed that enzyme activities and membrane transporters (number and density in tissues) are
altered by amino acid availability.
The significance of amino acid transport systems
for interpretation of laboratory results is that genetic
polymorphic variations in any of the several proteins of
the transport systems will have effects on observed levels
of amino acids. A case illustrating such an apparent
effect for the SN1 and SN2 system is presented in the
Histidine (His) section, later in this chapter.

## Amino Acid Transport
Intracellular and plasma levels of amino acids are
influenced by transporters. Amino acid transporters
reside in the plasma membrane and typically exchange
sodium ions (active transport) and/or amino acids
(passive transport). The transporters are classified as
System A (SA) or System N (SN) and the SN class is
further differentiated as SN1 and SN2 based on their differing responses to physiological stimuli.

Amino Acid Profiling in
Clinical Practice
Identifying Candidates for
Amino Acid Profiling
A primary reason for performing amino acid testing
is to identify patients who cannot maintain normal
plasma levels of essential and conditionally essential
amino acids. The finding of low levels in fasting plasma
or whole blood demonstrates that the patient is unable
to sustain postprandial concentrations adequate for
optimal cellular function for the reasons discussed
above. Because of genetic, environmental, or iatrogenic
factors that decrease stomach acid and pancreaticobiliary
secretions, low levels in plasma do not necessarily
coincide with low dietary protein intake.
High intestinal transit rates also can decrease
protein digestion efficiency. 82 Low blood levels of amino

threonine, methionine, tyrosine, sarcosine and alphaaminoadipic acid and lower valine, leucine and tryptophan) compared with controls.95 Characteristic and
significant amino acid patterns in plasma have also been
found in patients with Alzheimer’s disease.96 20 patients
with chronic fatigue syndrome displayed abnormally
low plasma amino acids and symptoms improved in
75% of the subjects with concurrent increase of plasma
amino acid levels.97 Some common clinical presentations
that suggest assessment of amino acids are shown in
Table 4.5.
In assessing chronically ill patients, it is important
to keep in mind both general protein synthesis and
special roles of amino acids. Table 4.8 shows commonly
used groupings of amino acids based on shared characteristics. A patient with a severely degraded intestinal
mucosal epithelium must replace many hundreds of
grams of tissue en route to restoration of full wellness. Meanwhile, their most disturbing symptoms may
indicate special roles of amino acids. The downstream,
neurotransmitter metabolites of tryptophan are important to consider in patients with insomnia. Urea cycle
stimulation by arginine may be relevant for ammonia
toxemia. Relative to a nulliparous woman with no digestive disturbances, a pregnant woman who uses protonpump inhibitors for heart burn is especially at risk of
amino acid insufficiency.

acids are generally treated with balanced formulas of freeform EAAs, not with individual amino acids, because they
are convenient and do not induce further imbalances.
Analysis of amino acids has been used to advance
knowledge of the molecular origins of diseases such
as depression,24 to monitor treatment in diabetic
ketoacidosis,83 and to predict responses to therapeutics
such as antidepressants.84,85 Abnormalities in plasma
amino acid levels have been reported in clinical research
of diabetes, Parkinson’s disease, Alzheimer’s disease,86,87
metabolic acidosis, muscle wasting associated with acute
uremia,88 and pre- and postoperative morbidity.89,90
Orally and tube-fed elderly patients with dementia have
significantly lower levels of methionine and branchedchain amino acids than healthy controls.91
Diets high in arginine and glycine are associated
with decreased serum cholesterol levels, whereas lysine
and branched-chain amino acids are associated with
increased levels.92 The association of these changes with
lower insulin/glucagon ratios has led to the hypothesis
that plasma amino acid levels exert primary control
over cholesterol synthesis.93 Increasing sulfur amino
acid composition of dietary protein in rats results in
lower cholesterol levels.94 In the chick, lysine-induced
hypercholesterolemia is not mediated by the antagonistic
effect of lysine on arginine or by the effect of lysine
on food intake. Rather, a direct stimulatory effect
on cholesterol biosynthesis occurs.92 These factors
may explain not only cholesterol modulation, but
also other favorable clinical responses to amino acid
supplementation regimens that achieve an improved
balance between individual amino acids.
Parkinson’s disease patients show significant alterations of plasma amino acids (higher phosphoserine,
Table 4.5 — Common Conditions Suggesting

Amino Acid Assessment

Condition

Reason

Aging

Decreased stomach acid output

Cancer

Cachexia

Chronic fatigue

Mitochondrial inefficiency

Depression

Impaired neurotransmitter or
receptor synthesis

Dietary restrictions

Poor protein intake

Medications to block
acid release

Insufficient stomach acid

Pregnancy

Increased requirements
Selecting A Test: Fasting Plasma,
Whole Blood, or Urine
Blood plasma has been the predominant specimen in
published studies on amino acids. To determine whether
a patient is in need of essential or conditionally essential
amino acids, either fasting plasma or fasting whole-blood
amino acid testing is the preferred test to avoid recent
dietary influences. Fasting blood plasma also has by far
the greatest validation of scientific studies and provides
higher levels of reliability for showing chronic stresses
that shift individual amino acid demands. Plasma from
blood drawn at any given moment will reflect the state
of the dynamic flux of amino acids leaving sites such as
skeletal muscle and flowing into sites of utilization in
liver, brain and other tissues.
To detect metabolic disorders due to genetic
polymorphisms, micronutrient deficiencies or toxicant abnormalities, all of which tend to interfere with
amino acid utilization, urinary amino acid testing is the
preferred test. Transient strong elevations during post

Table 4.6 — Specimen Preference According

to Critical Information

Desired Information

Specimen

Status of essential amino acids

Plasma

Leu, Ile, Val, Phe, Lys, Thr, Met, Trp
Status of conditionally essential amino acids

Plasma

Arg, Tyr, His, Gly, Ser
Markers of neurological dysfunction

Plasma

Trp, Tyr, Phe, Met, GABA
Markers of vitamin and mineral deficiency
His, Phe, Anserine, Carnosine

Plasma or
Urine

Markers of bone loss or muscle wasting

Urine

HPro, HLys, Cys, 3-MeHis
Markers of intestinal dysbiosis

systematically shifts the results.100 Details about certain
amino acids could be obscured in a 24-hour urine due
to decreased renal filtrate when blood concentrations
fall below the renal threshold. This makes it difficult to
determine deficiency states from urine amino acid data.
A properly obtained 24-hour urine, however, provides
valuable clinical information and is the preferred specimen for detecting abnormalities of some non-essential
amino acid derivatives. Reporting amino acid concentrations in overnight urine normalized to creatinine offers
an alternative that is free of most patient-dependent variability. Correction for dilution variation by creatinine is
inherently prone to error in the very young and very old.
Interpretation of Amino Acid Abnormalities:
The data from amino acid testing can reveal general and
specific patterns of elevated and decreased amino acid
concentrations. In general, if many amino acids are low,
then supplementation of essential amino acids is indicated. If many amino acids are high, then there is a cofactor
inadequacy or improper hormonal control. Single amino
acids that are high or low must be considered on an
individual basis. Each amino acid will be addressed in
the discussions that follow in order to provide the background for understanding the full range of nutrient, cell
regulatory and genetic issues that bear on interpretation.
With such knowledge the clinician can determine when
individual amino acids may be needed to affect specific

Urine

prandial periods tend to cause spillage into urine rather
than accumulation in plasma. These situations present
different clinical issues than those posed by essential
amino acid insufficiency that is detected by plasma testing and that may be correctable by supplemental amino
acids or digestive aids. The combination of amino acids
in plasma or urine with organic acids in urine provides a
more complete picture of amino acid abnormalities.
Technological improvements have allowed the
introduction of amino acid profiling of blood spots
obtained from finger-stick blood dried on filter paper.98
This specimen provides a lower cost, non-invasive way
to view concentrations of amino acids in whole blood
(plasma and blood cells). Most essential amino acid concentrations are similar in the two specimens as shown
in Table 4.7. Taurine is a notable exception, being much
higher in whole blood due to high concentration in
erythrocytes.99
A 24-hour urine amino acid analysis reveals amino
acid metabolism throughout the period of daily activity,
but has some limitations. Data from 24-hour urine is of
particular value for evaluating those amino acids that
primarily reveal tissue degradation. Hydroxylysine and
hydroxyproline, for example, are released from collagen
of connective tissue and bone. Reports of urinary amino
acid studies are virtually always based on data from subjects in metabolic wards where 24-hour urine collection
is done under the direction of medical staff. Collection
of urine for 24 hours and reporting the total volume by
free-living individuals are subject to frequent error that

β-Ala

Table 4.7 — Adult Amino Acid

Reference Limits for Plasma
and Blood Spot Specimens

Amino Acid

Plasma (µM)

Blood Spot (µM)

Arginine

42–130

18–101

Histidine

53–101

19–102

Isoleucine

37–98

33–118

Leucine

73–161

62–186

Lysine

109–235

72–232

Methionine

15–32

8–27

Phenylalanine

43–81

38–97

Threonine

67–166

51–203

Tryptophan

34–70

21–59

Valine

134–305

110–329

Taurine

26–103

138–355

Amino acid values from plasma are determined by high-performance liquid
chromatography with pre-column o-phthalaldehyde derivatization and
fluorescence detection. Values from blood spot are determined by highperformance liquid chromatography with tandem mass spectrometric detection.

Table 4.8 — Amino Acids Grouped by Shared Characteristics

Group

Members

Application

Branched-chain amino acids (BCAA)

Valine, Leucine, Isoleucine

Released from skeletal muscle during
strenuous exercise

Large, neutral amino acids (LNAA)

Tryptophan, Tyrosine, Phenylalanine,
Leucine, Isoleucine, Methionine

Compete for intestinal absorption and
for transport at the blood-brain barrier

Basic amino acids
(positively charged at neutral pH)

Histidine, Lysine, Arginine

Abundant in histones that bind to
negatively charged DNA

Glutamate (Glu)

A Class of Their Own for the Most
Versatile Amino Acids

Anabolic/Catabolic Responses
and Tissue pH Regulation

NH2

HOOC

COOH

Glutamine (Gln)
NH2
H2N

COOH
O

GLUTAMINE

Glutamine is the dominant free amino acid in
fasting plasma. Glutamate and glutamine are critical in
human physiology for the following reasons: tissue pH
buffering; carbon supply for gluconeogenesis, particularly in the kidney; hepatic ammonia removal; genesis of
glutathione; and neurotransmitter function (Figure 4.4).
Each of the four major fates illustrated constitute a large
flux of glutamine from plasma. The abbreviation “Glu
and Gln” will be used to denote the pairwise participation of glutamate and glutamine because they are so
intimately linked in their metabolic functions. Glu and
Gln play a crucial role in maintaining acid-base homeostasis and whole-body nitrogen balance.
In the central nervous system, glutamic acid is the
major excitatory neurotransmitter and source of the neurotransmitter γ-aminobutyric acid, an inhibitory neurotransmitter. Synthesis of glutamine from glutamic acid
is an important part of the detoxification of ammonia in
the liver and brain and glutamine synthesis in astrocytes
is critical for glutamic acid regulation to protect the
brain from glutamate excitotoxicity.
Glutamine functions include protein synthesis; the
provision of nitrogen for the synthesis of amino acids,
purines, pyrimidines and nucleotides; and the transport
of amino-nitrogen to the intestines, liver and kidney.
Glutamine plays roles as both precursor and inhibitor of
nitric oxide production.101,102
A large percentage of ingested glutamine may be
used for energy production by enterocytes.103 This role
has advantages for the enterocytes, but it means that
glutamine supplementation may be ineffective for raising plasma glutamine levels. Endogenous formation of
glutamine may be assisted by supplementation with
balanced formulas of essential amino acids.
The first goal in this section is to explain the principles underlying the interpretation of abnormalities in
laboratory evaluations where Glu and Gln are measured,
mainly plasma amino acid profiling. A secondary goal
is to provide understanding of the benefits and caveats
regarding the dietary supplementation of glutamate and
glutamine as individual amino acids.
Specimen collection and handling is critical for
accurate measurement of Glu and Gln. At room temperature, enzymes in plasma can degrade glutamine to

conditions. Abnormalities may also suggest other testing
to investigate metabolic impacts and needs for other
classes of nutrients or detoxification procedures.
The organization scheme used in Table 4.1 is followed throughout the chapter, but some amino acids
with multiple roles are mentioned in more than one
location. Several EAAs, which were discussed at the
beginning of this chapter, are in the category “Amino
Acids for Polypeptides and Energy.” Glycine, aspartic
acid and taurine are CNS-active compounds that might
be included under “Neurotransmitters and Precursors,”
but instead they are grouped according to their unique
metabolic functions such as detoxification.

glutamate. Therefore, specimens at room temperature
for extended periods of time can have increased glutamic acid concentration with proportionally lower
glutamine levels.
The distribution of fasting plasma values in a large,
diverse patient population from outpatient clinics
(Figure 4.5) reveals several useful points. First, one can
see that average glutamine is about sixfold higher than
glutamate. Overall, it is extremely rare to find glutamate
levels above 200 µM, while glutamine varies from below
100 to nearly 1,200 µM. Individuals in the abnormal
regions, labeled “A” and “B,” are considered to be in a

state of metabolic distress that is reflected by either low
or high ratios of glutamine to glutamate. The specimen
degradation issue mentioned at the beginning of the Glu
and Gln section may contribute to some points in “A,”
so metabolic distress interpretation depends on knowledge of specimen history. For those specimens that were
handled properly, the indiviudals are in danger of the
various sequelae of inadequate glutamine described in
this section.

## Ureagenesis and pH Modulation
When amino acids are degraded in the liver,

Polymers of Cell Matrix
INTRACELLULAR

4.

Glutamine

PDG

TCA
1.
Cycle Fumarate

OAA

GDH

Carbamoyl phosphate

AST

(γ-GT)

GS
NH3

NH3

Glutamate

ALT

α-KG Alanine
Aspartate

Urea
Cycle

Glutamine

Pyruvate

OAA

3.

Glutathione

2.

Glutamate

HCO3 NH3

Urea

ph-raising

α-KG

ph-lowering

GFAT

Nucleus

EXTRACELLULAR

γ-Glutamyl
GSH
Glucosamine
Cycle
Galactosamine
Pyroglutamate
Sialic acid
Fructose-6-P

MITOCHONDRION

Glucose
Alanine
Aspartate

Glutamate
semialdehyde
Arginine

Proline

Purine
Nucleotide
Cycle

Nitric Oxide
Fumarate

Figure 4.4 — Multiple Pathway Interactions of Glutamate and Glutamine
The enzymes glutamine synthetase (GS) and phosphate-dependent glutaminase (PDG) allow bi-directional control of
glutamate/glutamine conversions. Glutamate and glutamine interact simultaneously with the tricarboxylic acid cycle
(TCA), urea cycle, purine nucleotide cycle, and γ-glutamyl cycle (glutathione formation), exerting metabolic regulation
and rate adjustments at multiple points. Total-body glutamine metabolic flux shifts between four principal processes: (1)
gluconeogenesis (renal); (2) glutathione synthesis; (3) ureagenesis and proline synthesis (hepatic); and (4) glutaminefructose-6-phosphate aminotransferase (GFAT) pathway to cell matrix polymers. Glutamate is formed by transfer of amino
groups from Asp, Ala and other amino acids via the enzymes aspartate transaminase (AST) and alanine transaminase (ALT).
α-Ketoglutarate (α-KG) is reformed by deamination under the action of glutamate dehydrogenase (GDH).

Glutamic Acid vs. Glutamine
Plasma Glutamic Acid (uM)
C
B

A
1000

1200

1400

Plasma Glutamine (uM)

Figure 4.5 — Scatter Plot of Glutamate

vs. Glutamine

Each point represents the measured glutamine and
glutamic acid concentrations for an individual submitted
for routine amino acid profiling from an outpatient clinic.
The central ellipse with thick arrows emphasizing normal
distributions encompasses more than 90% of the 2,972
points. In this normal range, there is no tendency of
glutamic acid to rise as glutamine values increase. Ellipse
A: individuals where glutamine has fallen to abnormally
low levels, where the average glutamate still remains
constant. Ellipse B: individuals with very high glutamine,
none of which have elevated glutamate. Ellipse C: the
region where higher glutamate levels are found in
proportion to declining glutamine probably represents
improperly stored and transported specimens, where
conversion of glutamine to glutamate has occurred.

stress has been demonstrated by direct measurement of
brain glutamine using high-magnetic field MR.105
Glu and Gln regulate systemic pH in the kidney,
liver and brain especially during food intake, pulmonary
changes and cardiac exertion. Greatly elevated plasma
glutamine is favored by chronic alkalotic conditions
(insufficient bicarbonate clearance) or elevated ammonia, in which patients are in a state of metabolic fragility,
lacking normal ability to respond to the pH stresses of
everyday life. Conversely, chronic acidemia is associated
with low glutamine. Systemic pH influences enzymes
controlling Glu and Gln. The net effect of acidosis is
to increase the flow of glutamine from liver to kidney,
where the ammonium ion is removed, thereby lowering
systemic pH. Acidosis stimulates glutamine uptake in
the kidney, tending to produce low plasma glutamine,
especially in individuals with impairment of the enzyme
phosphate-dependent glutaminase.108 Thus, patterns of
simultaneously low or high fasting plasma glutamate
and glutamine are found in patients who have chronic
difficulty overcoming headaches, fibromyalgic pain, or
infectious diseases. They may benefit from the decreased
digestive burden and accompanying pH buffering demands achieved by lowering animal protein intake. The
more rapid digestion of animal proteins places stronger
demands on pH buffering systems during postprandial

glutamic acid is produced and nitrogen (or ammonia) is
then transformed into urea via the urea cycle. The other
product, alpha-ketoglutaric acid (α-KG), can be used to
produce energy by the TCA. Glutamate carries nitrogen
away from exercising muscle via α-KG. Experiments
done on animals show that hepatic ammonia clearance
can easily be exceeded resulting in increased circulating
ammonia.104
Glutamine is intimately involved in the detoxification of ammonia and ammonia disposal is a major contributor to systemic pH regulation. The chemical structure of glutamine suggests its role as an amine regulator.
It has both α-amine and side-chain amide groups. The
interchange of the side-chain nitrogen between glutamine and glutamate is a reaction common to all tissues,
facilitating movement of amine groups. In acidic conditions, hydrolysis of the glutamine side chain releases ammonia (NH3). Ammonia binds excess protons, thereby
making the pH more basic. Acute acidosis stimulates
renal cell uptake and metabolism of glutamine. The shift
toward higher glutamine transport during ammonia
intervals.109
Refer to Case Illustration 4.1

## Brain Regulation
Neurons and astrocytes have transport systems and
metabolic capacities that protect the brain from ammonia while stabilizing glutamate levels for use by glutamatergic neurons. Glutamate is the principal excitatory
neurotransmitter in the brain. Animal studies suggest
that the excitatory function of glutamate plays a key
role in controlling gastric function, with high glutamate
causing a depression of gastric motility.110 Stimulation
of endogenous synthesis of glutamate may contribute
to chronic neurodegeneration in such disorders as
amyotrophic lateral sclerosis (ALS) and Huntington’s
chorea.111 The effect on Huntington’s chorea is unrelated
to dietary intake of glutamate. Low plasma glutamate
levels, on the other hand, can impact a large class of
neurons in the central nervous system, which utilize glutamic acid as an excitatory neurotransmitter. Glutamic

Astrocyte
Presynaptic
Nerve Terminal
EAAC1
SN1
Glutamine
GLNase SN2

to CSF
Glutamine

Glutamate

GS

EAAC1

NH3

Glutamate

GLT-1

Capillary

GLAST
Glutamate

NMDA

KA
AMPA

Figure 4.6 — Astrocyte Recycling of Glutamate

Glutamate released from the presynaptic neuron elicits neurotransmission
through binding at postsynaptic N-methyl-D-aspartate (NMDA), α-amino-5hydroxy-3-methyl-4-isoxazole propionic acid (AMPA) and kainite (KA) receptors.
Synaptic glutamate ultimately is taken up into perineuronal astrocytes by
glutamate-aspartate transporter (GLAST) or the neuronal excitatory amino acid
carrier-1 (EAAC1). Blood ammonia uptake by astrocytes stimulates formation
of glutamine by glutamine synthetase (GS). The SN1-SN2 transporter is used
to transfer glutamine into the presynaptic neuron where it is reconverted to
glutamate by glutaminase (GLNase) for vesicle storage. Reuptake of glutamate
is, thus, quite different from the direct neuronal reuptake mechanism of
serotonergic and most other types of neurons. The complex mechanism
generates multiple sites of potential polymorphic effects that can impact the
primary excitatory glutamatergic system of the brain.

Postsynaptic
Neuron

acid is also important in ammonia detoxification in the
brain where it combines with ammonia to form glutamine (Figure 4.6).
The immune system is influenced by moderate
variations of plasma glutamate and high glutamate seems
to be a causative factor in immunopathology of diseases, including AIDS. Because of such associations high
fasting plasma glutamate has been proposed as a factor
causing low lymphocyte activity and low T4 counts.112
Low fasting plasma glutamate, on the other hand, can be

caused by 5 weeks of trazodone antidepressant therapy,
where amino acid status was found to predict response
to therapy.84 Patients with major depression who did
not show lowered serum aspartate, asparagine, serine,
threonine and taurine were found to not respond to
such therapy. The unidirectional outward transport of
glutamate from brain to blood is thought to be part of
the mechanism of glutamate perturbations relevant to
the pathophysiology of major depression.21

Notes:

Urea
Cycle

SN1
SN2

Gln

Glu

NH3

Gln

FLOW

High pH facilitates
receptor outward
pumping of Gln

of HCO3− keeps pH low

Perivenous
Hepatocytes

OW

FL

Inefficient removal
of HCO3− keeps pH high

Gln = Glutamine
Glu = Glutamic Acid

Figure 4.7 — The SN1-SN2 Transporter System
A section of a hepatic lobule is illustrated, showing a typical course
of blood from portal to venous vessels. This is the system that filters
postprandial blood before it enters extrahepatic circulation. Hepatocytes
that surround the vessel near the portal end have distinctly different
metabolic activities than those near the venous end. Relatively acidic
pH on the portal side causes membrane transporters called SN1 and
SN2 to pump glutamine inward where conversion to glutamate releases
ammonia. Simultaneous utilization of bicarbonate to form urea serves
to maintain relatively acidic cellular pH in the periportal hepatocytes. As
the glutamine-depleted blood flows on past the perivenous hepatocytes,
glutamine, synthesized from glutamate by glutamine synthetase is pumped
outward by the same SN1-SN2 transporter because of the higher pH
generated by the absence of urea-cycle enzymes. Only the perivenous
hepatocytes contain glutamine synthetase. The enzyme is not expressed by
the upstream cells near the portal end of the capillary. The net effect is to
allow adjustment of the relative rates of inward and outward flow to assure
blood glutamine supply in sinusoidal blood that flows toward the heart.
Polymorphism of the SN1-SN2 transporter proteins can be the origin of
abnormalities in plasma glutamine.

for neuroinflammation in the brain of patients with
autism.113 Her plasma amino acid profile revealed an
Refer to Case Illustration 4.2
extremely abnormal Gln/Glu ratio. This data indicates
several things about the metabolic state of the patient.
This patient described in Case Illustration 4.2 is in
She is so far away from normal Glu and Gln balance that
need of immediate metabolic support to prevent inflamshe will have difficulty responding to pH or ammonia
matory sequelae, especially in light of recent evidence
challenges. Neuronal maturation and cortical organization may be difficult due to altered
astrocyte-neuron glutamate metabolism. The neurotoxic effects of elevated
quinolinic acid are especially alarming
Periportal
Hepatocytes
when such an abnormal Gln/Glu ratio
Lymphatic Duct
Portal Vein
is found because of the known mechaLow pH facilitates
FLOW
receptor uptake of Gln
Hepatic Artery
nism by which both agents activate
FL
O
receptors of glutamatergic neurons (see
W
Gln SN1
Glu
“Quinolinate” in Chapter 6, “Organic
SN2
−
Acids”). Finally, the delivery of nitrogen
HCO3
NH3
to all organs is impaired by such a low
glutamine level, possibly contributing to
Urea
general developmental delay.
Sinusoid
Efficient removal

Gluconeogenesis
Recent evidence has shown how glutamine plays yet another pivotal role as a
regulator of total body energy metabolism
as a gluconeogenic substrate. Thus, fasting
plasma or whole-blood glutamine tends
to rise or fall with changes in demand for
glucose production. Glutamine is involved
in the hexosamine biosynthetic pathway
(HBP), a nutrient-sensing system involved
in the development of insulin resistance.
When postprandial glucose elevation
subsides, glutamine is found to surpass all
other amino acids, including alanine, as a
supplier of carbon for glucose synthesis.114
Though plasma glucose may be formed
from alanine or lactate released from skeletal muscle, only glutamine contributes a
net gain of glucose.114
Glucagon, acting through hepatic
receptors, can reduce plasma glutamine
by 30% under conditions of constant
insulin and glucose.115 Insulin supresses
the renal glutamine-glucose conversion, whereas epinephrine is a powerful
stimulator of this organ-specific glutamine uptake and glucose release.116

Glutamine

Fructose-6-Phosphate

Glutamate

D-Glucosamine-6-P

Glutamine-Fructose-6PTransaminase (GFAT)

UTP
UDP − N-Acetyl-D-Glucosamine
Polymers of
cell walls &
extracellular matrix

UDP −N-Acetyl-D-Galactosamine
Figure 4.8 — From Glutamine to Glucosamine
Glutamine supplies the amine group for synthesis of hexosamine polymers that characterize the
extracellular matrix and give identity to cells via the glycoproteins of their membranes.

step to pathways for polymers of glucosamine, galactosamine and sialic acid that are used to construct the cell
matrix (Figure 4.8).
In response to hyperglycemia, GFAT is overexpressed
in the kidney of diabetics with concurrent stimulation of
the plasminogen system and vascular injury.120 The GFAT
promoter gene is activated by angiotensin II.121 Restriction of structural and cell-recognition polysaccharides is
another potential result of low plasma glutamine.

Of Further Interest…

These cycles are shifted toward greater glucose synthesis
(gluconeogenesis) in patients with non–insulin-dependent diabetes mellitus (NIDDM),117 and the conversion
of glutamine to glucose in renal tissues is dominant.118
Thus, glutamine is intimately involved in energy control
through its major contribution to gluconeogenesis.
The enzyme glutamine-fructose-6-phosphate amino­
transferase (GFAT) activates the hexosamine pathway,
which is involved in energy metabolism and development of insulin resistance.119 GFAT is the rate-limiting

The SN1-SN2 Transporter System (Figure 4.7).
The mammalian liver is actually two separate organs
with respect to Glu and Gln metabolism. In periportal
hepatocytes, glutamine uptake is active and the amide
side-chain nitrogen is delivered for ureagenesis. In
perivenous hepatocytes, on the other hand, Gln synthesis and export is very active. These systems work in
tandem so that any ammonia left in periportal blood
is removed as it enters perivenous regions. Periportal
ammonia increases only when these two systems approach saturation.
There is a strong metabolic zonation produced
by the total lack of glutamine synthesis in periportal
hepatocytes and the total lack of glutamine uptake
for urea synthesis in perivenous hepatocytes. The
perivenous cell population is much smaller than
the periportal. Only 7% of all acinar hepatic cells

surrounding the terminal hepatic venules account for
all hepatic glutamate uptake.
In periportal hepatocytes, bicarbonate-rich portal
blood enhances uptake of glutamine and deamination
is driven by the bicarbonate substrate role in the urea
synthesis. On the perivenous side, lower pH drives
synthesis and export of glutamine. These cells contain
high activities of glutamine synthetase, an enzyme
totally absent in the periportal cells. The perivenous
hepatocytes are highly sensitive to oxidative damage
from alcohol consumption, being the first to show
signs of liver disease.106 Their loss will lead to declining plasma glutamine. Genetic defects in the SN1-SN2
transporter system produce simultaneous elevation of
plasma glutamine, asparagine and histidine. Individuals with such patterns have difficulty maintaining
normal tissue pH.107

## Dietary Protein Influences
One factor controlling circulating glutamine is the
total dietary supply of essential amino acids. In healthy
individuals, plasma glutamate and glutamine vary inversely with dietary protein intake and the changes are
attributable to changes in de novo production.122 When
humans shifted from normal to high protein intakes,
glutamine dropped more than 30%.123 In routine clinical
assessments of fasting plasma amino acid profiles, it is
common to find low levels of essential amino acids with
high-normal or even slightly elevated glutamine.

Table 4.9 — Patient Groups Likely
to Benefit from Glutamine125

Category
Examples
Burns

Severe
catabolic illness

Multiple trauma
Bone marrow supplementation
Acute/chronic infection
Other critical illness

Some of the more common clinical conditions with
relevance to glutamine and glutamate are summarized
in Tables 4.9 and 4.10, respectively. Plasma glutamine
is lowered in individuals placed on high-protein diets,
apparently due to decreased release from muscle and
lower net synthesis of glutamine.123 The average level
of 720 µM for healthy men on normal protein intake
(1 g/kg/d) fell to 444 µM when protein intake was increased by 2.5-fold during high protein intake. Plasma
glutamate levels decrease rather than increase with
increased dietary protein intake. This phenomenon apparently is due to the actions controlling fluxes through
pathways of glutamate synthesis and utilization and
the fact that little or no dietary glutamate or glutamine
reaches the portal circulation.122 When humans are fed
low-protein diets, rising levels of plasma glutamine is
an early-stage response to help assure adequate supply
for synthesis of glutamic acid in nerves, glutathione in
liver and other essential derivatives.122
Depressed patients have lower plasma glutamate
and glutamine levels than controls,124 consistent with
other studies where excitatiory amino acids, especially
glutamate, glycine and taurine were able to discriminate
depressed patients from controls.20 These perturbations
of amino acid circulating concentrations may reflect
altered brain metabolism or blood-brain barrier transport
differences.
A glutamine synthetase mutation has been reported in which glutamine was largely absent from
serum, urine and cerebrospinal fluid.126 This form of
congenital glutamine deficiency produces severe brain
malformations, multiple organ failure and neonatal
death. Milder variants of this genetic modification
will produce less profound glutamine insufficiency
with milder symptoms in older children and adults.

## Clinical Relevance and Treatment

Skeletal muscle activity is the primary contributor to
plasma glutamine in the postabsorptive state.
The normal inflammatory response involves interferon-γ stimulation of the class of lymphocytes called
T helper cells (TH1). In severe trauma patients, plasma
concentration of glutamine is routinely lowered by
approximately 50% of normal mean values.127 Severe
trauma leads to an impaired TH1 immune response
related partially to the low plasma glutamine concentrations, which can lead to a poor cell-mediated immune
response despite normal antibody levels.127 Glutamine
levels fall when it supplies amine groups (nitrogen) for
increased protein synthesis. To spare the fall of glutamine, hepatic catabolism of other amino acids falls,
restricting other biosynthetic activities dependent on the
carbon skeletons.
Starvation, injury, sepsis and other protein catabolic states result in reduced glutamine in muscle and
plasma.74,128 Glutamine is considered a conditionally
essential amino acid for critically ill patients because
of improvements in immune function of these patients with glutamine supplementation.129 Among
patients with cancer or human immunodeficiency

Inflammatory bowel disease
Infectious enteritis

Intestinal
dysfunction

Necrotizing enterocolitis or intestinal
immaturity
Short-bowel syndrome
Mucosal damage following
chemotherapy
Radiation or critical disease
Surgical gastrointestinal patients

Immunodeficiency
syndromes

Immune system dysfunction associated
with critical illness or bone marrow
transplantation
Acquired immunodeficiency syndrome

Advanced
malignant disease

Cancer cachexia

Low-birth-weight
babies

Premature infants

Table 4.10 — Clinical Disorders Associated with Altered Plasma Glutamate

Disease

Plasma glutamate

Metabolic dysfunction

Amyotrophic lateral sclerosis

High

Low activity of glutamate dehydrogenase154

Acquired immunodeficiency syndrome

High

Decreased immunological reactivity155

Headache, fatigue, confusion, poor concentration
and food intolerance due to hyperammonemia

Low

Urea cycle insufficiency156

Epilepsy

High

Glutamate-induced gene expression157

Acute liver failure

High

Impaired neuron-astrocyte glutamate flux158

Low Gln/Glu

Contraindications for Supplementation of
Glutamate or Glutamine: The safety of glutamine may
be considered as a special topic under the subject of
optimal protein intake. Considering optimal protein
intake, in turn, begs the question of the type of protein,
especially whether protein sources are plant or animal
based.65 In general, consumption of amino acids in excess of requirements for utilization results in conversion
of the amino nitrogen to urea. When protein intake is adjusted by addition of casein, lactalbumin, or ovalbumin,
the rate of urea synthesis reaches a maximum at about
80 g protein/d for a 70 kg individual. At intake of 200 g
protein/d for a 70 kg individual, maximal excretion was
sustained for 24 hours. Thus, within broad limits, urea
excretion may be measured to assess the degree of excess
protein intake.136 Although the mechanism is not clear,
studies in rats show that total blood LDL cholesterol
levels are closely related to the amount of animal protein
consumed.137 This conclusion is strongly supported by
epidemiological data on humans.65 Thus, commonly

virus infection, increased skeletal muscle catabolism,
low plasma glutamine and high venous glutamate levels
are common.130 These shifts in amino acid concentration
are part of the mechanism for halting the loss of body
cell mass in such diseases.
Because of the favorable responses to supplementation, glutamine is recognized as a conditionally essential
amino acid for patients in catabolic states.131 Clinical
responses to supplementation may be explained by
glutamine’s influences on the inflammatory response,
oxidative stress, cell protection and the gut barrier. By
inducing the production of heat shock proteins, glutamine assists the protection of cells against toxic agents
or pathologic insults.132 By modulating cytokine output,
glutamine decreases the inflammatory response.133 By
increasing splanchnic glutathione production, glutamine
protects the intestinal mucosa from the degenerative effects of oxidative stress.134
Mild hyperammonemia conditions are often seen
as low fasting plasma glutamic acid levels and high
glutamine levels. Symptoms include headache, irritability, fatigue, mental confusion, poor concentration and
food intolerance reactions, particularly to high-protein
foods. A low-protein, high-complex carbohydrate diet
with supplementation of α-ketoglutaric acid, vitamin
B6 and BCAAs will be useful in correcting this condition, particularly if glutamine is high. Supplementation
of α-ketoglutaric acid supplies additional substrate for
ammonia removal and generates additional energy as a
component of the citric acid cycle. Other agents employed against acute hyperammonemia include benzoic acid and sodium phenylacetate.135 The pattern of
simultaneously low glutamic acid and glutamine calls for
EAA supplementation with cofactors to enhance the flux
of amino acids in liver and normalization of glutamine
production in perivenous hepatocytes.

Negative nitrogen balance159

Tumor-induced cachexia

Notes:

and behavioral changes due to glutamate neurotoxic
effects.140 Although glutamine supplementation reduces
plasma nitrate in experimental animals, no such effects
have been reported for humans.143
Glutamic acid is not generally used in clinical interventions because of toxic effects from administration
of the free amino acid. Neurotoxic effects result from
exceeding the capacity of mechanisms that function to
regulate intracellular glutamate concentrations when
plasma concentrations are sharply increased.144–146 Postnatal administration of monosodium glutamate (MSG) to
weanling rats, an animal model for the study of human
obesity, produces insulin insensitivity and obesity.147
These effects are explained by MSG-induced damage to
the arcuate nucleus and subsequent interference with
circadian energy expenditure.148 MSG-induced obesity
produces a general defect of adipocyte cell membrane
characterized by impaired receptor proteins.144 Reports
of these effects have generated a public controversy over
regulation of MSG as a food additive.
Glutamate-mediated excitotoxicity resulting from
impaired astroglial uptake constitutes one of the current
hypotheses explaining the progression of ALS.149 In ALS,
plasma glutamate is elevated and treatment with BCAA
showed a significant benefit.150 Schizophrenia treatments (and etiologic mechanisms) have been linked to
the glutamatergic and dopaminergic excitatory amino
acid systems.151 Alterations in plasma levels of aspartate,
glutamate, glycine and taurine have been suggested as
neurochemical markers of epilepsy.152 Other reviews
have summarized the numerous neurodegenerative diseases involving stimulation of glutamate receptors.153

Notes:

available measures of urea and cholesterol provide markers for assessing excessive animal protein intake.
Numerous studies of high-protein effects in neonates, children and adults have been reported. Approximate doubling of cow’s milk protein intake for preterm
infants produced toxic effects manifested as fever,
lethargy and poor feeding.138 Follow-up at 3 and 6 years
showed increased incidence of strabismus and low IQ
scores in the children with lowest birth weight who had
been fed the high-protein diet.139 Other potential high
dietary protein effects include loss of calcium, calcium
oxalate stone formation and progression of renal disease.
Individual amino acid supplementation at excessive
levels also can produce a variety of effects specific to the
amino acid.140
Glutamine is widely used in doses of 10 to 20 g per
day for the reasons discussed above. As already mentioned, however, oral glutamine is not generally effective
for modifying plasma glutamine. Because of the biochemical conversion of glutamine to ammonia and glutamic acid, researchers have addressed the question of
toxicity from oral supplementation of glutamine. Some
authors have argued that therapeutic use of glutamine
is inappropriate for any condition,141 although earlier
studies had demonstrated safety in subjects receiving
parenteral infusions of up to 0.570 g/kg body wt/d.142
A review of more chronic effects of glutamine therapy
concludes that no adverse effects are reported during
short-term dosing as high as 50 to 60 g/d. However, patients under long-term supplementation with glutamine
should be monitored for metabolic diseases such as
diabetes or coronary artery disease and for psychological

UREA CYCLE

HO4P−

−

Citrulline

Mg+
Aspartate

C=O

H2N
HN

H3N
C=O
−
HO4P

2.

C-N-Asp

NH3+

Ornithine

Argininosuccinate

Urea

HYPERAMMONEMIA AND

producing

Low Urinary Orotate
Oroticaciduria
Citrullinemia
Argininosuccinic Aciduria
Hyperargininemia

1. Carbamoyl Phosphate Synthase I
2. Ornithine Transcarbamoylase
3. Argininosuccinate Synthase
4. Argininosuccinate Lyase
5. Arginase

C=O

FAULTY ENZYME

H2O

H2N

H2N

Fumarate

Mn++

Arginine

ca
pa

HN

5.
C-NH2

HN

cyc
le

Orotate

Arginase

4.

Urea

eded
xce
ye
cit

3.

Carbamoyl
Phosphate

ito
Cy cho
to nd
so ri
l a

HN

• Amino acid catabolism
• Intestinal bacterial metabolism

H2N

(Krebs Cycle)
Oxaloacetate

AMMONIA
NH4+ + H2O
CO2 + 2 ATP
1. Mg++

Figure 4.9 — The Urea Cycle

This figure illustrates the transfer of nitrogen from ammonia through the various intermediates to urea. The partial structures
are included to assist in following the flow of nitrogen atoms. The first nitrogen is transferred to ornithine from carbamoyl
phosphate and the second is carried to citrulline by aspartic acid. The reloading of aspartic acid requires several steps that
ultimately serve to gather the aspartate nitrogen from another molecule of ammonia. Enzymes for the formation of carbamoyl
phosphate and for driving the four reactions of the cycle are shown in the inset. Collectively, these four enzymes represent a
high incidence of genetic defects that manifest as hyperammonemia and the other amino or organic acidurias shown.

The Urea Cycle and
Nitrogen Management
The detoxification of ammonia is a critical metabolic
process that requires the functioning of the urea cycle
(Figure 4.9). Hepatic urea cycle activity changes as needed to manage the varying ammonia clearance demands
due to dietary nitrogen content fluctuations. Thus amino
groups are supplied to drive transamination reactions or
are removed to prevent toxic ammonia buildup. Subtle
impairments of the liver’s urea cycle function can lead
to sub-clinical or mild hyperammonemic conditions.
Symptoms include chronic fatigue, headache, irritability,

occasional diarrhea or nausea, lack of concentration,
mental confusion and intolerance of foods, particularly
high-protein ones. Urea cycle impairments tend to produce low blood urea nitrogen (BUN) levels.
Amino acid profiles include several markers of urea
cycle function, including arginine, ornithine, citrulline,
glutamine and aspartic acid. Ammonia toxicity problems
can deplete α-ketoglutaric acid and vitamin B6. Supplementation with these nutrients combined with a lowprotein, high-complex carbohydrate diet and branchedchain amino acids can reduce ammonia loads and help
to normalize urea cycle function.

## Arginine (Arg)
NH2+
COOH

N

ARGININE
Arginine provides a starting material
from which
products are formed that serve diverse functions (Figure
4.10). The hepatic urea cycle responds to protein intake
and ammonia clearance demands. It is catalyzed by four
enzymes, one of which, ornithine transcarbamoylase
(OTC), is located in the mitochondrial matrix, whereas
the other three are cytosolic (Figure 4.9). One enters
as carbamoyl phosphate and the other as aspartic acid.
Collectively, the four enzymes comprise the greatest incidence of genetic polymorphisms of any area of metabolism.160 The urea cycle enzyme arginosuccinate synthetase
(ASS) is ubiquitously distributed in human tissues for net
synthesis of arginine or nitric oxide (NO). In the kidney,
ASS and the enzyme arginosuccinate lyase (ASL) cause
the net conversion of citrulline into arginine to maintain
total-body arginine levels (Figure 4.10). Arginine supply
can be increased in kidney proximal tubular cells when
there is a nitrogen source available such as aspartic acid.
The synthesized arginine is passed back into circulating
blood. Arginine also is the direct precursor to the cell
regulator nitric oxide. ASS can also produce nitric oxide
from arginine in the presence of nitric oxide synthase.

NH2

H

H2N

Pathways of protein synthesis in all tissues and creatine synthesis in skeletal muscle account for the greatest
quantity of total-body arginine flux. The total physiological impact of arginine, in addition to its role in the urea
cycle, includes its role in cell regulation via production
of nitric oxide and polyamines such as spermine.161 Arginine insufficiency quickly leads to hyperammonemia
due to failure of ammonia removal. Citric acid, cis-aconitic acid, isocitric acid and orotic acid appearance in
urine are other biochemical markers of this condition
(see Chapter 6, “Organic Acids”).
Arginine has been found to be an essential amino
acid in many metabolic balance studies.162 Arginine is
the first amino acid to be depleted when mammalian
cells are grown in cell culture, indicating high cellular
turnover of arginine compared with other amino acids
such as leucine.163 Thus, arginine is one of the few compounds that needs to be supplied from dietary sources,
even though human tissues contain the enzymes necessary for its synthesis. Low levels of arginine in plasma
or urine could be reflective of low dietary intake of
arginine-containing foods such as legumes, whole grains
and nuts.164 On the other hand, chronic high blood
levels of arginine may be conducive to tumor growth.
Agents that induce arginine restriction are being investigated as anticancer therapy.165 The precise role of NO in
cancer is poorly understood, but it has the potential to
stimulate tumor induction, promotion and progression,

Table 4.11 — Clinical Symptoms of Hyperammonemia and Urea Cycle Disorder

Anorexia
Irritability

Symptoms of Hyperammonemia

Heavy or rapid breathing
Lethargy
Vomiting
Disorientation

Symptoms of Urea Cycle Disorder
General
Head, ears, eyes, nose and throat
Pulmonary
Abdominal

Hyperammonemia
Poor growth
Papilledema
Tachypnea or hyperpnea
Apnea and respiratory failure (in latter stages)
Hepatomegaly

Somnolence

Poor coordination

Asterixis (rare)

Dysdiadochokinesia

Combativeness

Hypotonia or hypertonia

Obtundation
Coma
Cerebral edema

Ataxia
Neurologic

Tremor
Seizures and hypothermia
Lethargy progressing to combativeness to
obtundation to coma
Decorticate or decerebrate posturing

Enzymes and
Polypeptides
TRANSPORTER

1.

Arginine

Fumarate

Aspartate

Fumarate

Aspartate

• Endothelial relaxation

6.

• Inflammatory signaling
• Neurotransmission

ASS

• Thyroid follicular cells

2.
ASL
HCO3− + NH3

NITRIC OXIDE
CYCLE

TOXIC AMMONIA

UREA CYCLE

NO + Citrulline

Ornithine
Urea

Arginine
Glycine

3.

CO2

Ornithine

Creatine

Ornithine

Agmatine

4.

Urea

Putrecine

Polyamines

Glutamate

Apoptosis trigger

Figure 4.10 — Overview of Arginine Metabolism

CO2

Nucleus

Collagen

P5C

5.

Muscle

Proline

In clockwise order from the top: (1) Arginine transporters perform regulated supply of the amino acid to protein synthesis
needs of all tissues. (2) Urea formation clears toxic ammonia. (3) Catabolism to proline can help maintain collagen synthesis.
(4) Up-regulation of polyamine formation is a signaling mechanism for apoptosis. (5) Net synthesis of creatine supplies the
substrate for energy storage in muscle as creatine phosphate. (6) Reversal of a urea cycle step by nitric oxide synthase is the
route to nitric oxide for multiple cell signaling functions. Renal tubule cells can convert circulating citrulline back to arginine
that is transported to blood for return to the arginine pool. P5C = pyrroline-5-carboxylate.

as well as angiogenesis, cell adhesion and other procarcinogenic factors.166 Regarding patient candidacy
for arginine supplementation, the central question is
whether the endogenous biosynthetic potential can meet
the total-body demand. Depending on glutamine status,
as much as 60% of absorbed arginine is metabolized by
enterocytes and never enters portal circulation. Arginine status depends on activities of enzymes in small
intestine, kidney, liver and nitric oxide-producing cells.
Pathway 6 of Figure 4.10 illustrates how renal tubular
cells can increase blood arginine from a supply of citrulline and aspartic acid, whereas the citrulline is mainly
produced in the small intestine.167
Proline biosynthesis for collagen production
can arise from either glutamic acid or arginine. If the
pathway from glutamic acid is inhibited, then arginine

deficiency can result from the increased conversion
of arginine to proline. Individuals with this problem
display low plasma arginine, ornithine, citrulline and
proline.168 The importance of intestinal activities of this
enzyme is further illustrated by the hyperammonemia
associated with intestinal resection surgery in rats.169 In
stable short-bowel patients, an arginine-free diet produces reduced levels of plasma arginine, ornithine and
hydroxyproline within 5 days.170
Intestinal bacteria can decarboxylate arginine to form
agmatine, which may increase the virulence of Helicobacter
pylori.171 Agmatine is also produced in human tissues172
and may have an important neurotransmitter role.173
Clinical Relevance: Arginine and nitric oxide are
involved in vascular tension. Nitric oxide is produced in
endothelial cells and diffuses into the underlying layer of

arginine, especially when given along with ornithine to
spare the utilization for urea cycle function. The effect
on penile erection is mediated by nitric oxide relaxation
effects on vascular sphincter muscles.181
Interpretation and Treatment: Arginine released
from dietary protein is absorbed in the jejunum and
ileum of the small intestine by a specific transport
system also used for lysine and histidine. This intestinal
transport competition is one reason that heavy supplementation with any one of these amino acids should be
done with caution.
High levels of arginine in plasma or urine may represent a functional block in the urea cycle. The arginase
enzyme requires manganese and the failure of this metabolic role may give rise to the early signs of manganese
deficiency appearing as ammonemic symptoms.182 If
ammonia toxicity symptoms (confusion and disorientation) and signs (elevated urinary citrate) were present, a
low-protein diet with the avoidance of lysine-containing
foods would be advisable to reduce the ammonia load.
Additional vitamin B6 and α-KG may also be useful to
remove excess intracellular ammonia.
In light of the favorable clinical responses to
arginine supplementation of up to 9 grams per day in
hypertensive patients, one must consider adverse reactions. Mammary tissue has a high capacity for arginine
catabolism due to high activities of arginase, ornithine
aminotransferase and pyrroline-5-carboxylate reductase.183 The principal products are proline and ornithine.
High doses of l-arginine were found to have inhibitory
effects on in vivo nitric oxide formation in rat substantia
nigral cells.184 Additional potential adverse effects of excessive arginine intake due to pro-oxidant formation are
discussed in Chapter 9, “Oxidative Stress and Aging.”
Patients with some types of cancer may benefit from
an arginine-restricted diet. Some tumor cell lines are
dependent on arginine for growth due to an inability to
express ASS. Selective elimination of arginine from the
circulation of animals causes tumor regression. Among
human cancers studied, sarcomas, invasive breast carcinoma and renal cell carcinoma, were sometimes found
to be ASS deficient,185 but the efficacy of arginine restriction in human cancer patients has not been investigated.

smooth muscle cells, where it elicits release of the final
modulator of muscular relaxation, cyclic guanosine monophosphate (cGMP). Asymmetrical dimethylarginine
(ADMA) regulates nitric oxide formation as discussed in
the next section.
Many of the reported effects of arginine in human
health are due to nitric oxide-related cell responses.
There is evidence of a relative deficiency of arginine in
diseased coronary arteries. Arginine administration reversed the effect of nitric oxide inhibitors and improved
coronary vasomotor tone in angina patients with angiographically narrowed coronary arteries.174 The treatment
resulted in greater dilation of diseased arteries, including
stenosed arteries. Arginine administered at the end of
surgery reduces intraperitoneal adhesion formation, a
major cause of infertility and pain following surgery.175
Arginine has a protective effect against the hypercholesterolemia induced in animals by simultaneous methionine- and lysine-enriched diets.176 The mechanism
for the protective effect is unknown. Lysine infusion (0.5
mmol/kg) in 10- to 14-year-old humans also produced
increases in plasma levels of arginine and ornithine,
apparently through an inhibitory effect on arginase. The
lysine infusion also resulted in increases of blood ammonia and urinary orotic acid.177
Other cell-regulatory effects of NO listed in Figure 4.10
are discussed further in Chapter 10, “Hormones”. Nitric
oxide participates in the cascade of events leading to
immune cell activation. A special form of nitric oxide synthase in neurons serves to regulate their function and NO
formation in the thyroid follicular cells regulates blood
flow locally as a mechanism to regulate thyroid activity.
Arginine may play yet another role as a supplier of
polyamines to stimulate healing in the wound response.
Mechanical wounding causes an increase in the expression of the arginine decarboxylase 2 gene and concurrent decreases of spermine with increases of putrescine
concentrations, indicating these metabolic changes are
associated with the healing response.178 Administration
of arginine after trauma-induced hemorrhage significantly improves macrophage function and interleukin-6
levels.179
Arginine is one agent found to increase sperm count
and motility, although the response is quite variable.
Of 15 patients with low sperm counts who received
arginine hydrochloride over a 3-month spermatogenesis
cycle, 3 pregnancies (20%) were obtained.180 Enhancement of penile erection is another effect of supplemental
Notes:

## Asymmetric dimethylarginine (ADMA)
H3C

H
COOH

N

N
C

CH

NH2+

ADMA is an endogenous inhibitor of angiogenesis.186
Many angiogenic factors require endothelium-derived
NO to exert their effects. Arginine is the compound from
which NO is formed and ADMA is a naturally occurring
compound that inhibits NO synthases.
Formation of ADMA from Arginine: Under the action of an enzyme called methionine-dependent protein
arginine N-methyltransferase (PRMT), ADMA is formed
by methylation of arginine residues of nuclear proteins
(Figure 4.11).187 On hydrolysis, the ADMA residues
are released to pass into blood, available for binding to
NOS to modulate the rate of NO production. A principal
mechanism of regulating concentrations of ADMA is
through the action of the catabolic enzyme dimethylarginine dimethylaminohydrolase (DDAH) that degrades
ADMA to citrulline. ADMA formation is increased by
methionine loading, producing endothelial dysfunction.
This effect can be reversed by administration of ascorbic

NH3+

H3C

acid that enhances DDAH activity.188 More than 4 mmol
(> 1 g/d) of ADMA is extracted by the liver (700 times
the amount circulating in blood).189 The other principal
mechanism for regulation of ADMA is renal clearance,
allowing ADMA above renal thresholds to pass into
urine.190 In addition, endothelial DDAH expression is
stimulated by all-trans retinol.191 On the other hand,
nerve damage causes marked increase in the expression
of ADMA as part of the mechanism to protect neuronal
cells from the effects of excess NO.192
To summarize the mechanistic studies, there are
multiple dietary and nutrient-dependent steps involved in the control of ADMA synthesis and clearance.
l-Arginine stimulates NO synthesis to overcome the
inhibitory effects of high ADMA. Low-fat meals help
to reduce the synthesis of ADMA by PRMT. Vitamin
A induces expression of DDAH, causing a lowering of
ADMA. Antioxidants prevent the inhibition of DDAH,
thus enhancing the removal of ADMA. Normalization
of elevated homocysteine with vitamins B6, B12 and folic
acid reduces ADMA by controlling endothelial oxidative
effects. In addition, individuals with persistent ADMA
elevations may be managed with hormonal interventions
such as acetylcholinesterase (ACE) inhibitors and natural estrogen replacement therapies. Exercise has a strong

NH2+

N
H

COOH
Nuclear
Protein

C
H2N

NH2+
H3C

Arginine

ADMA

(protein bound)

Methionine

Homocysteine

COOH

NH2+
H3C

Kidn

H3C

NOS
H

DDA

Vitamin C
Vitamin A

CH

C
N

ey

Nitric Oxide (NO)

H

Methionine-dependent PRMT

ADMA urine
Arginine

Nuclear
Protein

N

H3C

NH2

(protein bound)

C
N

N

Subsequent
Proteolysis

NH3+

H
ADMA

(free in plasma)

Citrulline
Oxidative Stress

ADMA
PRMT
DDAH
NOS

Asymmetric Dimethylarginine
Protein arginine methyl transferase
Dimethylarginine dimethylaminohydrolase
Nitric oxide synthase

Figure 4.11 — ADMA Synthesis, Clearance, & Regulation of NOS
Methylation of the terminal nitrogen atom of the arginine side chain in nuclear proteins produces protein-bound ADMA that
is released on proteolysis. The released ADMA binds to NOS, slowing its activity in NO formation, thus regulating the rate of
NO synthesis. The half-life of ADMA is governed partly by DDAH activity that causes degradation to citrulline. Because DDAH
is susceptible to damage by cellular oxidants, its protection by vitamin C and vitamin A allows normal ADMA removal and,
thus, normal NO formation.

ADMA ratios and attenuates monocyte and T-lymphocyte adhesiveness. For some patients, these changes may
lead to lower rates of atherosclerotic plaque formation
and lower risk of heart disease.208 Such responses are
modulated by other dietary and lifestyle factors. Acute
coronary events for middle-aged men in Finland, where
animal protein intake is among the highest, do not show
a relationship to dietary arginine intake.209

## Citrulline (Cit)
H
H2N

COOH

CITRULLINE

The amino acid citrulline gets its name from its
high concentration in the watermelon Citrullus vulgaris. In human kidneys, citrulline and aspartic acid are
united by argininosuccinate synthetase (ASS) to produce arginosuccinate (Pathway 6 of Figure 4.10). The
degradation of arginosuccinate to fumarate and arginine
is a primary mechanism for sustaining plasma levels of
arginine. The same enzyme acts in liver cells to complete
the urea cycle (Step 3 in Figure 4.9). Plasma citrulline
has been used as a marker for reduced small intestinal
mass,210 intestinal injury and rejection of small bowel
transplants.211 Plasma citrulline rises in proportion to enterocytes mass, reflecting the unique capacity of enterocytes for net conversion of glutamine into citrulline.
Both classic and type II citrullinemia are associated
with known gene alterations. Plasma citrulline elevation is also used as a marker of postoperative intestinal
failure.210 Nitric oxide (NO) synthesis from arginine
results in lower production of citrulline. Low availability
of NO may be due to inactivation of NO or inhibition of
synthesis, which may be detected by lowered production
of citrulline.212
High plasma or urinary citrulline can indicate a
functional block in the argininosuccinate synthetase
(ASS) enzyme, leading to a buildup of excess ammonia
in the system.
Supplementation of magnesium and aspartic acid
may help to drive this reaction forward. Arginine restriction may also be used to decrease citrulline levels.
Plasma citrulline declined by 30% in adult males receiving an arginine-free diet,181 and protein restriction in one
infant resulted in lowered plasma citrulline.213 Arginine
loading results in increased citrulline values.214

NH2

N
O

positive effect on the arginine/ADMA ratio. Pain-free
walking distance is linearly correlated with lower ADMA
levels in atherosclerotic patients.193
Clinical Relevance: High plasma ADMA signals
lack of nitric oxide stimulation of cell activities. Levels of
ADMA high enough to inhibit nitric oxide synthase have
been found in renal failure,194,195 hypertension, hypercholesterolemia, preeclampsia,196 diabetes mellitus,197 tobacco use and aging.198 Atherosclerosis is marked by impaired vasodilation in response to normal physiological
stimuli.199 A number of standard heart disease risk factors
(smoking, hypertension, hyperlipidemias) are related to
vasodilatory impairment, but the strongest correlation
may be the ratio of arginine to ADMA in plasma.200 This
ratio has been used to assess the balance of stimulatory
and inhibitory effects on NO synthesis.201 Elaboration of
endothelium-derived nitric oxide affects the behavior of
circulating T lymphocytes and monocytes.202
Patients with atherosclerosis or with risk factors
for atherosclerosis have a defect in endothelium-dependent vasodilator function, which is related to decreased
activity of NO. In hypercholesterolemia, elevated plasma
levels of ADMA reduce NO synthesis. The lipid-induced
impairment of angiogenesis can be reversed by oral administration of arginine. This mechanism may account
for the benefit of arginine in nutrient-based interventions for fibrosarcoma.203 A synthetic NOS inhibitor
has been found to have potent antiangiogenic effects in
multiple myeloma induced in mice.204 These findings
point up the need to assess arginine and ADMA status
when arginine therapy is considered.
In patients with type-2 diabetes mellitus, plasma
ADMA increases from 1.0 to 2.5 mmol/L 5 hours after
ingestion of a high-fat meal, indicating that ADMA may
contribute to abnormal blood flow responses and to
atherogenesis in this population.197 In essential hypertension, urinary excretion rate of nitrite plus nitrate (or
NO production) is lowered from 77 to 56 µmol/mmol
creatinine, whereas plasma levels of ADMA increase
from 1.1 to 2.4 µM, compared with normotensive
controls.205 This shows that the two molecules have an
inverse relationship. Other findings suggest that ADMA
plays an important role in the pathogenesis of hypertension-associated loss of kidney function.206
Treatment: The inhibitory effect of ADMA on NO
production may be overcome with the use of supplemental arginine.207 Oral administration of 14 to 21
grams of arginine daily normalizes plasma arginine-

## Ornithine (Orn)
COOH
H2N
NH2

In the final step in which urea is produced in the
urea cycle, ornithine is also produced (Figure 4.9). The
enzyme ornithine carbamoyl transferase then initiates
another turn of the cycle by catalyzing the reaction of
ornithine with carbamoyl phosphate. The most common inherited condition of the urea cycle enzymes is
ornithine transcarbamylase (OTC) deficiency where
hyperammonemia is the dominant clinical feature.
The incidence is estimated to be as high as 1:20,000.
A report appearing in 2006 indicated that 341 mutations of the OTC gene had been reported. 215 Patients
with these inherited traits may show elevated plasma
glutamine, proline, lysine, valine and methionine, but
ornithine is usually normal.216 An alternative scenario for
ornithine metabolism is genetic polymorphic impairment of ornithine transport into the mitochondria.
These patients show hyperammonemia and hyperargininemia along with the hyperornithinemia, leading
to the common abbreviation of HHH for this genetic
scenario. HHH patients have elevated plasma ornithine
even though the urea cycle fails due to inadequate ornithine in the mitochondrial matrix. Hyperammonemia,
again, is the cardinal sign that is detected by plasma
ammonia measurement or by urinary orotic aciduria as
described in Chapter 6, “Organic Acids.” Supplemental
ornithine (6 g/d) helps patients with HHH to achieve
lower ammonia, while raising plasma ornithine to even
higher levels.217 Many polymorphisms of the OTC
gene display as less severe symptoms that may lead to
diagnosis only late in life. One report describes a case

ORNITHINE

that was diagnosed at 32-years-old after a history of
recurrent episodes of vomiting, meat refusal, lethargy
and convulsions since childhood.10 Another adult-onset
form produces postpartum coma in women with the
polymorphism.218
When hepatic failure is induced in pigs, both
ornithine and citrulline become greatly elevated.219 High
levels are found when there is a blockage of the urea
cycle at the critical ammonia incorporation step, leading
to a higher body burden of ammonia.
α-Ketoglutaric acid, vitamin B6 and magnesium are
useful in clearing chronic minor excesses of ammonia.220
A low-protein diet will also decrease nitrogen as a source
of ammonia. Gut bacteria are also a major source of ammonia. Ornithine is also a precursor to the polyamines,
putrescine, spermidine and spermine.221 High ornithine
levels may have effects on these regulatory amines.
Cases of low levels of ornithine are rare, but could
suggest impaired control of growth hormone (GH).
Ornithine serves as a source of polyamines that regulate
cellular metabolism. Ornithine can stimulate release
of GH from the pituitary,222 and thus may serve as an
important anabolic substance for the body. Growth hormone responsiveness to ornithine stimulation has been
used to assess abnormal growth rates in children.223 Urea
cycle effects due to low ornithine may be corrected with
arginine supplementation.162
In patients with urea cycle deficits, sodium benzoate
therapy has been used to lower nitrogen load by causing
increased excretion of glycine. However, the therapy has
been shown to cause insufficiency of carnitine224 and it
can cause glycine insufficiency.225
Refer to Case Illustration 4.3

Notes:

## Aspartic Acid (Asp)
HOOC

COOH
NH2

## Asparagine (Asn)

COOH

H2N

ASPARTIC ACID

Aspartic acid, or aspartate, is pivotal in amino acid
metabolism. Aspartic acid aids in the detoxification
of ammonia via the urea cycle (Figure 4.9). It is also
a precursor of nucleic acids used in DNA and RNA.
Low levels of aspartic acid may reflect lowered cellular energy-generating capacity, experienced as chronic
fatigue. Aspartic acid can enter the citric acid cycle by
conversion to oxaloacetic acid in the presence of B6 and
α-ketoglutaric acid and equimolar amounts of citric and
aspartic acids drive both the citric acid and urea cycles,
in the presence of those cofactors. These metabolic considerations suggest that, when aspartate is high, B6 and
α-ketoglutarate may assist the conversion to oxaloacetic
acid. Magnesium and zinc are also relevant cofactors that
can help normalize high aspartic acid.
Simultaneous administration of aspartic acid and
arginine leads to increases in neurostimulatory amino
acids in the brain226 and to multiple organ-specific
changes.227 Increases of GABA in brain, ornithine and
proline in liver and serine, glycine and alanine in all
tissues were found when aspartic acid was given along
with arginine. Aspartic acid administration has been
shown to increase stamina and resistance to fatigue.228

Although, the plasma and urinary levels of asparagine can vary over relatively wide ranges with little
clinical consequence, evidence of physiological roles of
asparagine comes from treatment of lymphoblastic leukemia with l-asparaginase. This enzyme cleaves asparagine to aspartic acid and ammonia, resulting in depletion of asparagine levels and cleavage of the asparagine
attachment site for polysaccharide chains used in cell
identity. Serum asparagine concentrations decline approximately ten-fold during therapy.229 Administration of
asparaginase produces decreases of serum albumin, cholesterol, insulin, fibrinogen and clotting factors, along
with dramatic reduction in serum thyroxin-binding
globulin.230 Asparagine-rich proteins such as antithrombin III are reduced as a result of the lowered plasma
asparagine concentrations.231 Monitoring of plasma asparagine levels is a useful means of determining dosage
schedule of l- asparaginase.232 Plasma asparagine does
not fall in individuals who are resistant to the enzyme.
The evidence from such chemotherapeutic applications suggests that other patients with chronic low
asparagine levels may experience some degree of the
metabolic fates described. However, there are no reports
that allow firm conclusions of such effects.

O

NH2

ASPARAGINE

Asparagine is needed in all tissues for protein synthesis and it serves a special function for attachment of
carbohydrate residues to membrane proteins by which
cells are identified. The enzyme, aspartate ammonia
ligase, converts aspartate to asparagine by addition of
ammonia to form the amide group of the side chain.
This link to aspartic acid has two potential consequences
in amino acid profiles. Individuals with normal activity
of the ligase tend to have aspartic acid and asparagine
in similar relative positions, depending largely on the
availability of aspartic acid. On the other hand, reports
showing high aspartic acid with low asparagine suggest
polymorphism of the ligase that causes reduced activity.
Notes:

Essential Amino Acids for
Proteins and Energy
The Branched-Chain Amino Acids (BCAA):
Valine (Val)
H3C

COOH

H3C

NH2

Leucine (Leu)
COOH

H3C

NH2

H3C

means that brain synthesis of serotonin and dopamine
from dietary tryptophan and tyrosine is dampened due
to the presence of BCAA in food because the BCAA
reduce the rate of transfer across the blood-brain barrier.
Because of their nitrogen-sparing effects, the BCAA have
been used clinically for recovery from surgery, trauma
and sepsis and in diabetic regulation. The stress-induced
decrease of muscle protein synthesis can be prevented
by supplementation with a balanced BCAA formula.233
The Branched-Chain Ketoacid Dehydrogenase
Complex: In skeletal muscle, the BCAA are converted
to their respective ketoacids via a branched-chain amino
acid transaminase, requiring the cofactor pyridoxal
5-phosphate, which is the biochemically active form of
vitamin B6 (pyridoxine). This is the primary reason that
vitamin B6 is critical for amino acid metabolism.234 High
levels of BCAA in plasma may result from inadequate
vitamin B6. BCAA utilization is impaired and BCAA excretion in urine is elevated when the cofactor is lacking.
The ketoacids are catabolized by the branchedchain α-ketoacid dehydrogenase complex (BCKDC).
This enzyme is very active in skeletal muscle, which
is the primary site for catabolism of BCAA.235 The full
BCKDC system is a multienzyme complex with subunits
dependent on the nutrient-derived cofactors thiamin as
thiamin pyrophosphate (ThPP), riboflavin (FAD), niacin
(NAD) and pantothenic acid (coenzyme A, vitamin B5).
In addition, lipoate must be attached to one of the subunits as a prosthetic group. The net effect of these BCAA
catabolic reactions is to pass carbons into the citric acid
cycle for energy production. Normally, high urinary or
plasma levels of BCAAs indicate deficiencies of vitamin
B6 or the vitamins required by the BCKDC. Adequacy of
the nutrient cofactors for BCKDC can be measured in
urine (Chapter 6, “Organic Acids”). A genetic mutation
of BCKDC produces extreme elevations of plasma and
urinary BCAA seen in maple syrup urine disease.236
Pantothenic acid supplementation has also proven
useful in these situations since it conserves the sulfurcontaining amino acids by improving cellular energyyielding pathways.237 Chronic depletion of BCAAs will
eventually show up as low urine and plasma levels, with
loss of muscle mass and protein synthesis capabilities
sometimes experienced as alopecia and sarcopenia.
Catabolic and Anabolic Hormone Effects: Metabolic acidosis associated with the catabolic state inhibits
BCKDC, so the BCAA tend to rise. On the other hand,
the BCAA tend to fall when the BCKDC responds in

Isoleucine (Ile)

CH3

NH2

The branched-chain amino acids valine, leucine and
ISOLEUCINE
isoleucine are used for peptide and protein synthesis.
They do not serve as precursors to other non-peptide
products as do most other essential amino acids. The
BCAA are ubiquitous among the great variety of proteins
that serve as enzymes, transports and structural components of cells, where their hydrocarbon side chains
provide the majority of the hydrophobic inner protein
domains. The BCAA make up 35% of muscle proteins
and comprise almost 50% of the amino acids in dietary
protein. Collectively they make up the largest supply of
circulating EAA. The factors that govern their plasma
concentrations act so that the flow into metabolic
pathways meets whole-body demands during times of
metabolic crisis and renewal.
During strenuous muscle activity, BCAA serve as
a source of energy, because they participate in transamination reactions that result in flow of alanine and
glutamine from skeletal muscle to the liver and kidney,
where they may form glucose. The carbon skeletons of
isoleucine and valine are catabolized to succinate, a key
intermediate in the citric acid cycle. In the brain, the
BCAA play a role in the control of amino acid-derived
neurotransmitter metabolism by competing with other
large neutral amino acids like tryptophan for the pumping systems controlling the blood-brain barrier. That

COOH

H3C

diabetic microangiopathy.248 Skeletal muscle is a major
destination for plasma BCAA. Their incorporation into
muscle protein is dependent on insulin-like growth factor-I (IGF-I), but for different reasons. IGF-I stimulates
protein synthesis, whereas insulin inhibits protein breakdown by stimulating amino acid uptake. Muscle protein
synthesis is increased when plasma amino acid levels are
raised, as demonstrated in studies using phenylalanine
infusion.249 The net effect is that decreasing IGF-I levels
with insulin insensitivity leads to higher plasma BCAA
levels. Conversely, raising BCAA levels in plasma in the
presence of a normal insulin response increases lean
body mass in response to exercise.
Elevations in Plasma: Excessive dietary intake can
affect plasma levels of these amino acids and will generally cause elevation in urinary amino acid levels. Such
excessive intake is common among athletes, especially
body builders who may consume large amounts of protein powders in addition to maintaining a high-protein
diet. An enriched infusion of BCAA increases nocturnal
respiration in normal adults250 and normalizes food
intake in patients on total parenteral nutrition. The flow
of BCAA into blood suppresses gastric emptying after
a meal containing protein to allow proper digestion of
protein in the acid milieu of the stomach.251
Leucine-Specific Considerations: Leucine is
among the most abundant amino acids in animal tissues.
It has been proposed as a regulator of protein metabolism because it surpasses all other amino acids in inhibiting muscle protein degradation. Because of reduced
rates of release from skeletal muscle, plasma essential
amino acids tend to fall when leucine is abundant.252
The finding of such a regulatory role for a single amino
acid reinforces the benefit of balanced intake of all essential amino acids. It is not recommended to supplement leucine alone because it can have undesired effects.
Instead, a balanced amino acid mixture is appropriate.

a way that transmits catabolic and anabolic hormone
signals to exert metabolic control. Under a variety of
stressful conditions associated with changes in circulating glucocorticoids the BCKDC complex is activated
(Figure 4.12). In renal failure, two catabolic signals,
glucocorticoids and acidification, stimulate activation of
BCKDC, resulting in BCAA degradation, thereby lowering plasma concentrations of BCAA.238
Anabolic hormones act in an opposing manner by
inactivating BCKDC, thus decreasing the breakdown
of BCKA and raising plasma levels of the BCAA.239 In
females, the sudden need for protein synthesis for uterine reconstruction after menses is availed by a supply
of amino acids. Amino acid mixtures and testosterone
have similar anabolic effects in older men.240 Testosterone injection increases net protein synthesis without
changing amino acid transport,241 and plasma BCAA rise
along with testosterone and dehydroepiandrosterone
sulfate (DHEA-S) during intense athletic training.242 The
corresponding removal of BCAA from energy-yielding
pathways during such anabolic phases causes increased
oxidation of glucose and fatty acids, often accompanied
by increased appetite.
A reported case of high plasma BCAA was unremarkable until the patient became comatose during an
infection and died at the age of 4 1/2 years.243 Propionic
acidemia resulted from mutations in genes encoding propionyl-CoA-carboxylase. Plasma BCAAs were
elevated in spite of the associated acidosis that should
have activated BCKDC and consequently degraded the
BCAA.The two missense mutations found in this case
did not result in clinical presentation until an infection
caused failure of metabolic compensation. This case
demonstrates that late onset of symptoms may be found
in older populations with less disruptive mutations.
Late-onset propionic acidemia patients are found
to suffer from abnormal psychomotor development and
show mental and psychological disabilities.244 Accumulation of toxic metabolites can impair mitochondrial energy production, especially in regions of the brain with a
high rate of aerobic (mitochondrial) metabolism, such as
in basal ganglia.245,246 Toxic substances have been shown
to cause hyperammonemia in propionic academia by
inhibiting urea cycle enzymes.247
An active insulin response is required for clearing of
amino acids from plasma. BCAA levels are increased in
non–insulin-dependent diabetes mellitus (NIDDM) and
the sustained elevated levels may be a causative factor in
Notes:

Branch-chain
Amino Acids (BCAA)

Branch-chain
Ketoacids (BCKA)

Valine

BCAA
Transaminase

α-Ketoisovalerate

Leucine

B6

α-Ketoisocaproate

Isoleucine

α-Keto-β-methylvalerate

BCKDC

Glucocorticoids

Cofactors

B1 -TPP
B2 -FMN
B3 -NAD
B5 -CoA
Lipoic Acid

Metabolic Acidosis

FMNH2

NADH

Anabolic Hormones

Isobutyryl-CoA
Isovaleryl-CoA
α-Methylbutyryl-CoA

Glucose

Oxidized Intermediates
Succinate

Fatty Acids

CAC

ATP+CO2+H2O

Figure 4.12 — Multiple Levels of Plasma BCAA Regulation
The non-reversible committed step of the catabolic pathway is controlled by the branched-chain ketoacid dehydrogenase
complex (BCKDC). The BCKDC contains multiples of three separate enzymes shown as colored spheres. Cofactors derived
from five B-complex vitamins are required for the full enzyme activity to accomplish this single step. Hormones and
metabolic factors regulate the BCKDC via two other enzymes that activate (phosphatase) or inactivate (kinase) in the BCKDC
enzyme complex. The phosphatase and kinase, in turn, respond to various hormonal controls, transmitting their signals to
the metabolic level. The net effect is to regulate tissue building and breakdown via plasma amino acids. Normal responses to
hormones depend on activity of the BCKCD that, in turn, depends on supply of the essential nutrient cofactor precursors.

## Threonine (Thr)
OH
H3C

COOH
NH2

THREONINE

Threonine (Thr) is typically the second or third limiting amino acid in vegetarian diets, following methionine
or lysine. This means that dietary supply of proteins
with balanced content of threonine is critical for protein
synthesis and tissue maintenance. Since threonine is
metabolized differently in humans than in most animals
(Figure 4.13), data from animal studies should be interpreted with caution.253 Results from animal experiments
can still shed light on some aspects of threonine assessment. An early study of dietary influence in rats showed
plasma concentrations of threonine and threonine flux
into brain shifting in proportion to long-term dietary
protein content.254 Plasma threonine then increased from
3- to 5-fold when the animals were fed a very high-protein
meal (50% casein), indicating slow hepatic clearance of
threonine. α-Amino-N-butyric acid (α-ANB) is a competitor for the threonine transporter. Animals maintained on
low-protein diets with added α-ANB have low threonine
with decreased growth and food intake, which could be
corrected by adding threonine to the diet. These results
were interpreted as evidence that individual amino acid
supplements can induce imbalanced amino acid status.255
The matter of disposition of the α-ketobutyrate
from threonine catabolism is of importance and is

discussed in Chapter 6, “Organic Acids.” The urinary
organic acid α-hydroxybutyrate (AHB) is a marker
of hepatic glutathione synthesis via the conversion of
homocysteine to cysteine. The contribution of threonine
catabolism to urinary AHB levels should be relatively
constant for a given individual. Additionally, threonine
catabolism is not likely to significantly contribute to
urinary AHB because mitochondrial threonine dehydratase favors oxidation of the precursor, α-ketobutyrate,
to propionate rather than reduction to AHB. Evidence
for this in humans is found in an analysis of plasma
threonine versus urinary AHB in retrospective data from
analyses of a general outpatient population in a clinical
laboratory550 (Figure 4.14). There is no trend to higher
AHB levels as plasma threonine varies over a range of
20 to 200 µmol/L, confirming that increasing levels of
plasma threonine produce no proportional increase in
urinary AHB.
Exercise induces greater uptake of threonine than
any other amino acid in cardiac tissue of thoroughbred
horses.256 Humans on high-protein diets, however, may
have elevated plasma threonine due to the limited number of pathways for clearing this amino acid. In the early
stages of dietary protein deficiency, plasma threonine is
uniquely stable in contrast to most other essential amino
acids.51 This effect is likely due to the lack of metabolic
requirements for threonine other than protein synthesis.
After 12 months of human growth hormone (GH) treatment, children with GH deficiency had higher fasting
serum concentrations of most amino acids, whereas
Glycine + Acetaldehyde

lase

Aldo

Threonine

Dehydrogenase

Deh

2-Aminoacetoacetate

ydra

tase

NADH
NH4

NAD
α-Hydroxybutyrate

α-Ketobutyrate
Propionate

Succinate

Figure 4.13 — Differentiation of Human Threonine Metabolism
Biochemical pathway charts may indicate the three catabolic pathways for threonine shown in this diagram. Man and
chimpanzees have weak expression of genes for the aldolase and dehydrogenase enzymes, leaving only the deydratase
pathway for threonine clearance. The mitochondrial location of this enzyme results in efficient oxidation of α-ketobutyrate
to propionate. Reduction to α-hydroxybutyrate is favored when cytosolic conversion of homocysteine to cysteine produces
α-ketobutyrate (Figure 4.21). Dashed arrows indicate pathways active in bacteria and most vertebrates and solid lines indicate
human pathways. The light blue arrows indicate the improbable conversion in mitochondria.

Histidine (His)
Urinary α-Hyrdoxybutyrate (ug/mg creatinine)

Plasma Threonine vs. Urinary AHB

COOH
HN
N

NH2
HISTIDINE
Plasma Threonine (uM)

Figure 4.14 — Plasma Threonine vs.

No increase of urinary α-hydroxybutyrate is found over
the entire range of plasma threonine in 486 general
outpatient profiles where plasma amino acids and
urinary organic acids were performed. The evidence
argues against significant activity of ketobutyrate
dehydrogenase in clearing of excess threonine and it
suggests the conclusion that urinary α-hydroxybutyrate
is largely derived from the glutathione synthetic pathway
illustrated in Figure 4.20.

Urinary α-Hydroxybutyrate

Although histidine cannot be synthesized in human
tissues, nitrogen balance in healthy adults is sustained
even on a histidine-free diet. A histidine-free diet caused
a 26% linear decline in whole-body protein turnover,
whereas urinary excretion of nitrogen, urea, creatinine
and 3-methylhistidine were not affected.259 Plasma
histidine declined steadily over 48 days to 38% of initial
values, whereas urinary histidine dropped by 51% over
the first three days, then continued to decline to 18% of
initial levels. The rate of release from hemoglobin and
carnosine, both of which are in large supply in wellnourished individuals, suggests that these two sources can
act as a reservoir of His. Carnosine (β-alanyl-histidine) is
abundant in skeletal muscle (see the section, “Carnosine
and Anserine” later in this chapter).
Histidine, Folate Deficiency and Anemia: As
discussed more fully in the Chapter 2, “Vitamins” and
Chapter 6, “Organic Acids”, the appearance of formiminoglutamate (FIGLU), a degradation product of histidine
catabolism, in urine is a functional marker for folate
status (Figure 4.15). The histidine catabolic pathway
provides a sensitive source for such a biochemical
marker due to the relatively high flux of excess histidine
through this pathway.260 The FIGLU test sensitivity may
be increased by administering three 5 g doses of l-histidine hydrochloride monohydrate in 4-hour intervals as
a metabolic challenge on the day before the overnight
urine collection.14 The histidine challenge dose causes
a rapid rise of histidine that has been found to alleviate
the anemia associated with folic acid deficiency. Since
chronic folic acid deficiency reduces the flow of histidine
through the catabolic pathway, one might think that histidine losses would be lowered and there would be little
effect of added histidine. The explanation apparently lies
in the inefficiency of renal histidine recovery (causing
histidine to be the most abundant amino acid in healthy
urine). Histidine that is not catabolized in the liver due
to folate deficiency simply spills into urine because
the renal threshold is easily exceeded. Thus, folic acid
deficiency results in increased urinary loss of histidine,
leading to histidine depletion and lack of availability
for protein synthesis. Synthesis of hemoglobin falls as

threonine decreased significantly.257 The GH-induced
retention of nitrogen and increased amino acids was unable to prevent threonine losses.
Interpretation and Treatment: A pattern of low
EAA levels with threonine above the 4th quintile indicates inadequate assimilation of dietary protein. This
may be due to low protein intake or poor digestive
factors. The opposite pattern of low threonine while
other EAA are normal may be due to factors such as
hormonal imbalance causing a catabolic state.
Oral threonine doses of 7.5 g/d can raise plasma
threonine levels to the upper range of normal.258 In
multiple sclerosis (MS), supplementation of threonine
is a potential non-sedating, non-toxic approach to the
management of spasticity. The effect is due to threonineassisted glycine generation and postsynaptic inhibition
of the motor reflex arc in the spinal cord.258 The plasma
phenylalanine-lowering effects of threonine are described
under the section, “Phenylalanine (Phe) and Tyrosine (Tyr)”
later in this chapter.
Generation of glycine from threonine can provide for
special glycine needs in conditions demanding glycine,
such as glutathione loss due to oxidative stress or toxicant
challenge requiring glycine conjugation.

augmented the protective effects of phenytoin without augmentation of unwanted effects on memory and
motor performance.263 Similar effects were found with
carbamazepine in rats.
Histamine is critical for brain arousal264 and plays
a suppressive role in seizure development and sleep
disorders.15,16 The relationship of histamine to changing
histidine concentrations depends on the relative rates
of histamine formation and degradation. In the mouse
model, peripheral loading with a high dose of histidine
produces the same antinociceptive effect as activation
of brain histamine.265 Animals given oral l-histidine at
1,000 mg/kg twice daily showed increased histamine
levels in the brain, although plasma histidine did not
change.266 Thus, the brain can utilize excess histidine
to increase histamine and modulate neuronal activity.
(See the SN1 and SN2 transporters discussed in the “Of
Further Interest” box on page 193.)

Refer to Case Illustration 4.4

Interpretation of Laboratory Results: Chronic
high rates of histamine production tend to produce
lowered levels of plasma and urinary histidine because
of increased utilization. The origin of the histaminic
stimulation should be investigated and supplementation of histidine may need to be done carefully to avoid
further promoting histamine output. Moderate dosing
with formulas containing all essential amino acids in balanced proportions are generally safe and effective. Low
plasma histidine levels have been associated with rheumatoid arthritis.267 Histidine supplementation (around
4,000 mg per day) raises levels in blood and reduces
arthritic symptoms in rheumatoid arthritic patients.267 In
addition to the low folate contributions described above,
low dietary protein intake or malabsorption syndromes
should be considered as explanations of low histidine
levels, particularly if low levels of other essential amino
acids exist.
Elevated plasma or urinary histidine can result
from muscle protein breakdown because skeletal muscle
is relatively rich in histidine. High 3-methylhistidine
(discussed below) may confirm this situation. Finding a
pattern of elevated histidine, glutamine and asparagine is
indicative of either genetic polymorphism or toxic interactions at the SN1-SN2 transporter system because this
is the only mechanism known to uniquely affect these

histidine levels become a limiting factor (histidine comprises 10% of the amino acids in hemoglobin). Thus, the
histidine challenge procedure for assessing folic acid status provides an instance where the test for a deficiency
alleviates one of its effects (anemia).
Other studies confirm that histidine supplementation can overcome anemia in folic acid-deficient
patients, apparently by stimulating hemoglobin synthesis. In eight folic acid-deficient patients, doses of 5 g lhistidine hydrochloride monohydrate dissolved in apple
juice, taken 3 times daily, produced an average increase
in reticulocytes from 0.5 to 8.9 %, whereas mean hemoglobin rose from 8.1 to 12.1 g/dL.14 In folic acid deficiency, urinary excretion of histidine and the histidine
metabolite FIGLU is increased (see Chapter 6, “Organic
Acids”). Folic acid deficiency seems to exacerbate the
relatively poor renal resorption of histidine, causing
greater losses. With histidine administration, urinary
histidine increased by 4-fold, whereas FIGLU excretion
increased by 10-fold compared with normal controls.261
Histidine is converted into histamine by a singlestep reaction catalyzed by histidine decarboxylase (Figure 4.15). In extrahepatic tissues, histamine is cleared
by methylation via transfer from S-adenosylmethionine.
Hepatic tissue clears circulating histamine via a copperdependent amino oxidase, whereas postprandial excess
histidine is removed by conversion to glutamic acid via
FIGLU. Histamine elicits physiological responses by
binding to receptors in target tissues. Histamine receptor
types H1, H2 and H3 are found in a variety of tissues
and cell types.262
Histamine is synthesized and stored in mast cells,
basophils and enterochromaffin cells. In the allergic
response, mast cells degranulate, releasing histamine
that binds to H1 receptors in the smooth muscles of
airway, gastrointestinal tract and cardiovascular tissues.
The H1 receptor is antagonized by antihistamines. In the
stomach, histamine released by enterochromaffin-like
cells binds to H2 receptors initiating a cascade of events
that lead to secretion of hydrochloric acid.
Hypothalamic neurons that project into most cerebral areas of the brain synthesize histamine as a neurotransmitter, exerting control over sleep, wakefulness,
hormonal secretion, cardiovascular control, thermoregulation, food intake and memory formation. Because of
the enhancement of histamine neurotransmission, histidine has been found to serve as a beneficial adjuvant for
selected antiepileptic drugs. Thus, histidine (500 mg/kg)

three amino acids. Outpatient data collected at Metametrix, Inc., show a strong positive relationship between
histidine and glutamine in plasma amino acid profiles.
A similar relationship is found for histidine and asparagine and such associations are lacking for the other EAA.
These population-based correlations of Gln, Asn and His
provide evidence that SN1-SN2 transporter system effects
may be dominant factors in regulating His levels.

Salicylates and steroids lower histidine levels and
folic acid deficiency leads to increased catabolism in
addition to increased renal losses of histidine.268,269 Histidine supplementation of diabetic mice raises plasma and
tissue concentrations of histidine in a dose-responsive
manner with consequently improved hyperglycemia,
hyperlipidemia, oxidation and inflammation.270
Mammary histidine decarboxylase activity and
expression of H1 and H2 receptors undergo significant increase during pregnancy and lactation.271 This

Refer to Case Illustration 4.5

response increases the risk of histidine deficiency for
women during pregnancy and lactation.
Contraindications: In rats, excessive histidine
intake has been associated with hypercholesterolemia272
and increased hepatic glycogen.273 Oral l-histidine
should be used with caution in zinc- or copper-deficient
patients because rapid rises of plasma histidine cause
stripping of the elements from albumin binding sites
and tissue zinc depletion.274 This effect is easily offset
with extra zinc intake. However, patient responses to
oral histidine may be due to changes in zinc status. Food
intake suppression caused by l-histidine supplementation may be due to loss of taste due to zinc depletion
rather than to neuronal effects of the added histidine.275
Gene expression for metallothionein 1, the most abundant form in the liver, was markedly lowered in rats fed
a histamine-excessive diet for five days, apparently due
to complexation of copper and zinc.276 Reports of such
effects should lead to caution regarding aggressive histidine, except where laboratory data indicate a histidinedepleted or folic acid deficient status.

LYMPHOCYTES
AND
NEURONS

H

N+

See Chapter 6,
“Organic Acids”

HN

N

N(tau)-Methylhistamine
SAH
Histimine
N-methyltransferase

SAM
COOH

Histamine

Histidine decarboxylase
N

NH2

H3C

NH2

HN

CO2

L-Histidine

Amine oxidase
Formiminoglutamic Acid
THF
C

N

NH2

Cu2+
FAD

O

Glutamic Acid
HN

N

H

LIVER

Imidazole Acetaldehyde

Figure 4.15 — Histidine Metabolism
Histidine decarboxylase converts L-histidine into histamine in lymphocytes and histaminergic neurons. In those
tissues, methylation of the ring nitrogen causes the removal of histamine from the cell and ultimate excretion of
N(tau)-methylhistamine. Hepatic clearance of circulating histamine is facilitated by the alternative pathway of coppercatalyzed oxidation to imidazole acetaldehyde.

Lysine (Lys)
H2N

COOH
NH2
LYSINE

alpha-Aminoadipic Acid (α-AAA)
HOOC
NH2
α-Aminoadipic Acid

Pipecolic Acid

COOH

Lysine metabolism is unique in that its degradation does not involve an initial transamination, so lysine
plasma levels are not elevated like other amino acids
by deficiency of vitamin B6. Instead, lysine undergoes a
unique reaction with α-ketoglutarate in the mitochondria to form a stable intermediate called saccharopine
(Figure 4.16) that is further degraded to alpha-aminoadipic acid (α-aminoadipic acid, α-AAA). Elevated
α-aminoadipic acid is a clue that a patient is consuming
large amounts of lysine.277 Elevated lysine can result
from deficiency of any of the three enzymes required
for the catabolic pathway. Some evidence also points
to low mitochondrial α-KG as a cause of high plasma
lysine.278 Since further conversion of α-aminoadipic acid
to α-ketoadipic acid involves a transamination requiring
vitamin B6, elevation of α-aminoadipic acid could result
from vitamin B6 deficiency.
The normal hepatic mitochondrial pathway through
saccharopine to α-aminoadipic acid and glutamate is
strongly influenced by availability of α-KG. The hepatic
conversion of lysine to pipecolic acid is a peroxisomal
pathway used for removal of excess lysine under conditions of abnormal loading.279 In the brain, however,
lysine catabolism leads primarily to pipecolic acid formation. This tissue-specific catabolic end product is of
significance because pipecolic acid modulates neuronal
activity as discussed under “GABA Receptor Actions of
Pipecolic Acid,” on the following page.
Lysine is high in meats and dairy, whereas it is lower
in corn and many plant proteins. This accounts for the
higher risk of lysine deficiency among people whose

N

diet is low in animal products and restricted in a variety
of vegetables. Plasma concentrations of lysine and its
metabolite, carnitine, decrease in parallel fashion with
dietary intake of lysine when vegans, lacto-ovo-vegetarians and meat eaters are compared.280
Growth and Fatty Acid Metabolism: Lysine deficiency retards the growth rate of pigs, causing plasma
IGF-I levels to fall 52% lower than controls.281 Lysine is
the precursor for the synthesis of l-carnitine,282 which
shuttles fatty acids into the mitochondria for β-oxidation. Serum triglycerides are high in individuals on a
lysine-restricted diet because carnitine is essential in the
transport of fatty acids.283
The Gut and Anxiety: Enhancement of dietary
lysine has been proposed as part of the treatment plan
for irritable bowel syndrome.284 In rats, dietary lysine deficiency increases stress-induced anxiety with enhanced
serotonin release and greater fecal volume.284 In pigs,
transportation stress caused lowering of plasma lysine
and arginine. With lysine and arginine supplementation,
the effect was reversed, along with lowering of plasma
cortisol.285 Lysine fortification of wheat reduces anxiety
and stress in humans.286 The mechanism may be inhibition of stress-induced diarrhea via specific inhibition of
5-HT4 serotonin receptors. Lysine has not been shown
to affect other classes of serotonin receptors.287 These
findings can have relevance for 5-hydroxytryptophan
supplementation, which induces tachycardia via 5-HT4
receptors.288 In addition to their effect on diarrhea-predominant irritable bowel syndrome, 5-HT4 antagonists
(1) block corticosteroid secretion, (2) inhibit 5-HT-induced tachycardia and (3) reduce anxiety.289
Oral dosing with l-lysine (1 g/kg) reduced the effect
of stress on ureagenesis and reduced plasma arginine.290
These responses suggest that requirements for arginine
Notes:

Glutamate

2-Aminoadipate
Semialdehyde

Saccharopine
Saccharopine
Dehydrogenase
(Lysine forming)

Aminoadipate
Semialdehyde
Dehydrogenase

a-KG

Lysine

HN2

CH

B3

a-Aminoadipate

FADH2

aAAA

Pipecolate dehydrogenase

Pipecolic
acid

H2O+CO2

FAD

N

CH

B6, B2, Biotin
COOH

HOOC

Sacchoropine
Dehydrogenase
(Glutamate forming)

Figure 4.16 — Lysine Catabolism

The first step in lysine catabolism is dependent on availability of mitochondrial α-KG to form the stable intermediate,
saccharopine. Genetic deficiency of the enzyme saccharopine dehydrogenase produces hyperlysinemia that may respond to
the B-complex vitamins required for the alternate pathway. The bifunctional enzyme, saccharopine dehydrogenase, is also
used to cleave the peptide, releasing glutamate and α-aminoadipate semialdehyde. Ultimately, α-aminoadipate is formed.
The alternative, reversible pathway involving pipecolate formation occurs in peroxisomes, leading also to α-AAA formation.

are increased during lysine-modulated stress reduction.
The efficacy and safety of using customized mixtures
rather than individual high-potency essential amino
acids can be understood in light of these effects from
excessive or insufficient lysine.
Older therapeutic uses of lysine include herpes
simplex infections, cardiovascular disease and osteoporosis.291 The effect on herpes simplex, the most
extensively studied application, is apparently ascribed
to competitive inhibition with lysine residues on the
surface of the viral particles.292 The effect makes lysine a
useful prophylactic at serum concentrations of 165 µM
for cases of recurrent herpes simplex labialis.293 A similar
mechanism may be ascribed to the competition of free
plasma lysine with the lysine side chains of proteins
susceptible to glycation. Oral lysine supplementation
also reduces nonenzymatic glycation of glomerular basement membrane collagen and albuminuria in diabetic
rats.294 Amino acid mixtures with high levels of l-lysine
showed anticataractous and antidiabetic effects in rats.295

In diabetic human subjects lysine treatment increased
insulin sensitivity and decreased blood sugar an average
of 27%.296
GABA Receptor Actions of Pipecolic Acid: Pipecolic acid (PA) binds to GABA receptors in the brain.
Although pipecolic acid alone has little effect on brain
activity,297 it can potentiate the suppressing effects of
barbiturates on electrically and chemically induced convulsions.298 Pipecolate binding sites are most abundant
in cerebral cortex, thalamus and olfactory bulb,299 and
there is evidence that they are identical with the GABA
receptors.300
Refer to Case Illustration 4.6

Bicuculline and picrotoxin are agents that induce
convulsions similarly to strychnine. Coadministration of pipecolic acid protects against bicuculline- and
picrotoxin-induced convulsions induced via inhibition

to avoidance of dietary protein. As a result, attempts
to resolve the lysine deficiency with protein intake are
unsuccessful. Supplementation with l-lysine, however,
has been shown to normalize low plasma lysine that is
characteristic of LPI.310 To avoid profuse diarrhea it was
necessary to limit lysine doses to 7.3 mg/kg per dose,
given 3 times daily for 3 days.
Inability to absorb lysine may lead to bacterial overgrowth from lysine that passes into the transitional gut
where bacterial growth rates are maximal. From general
principles milder polymorphic forms of LPI are expected
to be encountered producing low plasma and urinary
lysine, possibly in the presence of normal levels of other
amino acids.
Interpretation of Laboratory Results: A low lysine
level is an indication of need for both l-carnitine and
lysine supplementation, particularly if there are signs of
muscle weakness, fatigue, or high serum triglycerides.311
Although lysine is not known to have direct influence
on brain function via neurotransmitters, the influence of
energy deficit due to lack of carnitine may be suspected
as a contributing factor in cases such as that illustrated
in the accompanying case illustration.

of GABAergic neurons.301 In rat brain, pipecolic acid
enhances GABA response without affecting glycine
responses.302 In cerebral cortex slices, pipecolic acid
inhibits neuronal GABA uptake and/or enhances its release, especially in the presence of β-alanine.303 Patients
with liver cirrhosis have elevated levels of GABA and
pipecolic acid in plasma. And plasma pipecolic acid
is closely correlated with plasma ammonia concentration.304 This study also revealed that the degree of portal
hypertension in cirrhotic patients may be predicted by
plasma PA. Intracerebroventricular injection of pipecolic
acid in chicks altered feeding and increased sleep-like
behavior,305 and the hyperphagic effect was attenuated
by both GABA-A and GABA-B receptor antagonists.305
Elevated plasma lysine can enhance pipecolic acid
formation in the brain. Central nervous system effects of
lysine loading like those found in Zellweger syndrome
can be due to modulation of GABA receptor binding
by l-pipecolic acid.306 Pipecolic aciduria and elevated
α-aminoadipic acid are found in the cerebrohepatorenal
syndrome of Zellweger.307
Genetics: Hyperlysinemia is found in many inborn
errors of metabolism, including urea cycle abnormalities,
pyruvate carboxylase deficiency and l-2-hydroxyglutaric
aciduria.9 Patients with one of the forms of ornithine
carbamoyl transferase (OCT) deficiency that causes
elevated lysine may benefit from extra α-ketoglutarate.
They may have concurrent high plasma levels of glutamate, glutamine, citrulline and argininosuccinic aciduria
(see Table 4.12). The evidence indicates that lysine degradation is regulated by bioavailability of mitochondrial
α-KG. Children with Down’s syndrome have higher
plasma lysine compared to controls.308
In contrast to hyperlysinemia, low lysine concentrations are found in the autosomal recessive disorder, lysinuric protein intolerance (LPI), caused by mutations in
the gene encoding the transporter of the dibasic amino
acids lysine, arginine and ornithine.309 Deficiencies of
lysine, arginine and ornithine are exacerbated in this
condition because post-prandial hyperammonemia leads

Refer to Case Illustration 4.7

High levels of lysine in fasting plasma or urine are
rare and if the cause is not identified as lysine supplementation, high levels may indicate an impaired ability
to metabolize lysine. Proper metabolism of lysine utilizes
vitamins B3 and B6. Vitamin C and iron are also needed
to normalize lysine.312 Elevated lysine in urine may also
be a result of urea cycle abnormalities that produce elevated plasma arginine. The high arginine seems to cause
excessive lysine spilling into urine by competition for a
shared transport protein active in amino acid resorption
in renal tubules. Also, carnitine supplementation tends
to raise plasma lysine through a sparing effect on lysine
conversion to carnitine.282

Table 4-12 — Genetic Variants Affecting Plasma Lysine

Lysine (pl)

Glu + Gln (pl)

High

High

Low

Low

α-KG (u)

Genetic Variants

Nutrient Therapy

Low

OCT def, Citrullinemia, Arginosuccinic aciduria

α-KG

High

α-KG dehydrogenase deficiency

Thiamin, lipoate

Plasma (pl), urine (u), alpha-ketoglutaric acid (α-KG) and ornithine carbamoyl transferase (OCT)

Neurotransmitter Precursors
Phenylalanine (Phe)
COOH

NH2

Tyrosine (Tyr)

PHENYLALANINE

COOH
NH2
HO

TYROSINE

In addition to the direct neurotransmitter roles of
glycine, aspartic acid, glutamic acid and γ-amino butyric
acid (GABA), the aromatic amino acids (phenylalanine,
tyrosine and tryptophan) are converted to catecholamines and serotonin by enzymes in adrenal, intestinal,
brain and peripheral nervous tissue. Plasma levels of
these amino acids influence neuronal concentrations of
the respective neurotransmitters. The blood-brain barrier, formed by astrocyte end plates that surround blood
sinuses in the brain, filters the entry of specific amino
acids, preventing rapid changes in concentrations within
the neuron. The transport system operates on all amino
acids that have large, neutral side chains (the LNAA). In
addition to the aromatic amino acids, the BCAA are also
LNAA. This transporter sharing is a reason that supplying an equal amount of any single amino acid in the
presence of other LNAA reduces the rate of transfer into
the brain compared with dosing with the pure amino
acid. Thus, tryptophan alone causes more serotonin
increase in the brain than a mixture of tryptophan with
other LNAA. The neurons store their respective neurotransmitters in granules and synaptic release initiates
neural responses.
Phenylalanine and tyrosine are in the chemical family of aromatic amino acids because they have benzene or
para-hydroxy benzene rings of their side chains. Phenylalanine is an essential amino acid that is ubiquitous in
the structure of major proteins except for collagen. Since
human tissues normally possess an enzyme that will
convert phenylalanine to tyrosine, both of these amino
acids are precursors to the catecholamines (DOPA,
dopamine, norepinephrine and epinephrine), melanin
and thyroid hormone (Figure 4.17). The catecholamines
are involved in basic nervous system activities such as
movement, memory, attention, problem solving, desire,

The high positive correlation between homocysteine and α-amino adipic acid suggests that they share
metabolic marker status in the etiology of atherosclerosis
and myocardial infarction.313 Elevations suggest reduced
tissue capability of amine group transfer and inhibited
lysine catabolism or excessive lysine intake. Elevated
α-aminoadipic acid is a risk factor for heart disease. Unlike homocysteine, α-aminoadipic acid is not vitamin B12
dependent and thus its elevation may indicate a specific
need for vitamin B6.314 In a mentally retarded girl with
a number of dysmorphic features, Raynaud’s phenomenon, hypotonia and petit mal seizures, treatment for
three months with vitamin B6 increased lysine conversion to α-AAA measured in blood and urine.277
Contraindications: Monitoring plasma concentrations of lysine is recommended in long-term oral dosing
with lysine, since excessive use of lysine may lead to
kidney pathology.315 A plasma level above 165 µmol/L is
required to obtain the herpes-inhibiting effect. This level
is in the upper-normal range. Prolonged supplementation at levels over 3 g per day can result in elevated
plasma and urinary lysine concentrations. Such levels
generally signal excessive intake that will only add to the
total-body nitrogen load, challenging ammonia clearance
capacity.

Notes:

THYROID

TH
O2
Iodine
peroxidase
Cu2+

DOPA

H2O

AADC
B6
Dopamine

Cu++

Melanin

SKIN

CO2

MAO

++
O2 Cu
Ascorbate

COMT

Homovanillate

DβH

H2O

Norepinephrine COMT

COMT
SAM

Thyroid Hormone

H2O

BH4
Fe+++

Tyrosine

PAH

Thyramine

BRAIN

Fe+++

BH4

I2

PAH
TH
AADC
DβM
MAO
COMT

ADRENAL MEDULLA

O2

2.7

Phenylalanine

Diet (g/d)

3.2

genetic polymorphisms for phenylalanine hydroxylase
and there are metabolic circumstances that prevent
adequate rates of recycling for BH4, making it a conditionally essential nutrient. Because of this situation, the
biosynthesis and regeneration for BH4 is fully described
in Chapter 2, “Vitamins.”
Other potentially significant aspects of the tyrosine
metabolite reactions are the requirement of the dopamine to norepinephrine step for copper (Cu2+) and the
need for S-adenysyl methionine (SAMe) for the conversion of norepinephrine (or noradrenaline) to epinephrine (adrenaline).
Genetics (PKU and HPA): The inherited metabolic disorder of phenylketonuria (PKU), which has
a prevalence of 1 in every 15,000 births worldwide,
results in greatly elevated phenylalanine in plasma
and urine due to insufficient activity of phenylalanine

motivation, “fight or flight” response, heart rate and
stroke volume, anaphylaxis and energy production
via glycolysis or lipolysis. Although the conversion of
phenylalanine to tyrosine is a facile reaction in most
individuals, a significant number of people have difficulty achieving a rate of this reaction needed to meet
demands for clearing phenylalanine and generating
tyrosine. Dietary tyrosine intake is approximately 18%
lower than that for phenylalanine,316 so if the conversion
from phenylalanine to tyrosine is blocked, the adequacy
of tyrosine becomes a clinical problem.
The enzyme that catalyzes the phenylalanine to
tyrosine reaction, phenylalanine hydroxylase, requires
molecular oxygen as a reactant and it requires iron, tetrahydrobiopterin (BH4) and the reduced form of niacin
as cofactors. BH4 can be produced in normal human
metabolism from GTP, but there are a number of known

MAO
Vanilmandelate

SAH

Epinephrine

Phenylalanine 4-hydroxylase
Tyrosine hydroxylase
Aromatic amino acid decarboxylase
Dopamine-β-monooxygenase
Monoamine oxidase
Catechol-O-methyltransferase

Figure 4.17 — Neurotransmitters and Hormones from Phenylalanine and Tyrosine
The values for dietary intake from the 1988–1994 NHANES III survey show only slightly lower intake of tyrosine than
phenylalanine. Three distinctly different classes of non-protein, cell regulatory products, thyroid hormone, melanin and
catecholamines are formed in thyroid, skin and adrenal medullary tissues, respectively, from tyrosine. The phenylalanine
hydroxylase enzyme used for the conversion of phenylalanine to tyrosine is also required for the further hydroxylation of
tyrosine to form dihydroxyphenylalanine (DOPA). Subsequent steps form the catecholamines that are cleared by MAO and
COMT reactions. Note the multiple requirements for tetrahydrobiopterin (BH4), iron (Fe+++) and copper (Cu++).

by standard neonatal inborn error screening, but easily
determined by quantitative amino acid analysis.
The histogram shows the distribution of the Phe/Tyr
ratios from Figure 4.18A. The horizontal axis is the
value of the ratio and the vertical axis is the number of
individuals in each segment. The data are quite normally
distributed. The cutoff values of 1.14 and 1.39 are those
reported by Mallolas as biochemical phenotype markers
of carriers of mutations leading to hyperphenylalaninemia or PKU.321
Cofactors and the Phe/Tyr Ratio: Even for individuals with normal phenylalanine hydroxylase activity,
deficiency of any of the related nutrients—iron, BH4, or
niacin (vitamin B3)—creates a functional metabolic block
at this step, resulting in low tyrosine or a high ratio of
phenylalanine to tyrosine in plasma.322 Regarding distinguishing heterozygous PAH deficiency patients, suppression of plasma tyrosine is more sensitive than plasma
phenylalanine for revealing the metabolic severity among
the many mutation possibilities. In other words, the
metabolic outcome of single nucleotide polymorphic
(SNP) mutations is revealed by testing of plasma tyrosine
concentrations. In these patients the tyrosine-lowering
effects were very apparent when measurements were
made 4 hours after a standard meal containing 140
kcal of protein.323 Apparently the insulinemic effect of
the meal drives available tyrosine into tissues, lowering
blood levels even below fasting levels. Therefore, the
relatively high percentage of people who are carriers of
Notes:

hydroxylase (PAH), the enzyme necessary for conversion of phenylalanine to tyrosine. To date, there have
been more than 400 mutations occurring in all segments of the gene encoding PAH.317 Some mutations
cause phenylketonuria; others cause non-PKU hyperphenylalaninemia (HPA). The majority of individuals
with HPA have mild clinical phenotypes.38
In humans with PKU, plasma phenylalanine is 30fold higher than normal and early symptoms include
vomiting, irritability, an eczema-like rash and a mousy
odor to the urine. Some may also have subtle signs of
nervous system function problems, such as increased
muscle tone and hyperreflexia. Later, severe brain symptoms occur, such as mental retardation and seizures.
Most symptoms of untreated PKU are avoided by early
identification and management.
Management of PKU requires frequent monitoring
of phenylalanine. Urine phenylalanine correlates with
plasma concentrations,318 whereas blood spot phenylalanine is also suitable for screening.319 The ratio of phenylalanine to tyrosine calculated from plasma concentration
data has been proposed as an even more sensitive way of
detecting not only PKU presence, but also the heterozygous carriers of the disorder.320
Some mutations cause PKU; others cause non-PKU
hyperphenylalaninemia, whereas still others are silent
polymorphisms (without phenotypic expression) present on both normal and mutant chromosomes. As the
residual enzyme activity falls in patients with each type
of mutation, the relative proportions of phenylalanine
converted to tyrosine decrease.
The ratio of plasma phenylalanine to tyrosine is
shown for a large outpatient population (n = 2,969)
including males and females over 13 years of age are
shown in Figure 4.18A. The linear trend line shows an
average relationship near 1:1. Very low phenylalanine
concentrations are usually associated with correspondingly low tyrosine. The cluster of several measurements
where phenylalanine is 40 to 50 µM and tyrosine is
below 10 µM indicates abnormally low PAH activity.
Figure 4.18B shows a histogram of the same population
with biochemical markers of phenylalanine-tyrosine ratios associated with HPA and PKU of 1.14 and 1.39 µM,
respectively.321 For distinguishing mild phenotypes of
PAH deficiency, plasma tyrosine may be more sensitive
than plasma phenylalanine because the phenylalanine
elevation may be moderate, whereas tyrosine may be
very low. These kinds of abnormalities are undetectable

Plasma Phe vs Tyr

Tyrosine (uM)

insufficient BH4 from impaired cyclohydrolase activity affects not only the formation of tyrosine, but also
the next required step in catecholamine biosynthesis
in which DOPA is formed. Human tissues can produce
BH4 from GTP, though the rate of production may be
inadequate to meet optimal demands in some individuals and supplementation of BH4 has been employed for
affected individuals.
Interpretation of Laboratory Results: Excessive
protein intake or a metabolic block in the conversion
of phenylalanine to tyrosine can elevate phenylalanine.
Iron is a cofactor required for the enzyme and supplementation improves the conversion of phenylalanine
to tyrosine. If phenylalanine is high, vitamin C, niacin,
iron, or BH4 and a low-phenylalanine diet may be indicated. In a murine model of PKU, hepatic iron accumulates, whereas hepatic copper and zinc decrease compared with control and PKU phenylalanine-restricted
mice, demonstrating that hyperphenylalaninemia alters
the metabolism of iron, copper and zinc.325 Other studies show that high plasma phenylalanine can adversely
affect bone status.326 High plasma phenylalanine seems
to interfere with cholesterogenesis, producing lower
plasma cholesterol and coenzyme Q10, although the

one or more mutation in the PAH gene may have difficulty maintaining normal plasma tyrosine levels and the
potential for tyrosine insufficiency is even greater in PKU
patients treated with low-phenylalanine diets.
Although PKU is usually caused by a congenital
deficiency of PAH, it also can result from defects in the
metabolism of biopterin, which is a cofactor for the
hydroxylase enzyme. GTP cyclohydrolase is the ratelimiting enzyme in the conversion of GTP to BH4. No
nutrient-derived cofactors are required by this enzyme.
Deficiency of GTP cyclohydrolase can limit the rate of
conversion of phenylalanine to tyrosine causing progressive encephalopathy and dihydroxyphenylalanine
(DOPA)-nonresponsive dystonia.324 The impact of

Phe/Tyr - Plasm a
Phenylalanine (uM)

Phenylalanine and Tyrosine in a
Large Outpatient Population

The data shown was collected from 2,969 patients in
a general outpatient population. All ages for both male
and female are included. The linear trend line shows
an average relationship near 1:1. The average Phe/Tyr
ratio is 1.1. Very low phenylalanine concentrations are
associated with correspondingly low tyrosine. The cluster
of several measurements where phenylalanine is 40 to 50
and tyrosine is below 10 uM (circled in red) are indicative
of abnormally low PAH activity. Similarly, at higher
phenylalanine values those points that fall far below the
trend line identify individuals with possible inhibition
of the Phe ➔ Tyr conversion. This relationship is more
easily seen when the data are plotted as the histogram
of the Phe/Tyr ratio as in Figure 4.18B. No restriction for
dietary supplementation of amino acids was made, so
the individuals with tyrosine concentrations above 120
are likely to be using dietary tyrosine or phenylalanine
supplements.
Frequency

Figure 4.18A — Relationship of Plasma
HPA Carriers
PKU Carriers
0.3

0.8

Phe/Tyr Ratio

1.3

1.8

Figure 4.18B — Histogram of the Phe/Tyr Ratio
The histogram shows the distribution of the Phe/Tyr
ratios from Figure 4.18A. The horizontal axis is the
value of the ratio and the vertical axis is the number of
individuals in each segment. The data are quite normally
distributed. The cutoff values of 1.14 and 1.39 are those
reported by Mallolas as biochemical phenotype markers
of carriers of mutations leading to HPA or PKU.

achieved with mixtures of large neutral amino acids to
restore balance in the transport of amino acids across the
blood-brain barrier.334 These considerations apply to the
various milder forms of PKU that have been discussed.
Assuming the patient has not been supplementing
with tyrosine, high tyrosine levels may indicate a failure
of one or more of the pathways of utilization. Vitamin B6
may help normalize high tyrosine levels.335 Tyrosine has
been used as a treatment for depression and blood pressure modulation.336
Low levels of tyrosine may reflect a chronic deficiency state leading to deficits in the biogenic amines.
High levels of stress lead to depletion of phenylalanine.337 In addition to supplemental tyrosine, iron and
vitamin C are potential nutritional interventions for low
tyrosine.322,338 Caution is needed regarding iron therapy
because of the potential for inducing oxidative stress.
Assessment of iron status is generally recommended before recommending iron. If tyrosine is low, then formation of thyroid hormone may be compromised. Possible
symptoms include hypothyroidism, chronic fatigue, autonomic dysfunction, depression, impaired learning or
memory, or behavioral disorders.26 Plasma tyrosine has
been proposed as a useful assessment of thyroid function. Low plasma levels of tyrosine have been associated
with hypothyroidism.339,340 Since the low-phenylalanine
diets used to treat PKU are also low in tyrosine, they
may produce a tyrosine deficit. Since the enzyme defect
is prior to the formation of tyrosine, supplementing dietary tyrosine to enhance tyrosine-dependent functions
should have no adverse effect on PKU patients. Endstage renal disease patients become tyrosine deficient
because of their inability to sustain adequate rates of
conversion of phenylalanine to tyrosine. Their routine
dialysis therapy frequently results in iron depletion.
Tyrosine dietary supplementation has been proposed as
a therapy in these patients.341

special diets used to control phenylalanine intake may
contribute to the effect.327,328
Published data on the causes and effects of low
plasma phenylalanine are rare. The general phenylalanine requirement for protein synthesis means that
phenylalanine-depleted individuals will have difficulty
maintaining organ reserve.
Treatment for Phenylalanine and Tyrosine
Abnormalities: Regarding the elevated phenylalanine
detected as neonatal PKU, the reader is referred to one
of the excellent reviews of PKU, including the low-phenylalanine diet.329 Recent reports indicate the need for
long-term maintenance of the phenylalanine restriction.330 Recent studies have shown that the effectiveness
of supplemental BH4 is low because it is rapidly degraded. A better response was found with use of sepiapterin,
a compound in the normal biochemical recovery
pathway for BH4.331 Other work on the possible effects
of BH4 in hypercholesterolemia alerts us to adverse effects of oxidation products of BH4 on endothelial nitric
oxide formation.332 When there is a deficiency of iron,
vitamin C can help restore tyrosine formation because
it enhances intestinal absorption of iron. Relatively high
doses of niacin are usually included in low-phenylalanine diet formulas (22 mg/100 g powder) for use in PKU
treatment. The extra niacin assures adequate NADH for
reduction of dihydrobioptyerin back to BH4.
Refer to Case Illustration 4.8

Supplementation of threonine at 50 mg/kg per day
resulted in a significant decrease of plasma phenylalanine levels.333 The mechanism for this effect is unknown,
so this treatment is not a standard practice. Although
tyrosine supplementation is an obvious consideration
for remediation for the restricted conversion from
phenylalanine in PKU, more effective therapy may be
Notes:

Tryptophan (Trp)

metabolism are BH4, iron and vitamins B6 and B3. In the
pathway from tryptophan to serotonin, there is only one
intermediate, 5-hydroxytryptophan.
Approximately 10% of dietary tryptophan is normally used for serotonin synthesis. Serotonin is well
known for its roles in mood, sleep, emesis, sexuality and
appetite, whereas it has been implicated in neuropsychiatric disorders such as depression, migraine, bipolar
disorder and anxiety.342
Neuropsychiatric Disorders: Numerous studies
have demonstrated that plasma tryptophan is an indirect marker of changes in brain serotonin synthesis.343
Serotonin is produced in the brain and in the numerous
chromaffin cells in the small intestine where it plays
a large role in regulating motility. Rapid tryptophan
depletion and reduced serotonergic activity is associated with impulsive behavior.344,32 Plasma tryptophan
and the tryptophan-neutral amino acids ratio have been
proposed as useful indicators of brain serotonergic activity and neuropsychiatric disorders in diabetic school
children.345 A pathophysiologic role of decreased brain
serotonin in primary fibromyalgia has been suggested

COOH
NH3
N

In addition to supplying about 3% of total-body
protein composition, tryptophan serves as precursor to
serotonin and niacin. As shown in Figure 4.19, tryptophan is metabolized via the serotonin pathway and
excreted as 5-hydroxyindoleacetate or via the kynurenine pathway from which xanthurenic acid, quinolinic
acid and kynurenic acid intermediates may be found
in urine. In addition, unabsorbed dietary tryptophan
may be metabolized by intestinal bacteria, producing
indican as a final excretory product. The significance
of abnormalities in concentrations of these compounds
is discussed more fully in Chapter 6, “Organic Acids.”
Tryptophan monooxygenase starts the two-step conversion to serotonin, whereas tryptophan dioxygenase initiates conversion to kynurenin. To summarize,
nutrients that are involved at various steps in tryptophan

TRYPTOPHAN

H

hepatic and renal metabolism

Protein Synthesis

Tryptophan

L-Tryptophan monoxygenase
BH , Fe2+
Tryptophan
5-Hydroxytryptophan

Protein Synthesis

Indican

Indican +
Intestinal bacteria
+
Intestinal
bacteria
hepatic and renal metabolism

Melatonin

Melatonin

HOMT

HOMT

N-acetylserotonin

monoxygenase
5-Hydroxytryptophan
L-Tryptophan
SNA
Mood enhancement, sleep promotion
BH , Fe2+

Tryptophan
dioxygenase
NMDA receptor antagonist

Kynurenine

Tryptophan Kynurenate
dioxygenase

Kynurenine

3-Hydroxykynurenine

Markers of B6 deficiency

Serotonin

AADC

Serotonergic

receptor
Mood enhancement,
sleep promotion
activation

SNA

Serotonin

Serotonergic
receptor
activation

NMDA receptor
2+
Cu2+, Feantagonist
MAO

Kynurenate
B3 ALD

Xanthurenate

B6

N-acetylserotonin

AADC

5-Hydroxyindoleacetate

Cu2+, Fe2+ MAO

Markers of B6 deficiency

Quinolinate

B3

Product of inflammation

Brain NMDA receptor agonist ➛ Neurodegeneration

3-Hydroxykynurenine Liver

Xanthurenate
Nicotinic Acid

ALD

5-Hydroxyindoleacetate

B6
MAO
COMT
HOMT
AADC
SNA
ALD

Monoamine oxidase
Catechol-O-methyltransferase
Hydroxyindole-O-methyltransferase
Aromatic L-amino acid decarboxylase
Serotonin N-aceytlase
Aldehyde reductase

Quinolinate

Product of inflammation

Brain NMDA receptor agonist ➛ Neurodegeneration
Liver

Nicotinic Acid

Figure 4.19 — Formation and Catabolism of Serotonin, Nicotinate and Indican
MAO every
Monoamine
oxidase
Almost
protein
in human tissues requires a few residues of tryptophan for completion of its synthesis. Hepatocytes and,
COMT Catechol-O-methyltransferase
under interferon-gamma stimulation, macrophages and astrocytes divert tryptophan into the kynurenine pathway. In the liver,
HOMT Hydroxyindole-O-methyltransferase
this pathway can lead to production of nicotinic acid. Other special tissues use tryptophan for production of serotonin, whereas
AADC Aromatic L-amino acid decarboxylase
intestinal
bacteriaN-aceytlase
may degrade tryptophan, as indicated by the appearance of indican in urine. Kynurenate and quinolinate
SNA
Serotonin
can
end reductase
products in neural tissue where they modulate glutamatergic neurons via actions at the NMDA receptors.
ALDbecome
Aldehyde

Low urine levels can indicate lowered production of the
neurotransmitter (see Chapter 6, “Organic Acids”).
Contraindications: Tryptophan and 5-HTP should
be used with caution in patients on selective serotonin
reuptake inhibitors (SSRI), as adverse effects have been
reported.356 Tryptophan is utilized in a variety of reactions whereas 5-HTP is the direct precursor to serotonin.
For practitioners intending to remove the patient from
SSRI use, care must be taken when titrating the doses
of SSRI and 5-HTP. Tryptophan in a free-form balanced
amino acid mixture does not appear to cause adverse
reactions for patients on SSRI medications.

alpha(α)-Amino-N-Butyric Acid (AANB)

COOH

H2N

α-Amino-N-Butyric Acid

Although glutamine appears to be the origin of
the neurotransmitter, α-amino-N-butyric acid in the
brain,357 details of the biosynthetic pathway have not
been elucidated. Exercise reduces rat brain levels of
α-amino-N-butyric acid levels,358 and it is also decreased
in cerebrospinal fluid of patients with Parkinson’s disease.95 Chronic alcohol intake causes elevated levels of
plasma and tissue concentrations of leucine, alanine and
α-amino-N-butyric acid.359 This effect was prevented by
the addition of pyruvate, dihydroxyacetone and riboflavin to their diet.359,360 Because blood α-amino-N-butyric
acid is specifically elevated by high blood alcohol, the
ratio of α-amino-N-butyric acid to leucine has been proposed as a marker for alcoholism.279 Studies have shown
that the effect is related to hepatic functional loss rather
than a specific alcohol intake effect.361–363
Elevated plasma α-amino-N-butyric acid indicates
vitamin B6 insufficiency since this amino acid is metabolized via the usual hepatic transamination reaction
requiring pyridoxal phosphate.364

from observations that these patients have lower plasma
tryptophan.346
Tryptophan has been shown to help induce sleep
in insomniacs due to increased serotonin production in
the brain stem. Plasma tryptophan levels are increased
with sleep deprivation because of decreased utilization.347–349 Tryptophan has been used extensively to treat
depression and it is thought to potentiate the therapeutic
action of tricyclic antidepressants. Low plasma levels of
tryptophan have been reported in depressed patients350
and are correlated with the degree of depression.351
Interpretation and Treatment: It is important to
remember that, for the chronically ill patient, the special
roles of tryptophan just discussed may be of minor
significance compared with tryptophan requirements
for protein synthesis. Full recovery for the patient with
long-term gastrointestinal, skeletal muscle, or hepatic
organ reserve loss, for example, requires high activity
of the entire protein synthetic system where tryptophan
tends to be the limiting factor. The practical application
of this knowledge is to prefer l-tryptophan* rather than
5-HTP for repletion. In cases where serotonin synthesis must be sustained at high levels, concurrent use of
both forms may be considered. Although 5-HTP can
serve only as a precursor to serotonin, its use can spare
approximately 10% of tryptophan intake for protein
synthesis.
High plasma levels may indicate either excessive
intake of tryptophan or poor metabolic utilization. Niacin supplementation may be needed if the conversion of
tryptophan to niacin via the kynurenin pathway is inhibited due to vitamin B6 insufficiency. For patients with
low plasma levels, oral supplementation of tryptophan
or the metabolic equivalent, 5-hydroxytryptophan (5HTP) is effective in maintaining adequate tissue supply
of tryptophan. Used alone or with amitriptyline, tryptophan is effective against depression in general practice.352
It is useful because it provides tryptophan for numerous
other functions in the body. In contrast, 5-HTP uptake is
correlated with serotonin tissue concentration and synthesis rates in healthy humans.353 Levels in plasma may
not rise with supplementation in depressed patients,
presumably due to high utilization rates.354,355
The principal catabolic product of serotonin that
appears in urine is 5‑hydroxyindole acetate (5-HIA).

Notes:

* The FDA ban on OTC tryptophan remains in effect. Only with a
doctor’s prescription can people obtain L-tryptophan.

Sulfur-Containing Amino
Acids for Methylation and
Glutathione Synthesis

Gamma(γ)-Aminobutyric Acid (GABA)
H2N

COOH

Humans meet their sulfur amino acid needs largely
by intake of protein containing the essential amino acids
cysteine and methionine. Methionine is a major methyl
(-CH3) donor in the body and is required for the synthesis of acetylcholine, choline, creatine and epinephrine
(Figure 4.20). Cysteine, a product of methionine, is a
component of glutathione, coenzyme A and taurine. All
connective tissue proteins, sulfo-mucopolysaccharides
and antibodies require adequate metabolism of the sulfur-containing amino acids.

GAMMA-AMINOBUTYRIC ACID

Methionine (Met)

H 3C

Notes:
S

NH2
COOH

METHIONINE

Methionine is the essential precursor in sulfur
amino acid metabolism. Low methionine levels may
adversely affect these crucial pathways and may reflect a
poor-quality protein diet. Methionine is one of the amino acids most frequently found to be deficient, because
the methionine content of poor-quality protein sources
is very low. Plasma methionine concentrations reflect total-body utilization of cysteine for synthetic reactions in
tissue maintenance. Any chronic detoxification challenge
requiring glutathione conjugation or oxidative challenge
requiring glutathione redox activity tends to deplete
methionine and lead to low plasma methionine levels.
For example, even dietary intake of tannins found in
vegetables and tea increases the rate of methionine utilization to support hepatic tannin clearance.373 Urinary
as well as plasma levels of methionine fall when humans
are placed on a methionine-free diet.374
Methionine is the principal sulfur-containing dietary
component. The metabolism of methionine to homocysteine with transfer of the methyl group to form the active methyl compound, S-adenosylmethionine, is shown
in Figure 4.20. Alternatively, hepatocytes express betaine
homocysteine methyltransferase that uses betaine as a
substrate for methyl group transfer to homocysteine. The
figure emphasizes the reciprocal regulation of the two
enzymes, methionine synthase and cystathionine-β-synthase. These enzymes respond to oxidative stress in such
a way that homocysteine is diverted from transmethylation with formation of methionine to transulfuration

Gamma-aminobutyric acid is an inhibitory neuro­
transmitter in the central nervous system. GABAnergic
neuronal defects are thought to be involved in the
etiology of epilepsy.365 Granule cells of the dentate gyrus
have the unique capacity to release both glutamic acid
and γ-aminobutyric acid. Granule cell firing causes
GABA receptor activation that mediates antiepileptic and
neuroprotective actions.366
In the brain, GABA is produced from glutamate in
a single decarboxylation reaction. Isoforms of glutamic
acid decarboxylase, the enzyme used for conversion,
are expressed in tissues other than the brain, where
they play a role in diseases of autoimmune character,
including neurological disorders and insulin-dependent
diabetes.367 Although the subject of such autoimmune
mechanisms is beyond the scope of this book, the presence of the enzyme for its formation means that GABA
can arise in various tissues, even though its function is
not known. GABA may be synthesized from glutamic
acid and ornithine in muscle, but concentrations in
plasma reflect CNS levels derived from glutamic acid.
Low levels in plasma are characteristic of one
subset of patients with depression.368 The neurodegenerative condition, Huntington’s disease, also manifests
as lowered levels of GABA as neuron loss proceeds.369
Vitamin B6 deficiency impairs GABA formation, offering
one option to help assist patients with inadequate GABA
production.370 In animal models of seizure, lysine has
dose-dependent anticonvulsant effects that appear to be
due to GABA receptor modulation.371
Elevated plasma GABA may reflect low conversion
to succinic acid (a vitamin B6-dependent reaction) for
utilization by the citric acid cycle. Gamma-hydroxybutyric aciduria is characteristic of genetic variants with
succinic semialdehyde dehydrogenase deficiency. The inevitable retardation of language development in children
with this polymorphism is sometimes accompanied by
other autistic features.372 This disorder constitutes one of
the potential genetic origins of autism.

OXIDATIVE STRESS
ATP

Methionine

MAT

ADP

Mg

DMG

SAM
S-Adenosylmethionine
BHMT
(liver)
SAH
S-Adenosylhomocysteine

B12
Folic Acid

SAHH

X

Decrease

MS

Trans-methylation

Betaine

Homocysteine
X-CH3

Increase

Cystathionine
Cystine

NADH

NAD

B2
Se

NADH

Cysteine

NAD+

Reduction

Reduced

Mg,K

Glutathione

B6

a-Hydroxybutyrate
(Glutathione synthesis)

Taurine

Fat Digestion
Neurotransmitter
Antioxidant

Glutathione

Oxidation

NAD

NADH

Oxidized

Glu Gly

a-Ketobutyrate

B6, Betaine

Trans-sulfuration

B6, CGL

CBS

MAT
SAHH
CBS
CGL
MTHFR
MS
BHMT
Serine

(Methylations)

Methionine adenosyltransferase
S-Adenosylhomocysteine hydrolase
Cystathionine β-Synthase
Cystathionine g-lyase
Methylenetetrahydrofolate reductase
Methionine synthase
Betaine homocysteine methyltransferase

Oxidative balance
Detoxification

Sulfate
Amino acid
transport

PAPS
(Activated Sulfate)

Toxin X
Sulfated
derivative
X (SO4)
in Urine

Pyroglutamate
(Glutathione-wasting)

Figure 4.20 — Relevant Sulfur-Containing Amino Acid Pathways
The essential amino acid, methionine, is used in a cyclic manner to supply methyl groups for the multiple pathways of
biosynthesis, cell regulation and detoxification. The regeneration is initiated by the trans-methylation reaction catalyzed
by MS. Under conditions of increased oxidative stress, however, homocysteine is diverted into the trans-sulfuration pathway
to form cysteine for sustaining glutathione levels. This diversion is carried out by reciprocal regulation, in which MS is
inhibited, whereas CBS is stimulated by oxidants formed as a result of the oxidative stress. Other demands for cysteine are
shown as products formed from taurine or sulfate. Under conditions where homocysteine conversion to methionine is the
dominant flow, folate and vitamin B12 status are the critical micronutrient factors. During chronic oxidative stress, vitamin
B6 becomes the critical micronutrient. Functional vitamin B6 deficiency causes accumulation of homocysteine and failure
to maintain glutathione, taurine and sulfate status. Even in normal vitamin B6 status, chronic oxidative challenge can cause
depletion of methionine and homocysteine that ultimately restricts the formation of glutathione, taurine and sulfate by
substrate depletion. For furthur details see Figures 2.11 and 6.21.

on vitamins B6, B12 and folate (Figure 4.20).383 When
methionine is high, vitamin B6, α-ketoglutarate and
magnesium may be needed to support utilization. This
scenario can be distinguished by concurrent elevated
homocysteine. High methionine with low homocysteine
indicates that the elevation is due to inhibition of methyl
transfer to adenosine (possibly due to polymorphism in
methionine synthase) and SAM supplementation may be
needed. Other biomarker scenarios have been summarized in Chapter 2, “Vitamins.” Low plasma methionine
indicates inability to sustain methionine levels during
overnight fasting. A balanced free-form amino acid
mixture is generally safe and effective for raising low
methionine status.
Cirrhotic patients have significantly subnormal values for cysteine, glutathione and albumin. In addition,
they have elevated methionine during a high-protein liquid diet and low taurine during either mixed-foods diets
or total parenteral nutrition. There appear to be multiple abnormalities in sulfur metabolism in cirrhosis.384
Reduced urinary excretion of methionine was observed
in patients with gastric resection, ileocecal resection and
abnormal gut flora, whereas patients with jejuno-ileal
bypass showed increased excretion of methionine, probably a consequence of the impaired liver function.385
Supplemental methionine given to a patient who
has normal plasma methionine, indicating that they are
already replete in the amino acid (with normal plasma
levels), increases the risk of production of the heart risk
factor, homocysteine, as well as the risk of methionine
toxicity discussed above. Folate, vitamins B12 and B6
and betaine may be helpful to clear homocysteine.383
Methionine loading (50 mg per kg body weight) prior to
measuring plasma homocysteine has been used to test
sufficiency of these nutrients for this metabolic pathway.
The pattern of lower plasma methionine, S-adenosyl­
homocysteine, cystathionine, cysteine and total glutathione and higher concentrations of SAH and oxidized
glutathione in autistic children, has been described as an
indication of increased vulnerability to oxidative stress.
Intervention with folinic acid, betaine and injectable
methylcobalamin normalized the metabolic imbalance
and produced improvements in autistic symptoms.386

to allow greater rates of glutathione synthesis. Increased
cellular glutathione concentrations serve to modulate the
oxidative stress. Other aspects of cysteine metabolism
are discussed in the section “Cysteine.”
The importance of evaluating methionine status
before using aggressive methionine supplementation is
emphasized by studies showing that high-methionine
diets induce hypercholesterolemia in several species.176
One possible mechanism is excess methyl group stimulation leading to hepatic accumulation of S-adenosylmethionine with toxic consequences of hepatic methionine
adenosyltransferase stimulation and spermine synthase
repression associated with elevated glutathione.94,375 The
cholesterol accumulation effects were reversed by adding cysteine, further indicating that methylation pathway stimulation is involved to mediate the effect. It is
interesting to speculate that such methionine-mediated
methylation stimulation may be a factor in the multitude
of adverse health effects associated with high-animal
protein diets.65
Methionine chelates metals and may be useful as a
supportive therapy in chelation of lead.376 Methionine
has a similar chelation effect in cobalt intoxication.377
The chelating property extends to nutrient elements
such as copper, which can be depleted by excess methionine. In addition, methionine toxicity causes growth
inhibition and hematologic changes leading to hemolytic
anemia.378 See “Cystathionine” below for a discussion
of methionine toxicity biomarkers more sensitive than
plasma methionine levels.
S-Adenosylmethionine (SAMe, SAM, or AdoMet):
Methionine must be activated through formation of the
adduct S-adenosylmethionine (SAM) by the action of the
enzyme SAM synthetase. In diseases where the activation
process is impaired, treatments may be accelerated by
supplying the active form as oral SAM. SAM is a normal
constituent of human cells, however it can become a
conditionally essential nutrient, making it an effective
therapeutic intervention.379,380 Impaired activity of SAM
synthetase results from liver disease induced by alcoholism and the toxic pathological consequences of the
disease are reversed by SAM therapy.381,382
Clinical Relevance, Interpretation and Treatment:
Methionine metabolism disorders have a diverse symptomatology, including allergic chemical sensitivities,
headaches, eye strain, muscle weakness, brittle hair, hair
loss, myopia, mild myopathy, osteoporosis and cardiovascular symptoms. The pathways are heavily dependent
Notes:

Glutathione: Glutathione is a tripeptide, γ-glutamyl-cysteinyl-glycine. As much as half of the total-body
flux of cysteine may be accounted for by turnover of
glutathione.387 Under oxidizing conditions, two tripeptides join via disulfide formation to create a double molecule (Figure 4.21). The enzyme, glutathione reductase
requires copper and FAD (from vitamin B2). This ability

Cysteine (Cys)
COOH

HS

NH2

Cystine (Cyss) CYSTEINE
HOOC

S

COOH

S

NH2

NH2
CYSTINE

g-Glutamyl—Cysteinyl—Glycine
O

NH C

CH2

HS

NADP+ (B3),
FAD (B2)

Oxidized substrate
Cofactors:
Se++, Cu++, Zn++

Cysteine

Reduced Glutathione

NADPH,
FADH2

Reduced product

Oxidized Glutathione
g-Glutamyl—Cysteinyl—Glycine
O

CH

Sulfhydryl

Most of the sulfur in food is in the form of proteinbound cysteine/cystine. High-sulfur foods such as eggs
and legumes, therefore, are high-cysteine foods. Cysteine
residues are found at the catalytic site of many enzymes
because of the unique substrate-binding properties
offered by the electron-rich sulfur atom. The same electron-dense character makes sulfur compounds such as
reduced glutathione and DMSA some of the best heavy
metal-complexing agents (see Chapter 3, “Nutrient and
Toxic Elements”). The cysteine-rich protein, keratin,
which is so abundant in hair, confers extremely high
metal-binding capacity to hair. Cystine (Cyss) is the
oxidized dimer of cysteine (Cys) in which the sulfhydryl group is converted into a disulfide with extraction
of two hydrogens similar to that shown for glutathione
in Figure 4.21. Some assays oxidize the specimen so
that all cysteine is converted to cystine; therefore, these
laboratory reports may show only cystine. The term
tCys indicates the combined presence of the two forms
in the original specimen, whereas cyst(e)ine is generally
used to indicate a combination of reduced (cysteine) and
oxidized (cystine) forms.
It is important to distinguish between the concentrations of protein-bound and free cysteine. Although
virtually all proteins of blood plasma contain cysteine
residues, normally there is very little cysteine present in
the unbound or free form that is measured in plasma or
urine amino acid testing. Both the reduced (sulfhydryl)
and oxidized (disulfide) forms occur in proteins. When
two cysteine residues in a single polypeptide chain join
to form cystine, the structure is greatly stabilized. These
points are relevant to laboratory assessments because
most laboratories do not report the reduced (–SH) forms
and the oxidized (–S-S-) forms that are reported are in
dynamic equilibrium with the reduced forms. Therefore,
abnormal levels have a direct relationship to the total
levels of reduced plus oxidized forms.

NH C
CH
CH2
Cystine

Disulfide

S
S
H2C
CH

NH C
g-Glutamyl—Cysteinyl—Glycine

Figure 4.21 — Reduced and Oxidized Glutathione
The central cysteinyl residue of the glutathione tripeptide
undergoes oxidation as electrons are accepted from
substrates for the enzyme glutathione peroxidase.
Glutathione reductase then uses reduced NADH and
FADH2 to regenerate reduced glutathione. Various
isoforms of the enzymes require the cofactors shown.
The –SH group of reduced glutathione (GSH) becomes
the –S-S- group of oxidized glutathione (GSSG).

age, probably due to declining glomerular filtration rates
accompanied with increasing urinary tCys.394 It may
explain the elevated tCys found in diabetic patients.395
Correct specimen collection and storage are very
important because plasma cystine undergoes slow degradation even when stored at –20oC. If a specimen takes
more than 48 hours to reach the laboratory, the cystine
level may be significantly lowered from the level in the
freshly drawn blood. Therefore, it is helpful to record
the specimen collection time on the test request form
when ordering laboratory assessments.
Interpretation and Treatment: Patterns of plasma
cystine, serine, cystathionine and taurine can indicate
the location of a metabolic conversion block. Concurrent low cystine and serine, for example, indicate a restriction of the serine-glycine supply (see “Precursors of
Heme, Nucleotides and Cell Membranes” section on the
following pages). Low cystine levels may impair cellular
synthesis of taurine (see Taurine section on the following
pages), in which case plasma and urinary taurine will
also be low.
Low plasma cyst(e)ine may reflect a dietary deficiency of methionine and/or cysteine in which case
N-acetylcysteine (NAC) would be an appropriate intervention. High dietary intake of condensed tannins as in
heavy users of tea can lower plasma cystine.373 Elevated
plasma or urinary cystine can reflect either excessive
dietary intake of cystine rich foods or impaired metabolism of cystine. High levels can indicate a need for
vitamin B6 and folic acid.396

Notes:

to buffer oxidizing and reducing conditions, which shift
with the flow of NAD+ and NADH, allows glutathione
to help regulate oxidative cell processes. Hepatic phase
II detoxification also consumes glutathione as it participates in many reactions to conjugate and excrete toxicants (see Chapter 8, “Toxicants and Detoxification”). In
high-oxygen environments, cysteine is lowered due to
the high glutathione demand.388
Hepatic cholesterol biosynthesis is modulated by
dietary cyst(e)ine. Cysteine has been found to be significantly elevated in patients with primary biliary cirrhosis
and other forms of liver disease.389 Hypercholesterolemia can be induced in laboratory animals by feeding
excessive cystine.390 The effect may have limited impact
on heart disease risk, because the increase in cholesterogenesis is accompanied by 65% lower levels of the heart
disease risk factor lipoprotein(a). In fact, other studies
in rats have demonstrated that if, instead of imposing
a gross excess of cysteine, the amino acid is added at
moderate levels, plasma cholesterol is lowered significantly and HDL cholesterol is increased.391 These effects
are thought to result from enhanced conversion of
cholesterol to bile acids. Dietary supplementation with
N-acetylcysteine (NAC) does not increase the circulating concentrations of tCys.392 The variation in responses
to increased oral cyst(e)ine underscore the benefit of
testing for individual amino acid profiles to determine
patient status before implementing amino acid therapies.
Cysteine plays a regulatory role in the physiological
control of body cell mass.130 Plasma tCys is highly correlated with serum creatinine.393 Plasma tCys rises with

Homocysteine
COOH
NH2

HS

Homocystine CYSTEINE
(HCys)
COOH
S

HOOC

NH2

S

NH2

HOMOCYSTINE

Cystathionine
NH2

Homocysteine
HOOC

S
COOH
NH2

disorder is impaired function of the enzyme cystathionine β-synthetase for conversion to cystathionine (see
Figure 4.20). This enzyme is vitamin B6-dependent and
supplementation of the vitamin has been used to treat
elevated homocysteine. A second route in metabolism
of homocysteine is remethylation to methionine using
vitamin B12, folic acid and betaine (trimethylglycine).
Supplementation of betaine has proven useful for
people with high homocysteine who do not respond
to vitamin B6.399 Adequate intake of vitamins B6 and
B12, folic acid and magnesium is necessary for insuring
proper methionine metabolism to prevent the accumulation of homocysteine.
For lowering of elevated homocysteine, in addition
to the supplementation of folate, B12 and B6, some have
advocated the use of betaine to support the betainemethyl transfer reaction in reformation of methionine.
Recent evidence demonstrates that plasma betaine
concentration is, indeed, inversely related to homocysteine levels. Because betaine levels are raised by folic acid
supplementation, additional betaine supplementation is
less likely to be effective when the B vitamins are used at
appropriate doses.400 In patients with homocysteinuria
due to cystathionine β-synthase deficiency, endothelial
function is improved by 1 to 2 g/d vitamin C.401 Although the molecular origin of this effect is unclear, the
protective role of vitamin C for tetrahydrobiopterin, the
cofactor for nitric oxide synthase, is a good candidate
mechanism.
Although high plasma homocysteine is widely
recognized as a cardiovascular disease risk factor, individuals with low homocysteine are also at risk of other
conditions related to sulfur amino acid metabolism. The
risk of hypohomocysteinemia derives from the fact that
homocysteine is the normal precursor for formation of
cysteine and thus for production of glutathione, taurine
and sulfate from methionine.
Individuals with low homocysteine have limited
capacity for up-regulation of glutathione synthesis in
response to oxidative stress and certain kinds of toxin
exposure. The most common treatment for low homocysteine is administration of sulfur-containing amino
acids such as N-acetylcysteine and taurine. Preformed
glutathione and inorganic sulfate salts (potassium
sulfate) may also be employed to support hepatic and
renal demands for toxin removal through sulfation and
mercaptan formation. Plasma methionine and urinary
sulfate, pyroglutamate or α-hydroxybutyrate may be

Cysteine

The relation between homocysteine and homocystine is parallel to that described above for cysteine
and cystine. Values reported from clinical laboratories
are also similarly related so that total homocystine may
reflect the sum of reduced and oxidized forms in the
original specimen. Elevated homocysteine tends to coincide with high homocystine.
Age, gender, folate, serum vitamin B12, serum
creatinine and multivitamin usage are determinants
of plasma homocysteine concentration (discussed in
Chapter 2, “Vitamins”). In population studies, total
plasma homocysteine concentrations are higher in men
than in women, increase markedly with age and are
inversely correlated with blood folate, serum vitamin B12
and serum creatine. Users of multivitamins have lower
homocysteine levels than nonusers.394
Elevated homocysteine commonly affects the central
nervous system (CNS), primarily as mental retardation,
seizures and stroke.397 Elevations indicated by increased
plasma or urinary levels are etiologic factors in osteoporosis due to impaired cross-linking of collagen.398
Smoking has been shown to increase the incidence of
homocysteinuria, probably due to lowered levels of the
controlling vitamins.
Moderately elevated levels of homocystine are associated with a significantly increased risk of atherosclerosis. High levels in body fluids of this amino acid have
been associated with increased risk of cardiovascular disease as well as ocular, neurological, musculoskeletal and
joint abnormalities. A common cause of this metabolic

CYSTATHIONINE

Autistic patients have lower plasma concentrations
of homocysteine, methionine, SAMe, cystathionine,
cysteine and total glutathione and higher concentrations
of SAH, adenosine and oxidized glutathione. The biochemical abnormalities were normalized by a targeted
nutritional intervention trial with folinic acid, betaine
and methylcobalamin. These findings led to a conclusion that chronic oxidative inactivation of methionine
synthesis through adenosine inhibition of SAH hydrolase
is a propagating factor in autism.386
Cystathionine is the product of the vitamin B6dependent degradation of homocysteine. It is produced
by conjugation of serine with homocysteine via the action
of cystathionine-β-synthase, the pyridoxal-5-phosphatedependent enzyme that is deficient in hyperhomocysteinemia. Increase in cystathionine-β-synthase activity
accounts for the principal effects of vitamin B6 supplementation in lowering homocysteine. Cystathionine lyase
cleaves cystathionine to cysteine and α-ketobutyrate,
the immediate precursor of α-hydroxybutyrate (see
Chapter 6, “Organic Acids”). High cystathionine levels
may indicate a functional vitamin B6 or serine deficiency.
Metabolites of cystathionine stimulate superoxide
generation in leukocytes, placing increased demands
on antioxidant capacity.417 A decreased ratio of plasma
cystathionine to homocysteine is a toxicity biomarker
of methionine excess. In rats, as methionine intake is
increased to levels that produce toxic effects, ratio values
suddenly fall from 1.5 to less than 0.3.378 This finding
indicates that the conversion of homocysteine to cystathionine is rate limiting in disposal of excess methionine.

preformed for confirmation of significant cysteine deficit
(see Chapter 6, “Organic Acids”).
Hypohomocysteinemia causes reduced availability
of cysteine. Cysteine restriction causes limitation in
production of sulfate, taurine and glutathione.414 The
limited production ability is exacerbated in conditions
that cause increased demand for any of the sulfur compounds produced from homocysteine. Alcohol intake
greatly increases the production of taurine,415 and many
drugs and xenobiotics increase sulfate requirement
for conjugation and elimination.416 One of the body’s
main uses of sulfate and taurine is in the phase II liver
detoxification.
Taurine is involved in the formation of bile acids,
whereas the sulfation pathway is required for removal of
steroid hormones, phenolic compounds and numerous
drugs. Glutathione metabolic activities include phase
II conjugation reactions, prostaglandin synthesis and
reduction/oxidation reactions. Indeed, a survey of the
literature shows that a reduction in glutathione is associated with diseases impacting virtually every major organ
system (see Table 4.13). Any condition that increases
oxidative stress tends to increase the demand for hepatic
glutathione production. Thus oxidative stress draws
homocysteine into glutathione synthesis, potentially
causing a drop of plasma homocysteine to levels where
total-body glutathione status is critical.414 The studies
cited here are only a small fraction of those suggesting
that detection of low plasma homocysteine is of clinical
utility in any scenario requiring increased use of glutathione, taurine, or sulfate.

Table 4-13 — Pathologies and Diseases Associated with Limited Glutathione Status

Organ Pathology Associated With
Decreased Glutathione Status402
Hepatic
Cardiovascular
Lungs
Kidney
Genitourinary
Endocrine
Gastrointestinal
Gallbladder
Musculoskeletal
Neurological
Specific Conditions Associated With
Reduced Glutathione Status
Schizophrenia403
Autism404
Cataracts405
Accelerated aging406
Hyperlipidemia407
Hepatitis C408,409
AIDS410
Adult respiratory distress syndrome411
Diabetes407,412
Cystic fibrosis411
Symptoms associated with environmental toxicity413

Taurine (Tau)

Notes:

Taurine is the two-carbon, sulfur-containing, βamino acid, β-aminoethylsulfonic acid. Taurine serves
antioxidant roles in various tissues, but it does not form
a part of general protein structure like most of the other
amino acids that have been discussed. Because taurine
is a normal component of skeletal muscle, dietary fish
and meats can supply significant taurine. Many cooked
meats supply taurine in the range of 100 to 200 mg/100
g wet weight.418 Consumption of a meat-restricted diet
results in very low taurine intake. Taurine requirements
for optimal human function are quite significant, especially in certain disease states. Thus, taurine is a conditionally essential nutrient that can be synthesized from
cysteine when vitamin B6 is adequate.
The cysteine relationship has been demonstrated by
showing that cysteine supplementation results in normalization of plasma taurine concentrations in children
receiving home parenteral nutrition.419 Taurine is important during mammalian development, especially for cells
of the cerebellum and retina.420–422
Care must be taken when comparing plasma and
whole-blood (blood spot) taurine concentrations because the level in whole blood is more than five times
higher, indicating an active pumping mechanism to
sustain erythrocyte levels. In cats where dietary taurine
is usually much higher, whole-blood levels respond to
taurine supplementation slower than plasma levels.423
Taurine status has been extensively studied in patients
on long-term total parenteral nutrition where 10 mg
taurine/kg/d intravenously normalizes plasma and blood
cell taurine concentrations.424 During supplementation,
urine taurine-creatinine ratios rose to approximately five
times normal. Another tissue distribution effect is found
in horses, where cardiac tissue-plasma ratio is highest
for taurine.256 Plasma levels of taurine rise when glutamine is supplemented in stressed rats and patients with
severe trauma.425
The antioxidant potential of taurine accounts for
some of its clinical effects. When taurine is added to
supplementation of vitamin E and selenium, diabetic
retinal abnormalities are reduced in a dose-dependent
fashion.426 Patients with diabetic nephropathy also respond positively to taurine and vitamin E.427

NH2

HO3S

Zinc Deficiency: Urinary taurine becomes elevated
in zinc deficiency, apparently due to the decreased rate
of protein synthesis. The cysteine that is not drawn
into formation of Cys-tRNA is degraded to taurine and
sulfate. If dietary intake is normalized, the degree of
taurine elevation may be used to infer the severity of
zinc depletion.428
Inflammation: High plasma taurine is found associated with various stress reactions,429 apparently mediated
by release of interleukins.430 A high plasma level can indicate excessive production of taurine due to an inflammatory process mediated by white blood cells. Taurine is
found in high concentrations in heart muscle and white
blood cells. Taurine is involved in control of chemical
oxidation by white blood cell phagocytes in response to
respiratory burst activity. Inadequate taurine supplies
allow the oxidative activity to go unchecked, leading to
excess oxidative damage and formation of aldehydes. Individuals with this condition are allergy prone and often
extremely sensitive to environmental chemicals.
Cardiovascular and Neurological Effects: Taurine
deficiencies have been implicated in both neurological
(epilepsy) and cardiovascular dysfunction. Heart and
brain cells require taurine for intracellular retention of
calcium, magnesium and potassium. Taurine has been
used successfully in the treatment of congestive heart
failure and is implicated in night blindness, arrhythmia,
angina, hypercholesterolemia and atherosclerosis.431
Beta-agonist drugs cause a reduction in the body pool
of taurine.432,433

Taurine also stabilizes platelets against aggregation.
Platelets from taurine-depleted animals are twice as
sensitive to aggregation as platelets from those receiving
taurine. In addition, human subjects with normal taurine status show increased resistance to platelet aggregation by 30 to 70% when supplemented with taurine
at 400 or 1,600 mg/d, respectively.434 Cats have a high
requirement for dietary taurine and they easily develop
dilated cardiomyopathy on low taurine diets. The same
effect is seen in dogs on low-protein diets. Taurine
supplementation helps to reverse the cardiomyopathy.435
Increased plasma taurine is found in patients suffering from episodic acute psychosis, characterized by
sensory perceptual distortions. In such patients, oral
loading with either serine or glycine can increase synthesis of taurine from homocysteine and serine, inducing
psychedelic symptoms.436

homocysteine for transulfuration, a requisite step for
taurine biosynthesis.440
β-Alanine is a competitive inhibitor of the taurine
transport system required for moving taurine across cell
membranes. Addition of 3% β-alanine to the drinking
water of mice causes a 35 to 50% reduction of taurine
content of spleen and thymus with concurrent decline
of functional immune response.441 An individual with
elevated plasma β-alanine who also shows high taurine
(unsupplemented) may have impaired immune function
that is responsive to taurine supplementation or other
measures that lower β-alanine.

Precursors of Heme,
Nucleotides and Cell Membranes

Glycine (Gly)

Refer to Case Illustration 4.9

H2N

GYLCINE

Serine (Ser)

Interpretation and Treatment: In the rat model,
bile duct ligation causes elevated plasma taurine associated with reduced hepatic taurine conjugation to form
bile acids. The absence of bile acids produced a gut-derived endotoxemia with lowered hepatic glutathione and
increased lipid peroxidation that were offset by cholesteramine treatment.437 Higher plasma taurine values are
part of a pattern of amino acids associated with major
depression.20 Depression is accompanied by decreased
excitatory amino acids such as glutamate and increased
inhibitory amino acids such as taurine.
Taurine in the form of taurocholic acid is a key
component of bile. Low taurine may accompany fat digestion problems,438 fat-soluble vitamin deficiencies and
high serum cholesterol levels.439 Concurrent low cysteine
is also relevant in taurine depletion. Low or low-normal
cystine may indicate rapid conversion of this amino acid
to taurine.
When plasma levels are low, the clinician can
consider supplementation with taurine and vitamin B6.
Plasma taurine is easily raised by taurine supplementation of the diet. Cysteine addition to formulas used for
home parenteral nutrition normalizes plasma taurine
concentrations in children with short-gut syndrome.419
Choline supplementation may stimulate taurine synthesis due to its sparing effect on methyl group supply
by methionine. Methionine is more available to supply
COOH

NH2
HO

COOH
SERINE

The amino acid with the simplest structure, glycine,
is also one of the most versatile. Glycine is classified
as conditionally essential because clinical deficiency
effects have long been known. Patients can become
glycine‑depleted due to the many metabolic demands
for glycine, including heme biosynthesis for blood
formation, collagen formation for growth and repair,
glycocholic acid formation for digestion, glycine conjugation in detoxification and direct neurotransmitter
action in brain function (Figure 4.22).
Collagen, the most abundant protein in the body,
is one-third glycine and all enzymes, transport proteins and membrane receptors contain roughly 10%
glycine. The glycine cleavage system, discussed below,
transforms the single carbon atom of glycine into a key
starting material for the multitudes of metabolic requirements for single carbon chemistry. Glycine is required
for porphyrin synthesis to initiate the pathway leading
to heme formation and for every cell function, including formation of RNA or DNA, synthesis of glutathione, bile acids and phase II conjugation reactions. To
a lesser extent, glycine can also be used directly as an
energy source or for synthesis of glucose. Glycine is

Acetyl CoA (Brain)

SAH

Folate, B12

Betaine

SAM

B2

Choline

DIET

Dimethylglycine
B2

(N-Methylglycine)

SAM

Threonine
B2, THF

DIET

B6
Folate
Mn, B6

Glycine

Phosphotidyl choline
SAH

(x3)

SAM

Phosphatidylethanolamine
Phosphatidylserine

Phosphoserine

Phosphatide

Glycerol-3-phosphate

Stearate
Palmitate
Arachidonate
Linolinate

CAC

blood formation
growth
repair
digestion
brain function
detoxification

Proteins
Purines
DNA, RNA
Porphyrins
Glutathione
Glycocholate
Hippurate and other
hepatic phase II
conjugates
Creatine

Oxaloacetate

Mg

Ethanolamine

Serine
Pyruvate
Phosphoethanolamine

CELL MEMBRANES

SAH

Sarcosine

Figure 4.22 — Metabolic Roles of Glycine and Serine

One main point of this figure is to illustrate the reasons for glycine being the most heavily utilized of all amino acids. Its roles
span from forming one-third of the most abundant protein in the human body (collagen) and participating in the initial step
of heme synthesis, to highly variable roles in detoxification and synthesis of glutathione. The close biochemical association of
serine means that the two amino acids tend to rise and fall in tandem as metabolic demands shift. Serine is the precursor for
biosynthetic pathways that produce the phospholipids of cell membranes. See Figure 4.26 for detail about the limitation of
human tissues for phosphatidyl serine conversion, indicated by the dashed arrow to phosphatidylethanolamine. Variations in
status of cofactors, especially folate and vitamin B6 and variations in activity of the glycine cleavage system illustrated in the
following figure can produce glycine-serine ratio abnormalities. Dietary intake of glycine-containing proteins or choline from
fats and oils can supply exogenous glycine. Little glycine is formed by synthesis from non-protein metabolites, so restriction
of dietary protein supply can restrict the myriad processes dependent on glycine and serine.

the precursor of serine for the membrane components,
phosphoethanolamine and phosphoserine.
Detoxification Roles of Glycine: The role of
glycine in detoxification is especially critical during
episodes of multiple exposures to several classes of
chemicals. Glycine is used for direct conjugation to
many compounds, including benzoic acid. Benzoic acid

is a food component, food additive and a product of intestinal bacterial action on unassimilated phenylalanine
(Chapter 6, “Organic Acids”). Because glycine is also one
of the precursor amino acids for glutathione, individuals
experimentally stressed with benzoate show inhibition
of glutathione synthesis.442 Plasma glycine is lower in patients with aspirin overdose than in healthy individuals,

Folate Rings
H2N

COOH
CH2

Glycine

NAD+

NADH

NH3

CO2
N

Glycine Cleavage System
B6

N — THP
CH2

5,10 Methylene THF

One carbon pool of
folate derivatives
See Figure 2.11 in
Chapter 2, “Vitamins”

Figure 4.23 — The Glycine Cleavage System
The reaction catalyzed by the glycine cleavage system enzymes results in the total destruction of glycine with the capture of
the central carbon atom as 5,10-methylene-THF. Thus, glycine availability enhances the capacity for maintaining the single
carbon pool for biosynthesis and methylation reactions.

concentrations are under significant genetic control via
a single major gene locus encoding the enzyme, serine
hydroxymethyltransferase.445 Individuals with profound
nonketotic hyperglycinemia, who survive infancy, are severely mentally retarded, demonstrating the pathological
potential of excessive glycine neuroinhibitory action.225
Clinical presentation in atypical, mild NKH is heterogeneous, most often presenting in adults as mild mental
retardation and behavioral problems.446 Residual GCS
function may be present, producing less severe elevations
of glycine in plasma and CSF. Genetic polymorphisms of
the glycine cleavage complex produce a specific glycine
elevation rather than the concurrent high levels of glycine and several other ketoacids found in other abnormalities of branched-chain amino acid metabolism.
The GCS serves to maintain normal blood glycine levels by providing a clearing mechanism for high levels and
a biosynthetic route from serine during episodes of falling

Notes:

suggesting depletion of available glycine, which is used
for formation of the excretory product, salicyluric acid.22
These reactions are part of phase II hepatic detoxification. High serine and glycine found in hemodialysis
patients may be normalized with erythropoietin (EPO)
therapy.443 The stimulation of erythropoiesis increases
the rate of utilization of glycine for heme formation.
Genetics: A well documented reason for elevated
plasma and urinary glycine is the condition of nonketotic
hyperglycinemia (NKH) due to failure of the glycine
cleavage system (GCS). The GCS is composed of a group
of mitochondrial enzymes that mediate the reversible
conversion of glycine to serine (Figure 4.23). Pyridoxal
phosphate and tetrahydrofolate are cofactors in this
reaction. By this pathway glycine is a major supplier of
the “one-carbon pool” of folic acid intermediates that
are pivotal to many biosynthetic, detoxification and
gene-regulating reactions.444 Plasma serine and glycine

Table 4.14 — Manifestations of Non-

Severe form

Arrhythmia, myoclonic jerks,
profound hypotonia and death
within the first few weeks

Manifestations

Ketotic Hyperglycinemias

Form

Psychomotor retardation and growth failure

Mild form 2

Initially normal development followed by a
progressive loss of developmental milestones,
spinocerebellar degeneration and other
symptoms of motor dysfunction

Mild form 1

The evidence that has been summarized points to
a direct relationship between plasma glycine levels and
brain neurotransmitter effects. Neuronal activity is overstimulated by elevated plasma glycine levels and underactivated by low plasma glycine, leading to neuromotor
or psychotic manifestations, respectively. Treating glycine
insufficiency with oral glycine is quite effective. Elevated
glycine is more difficult to manage, requiring steps to
increase glycine utililzation and clearance. In the severe
form of NKH, blood glycine is extremely elevated, often
reaching values above 1,000 µM. Severe forms have been
treated with moderate success with benzoate (to lower
glycine by conjugation and excretion) and carnitine.448
Treatment with 250 to 750 mg/kg/d of sodium benzoate
have achieved sufficient reduction of cerebrospinal fluid
glycine to reduce seizure activity.225 Glycine potentiation
of glutamatergic (NMDA) receptors may be the cause
of myoclonic encephalopathy and seizures. Thus, some
affected infants have been treated with benzoate along

with NMDA antagonists such as dextromethorphan.449
The NMDA agonistic role of glycine also places patients
with hyperglycinemia at higher risk of glutamate toxicity during febrile episodes that cause elevation of the
even stronger coagonist, quinolinic acid. In other words,
the neuronal degenerative risk of elevated glycine is
exacerbated by concurrent high quinolinate as further
explained in Chapter 6, “Organic Acids.”
Interpretation and Treatment: Low serine is
associated with disordered methionine metabolism
and methionine intolerance. Individuals with elevated
levels of homocysteine, a heart disease risk factor,
also have low levels of plasma serine and both factors
show normalization with vitamin B6, B12 and folate
treatments.450 Serine combines with homocysteine via
a B6-dependent step to produce cystathionine, which is
then metabolized to cysteine and taurine. During periods of elevated total plasma homocysteine in humans,
increased amounts of serine may be diverted to lower
plasma homocysteine. Increased demand for glutathione
synthesis increases serine conversion to cysteine, which
is one of the three amino acids required for the creation
of glutathione.
Plasma serine levels are lower than normal in homocysteinuria patients on folate therapy, compared with
healthy adults.450 Renal transplant recipients with mild
elevations of serum creatinine also have lower than normal serine levels. Treatment of renal transplant patients
with pyridoxine, folic acid and vitamin B12, cofactors
required for homocysteine metabolism, caused declines
in plasma homocysteine levels, with a concurrent rise in
plasma serine levels. Treatment of both pyridoxine responsive and non-responsive homocysteinemic patients
with betaine lowered plasma homocysteine and normalized plasma serine levels.
In summary, low fasting plasma glycine and serine
levels indicate chronically increased demand for glycine,
including possible high rates of degradation for loading
of folate through the glycine cleavage system. Conversely,
elevated glycine can result from enzyme polymorphisms
that decrease activity of the GCS, in which case there
is potential for increasing the various clearing enzyme
activities by raising concentrations of substrates such as
benzoic acid or cofactors derived from folic acid, vitamin
B6 and niacin. Elevated serine may respond to betaine
and, in hemodialysis patients, high serine and glycine
may be normalized with erythropoietin (EPO) therapy.443

levels. The efficiency of this system makes it highly unlikely that oral glycine will produce elevated plasma glycine in
individuals with normal GCS function. The several known
genetic variants are summarized in Table 4.14.447
Because of their neurotransmitter roles, glycine and
serine have been subjects of investigations into psychiatric disorders. Serine is a critical component in the
biosynthesis of acetylcholine, an important CNS neurotransmitter used in memory function and mediator of
parasympathetic activity. Depressed subjects show lower
glycine levels than controls.20,21 Depression is accompanied by elevation of the serine/glycine ratio.20 Patients
suffering from episodic acute psychosis display a disturbance of serine-glycine metabolism,436 and a higher serine-glycine ratio is observed in depressed individuals.20
Recent evidence has linked the severity of depression
with lowered plasma serine, alanine and glutamate.124

Sarcosine (N-Methylglycine)
H
H3C

N

COOH

Sarcosine

A rarely discussed aspect of its biochemistry
expands the scope of sarcosine’s potential clinical
significance. Simply put, sarcosine can serve to buffer
the methyl group or single carbon supply system. In
times of excess supply, methyl groups may be transferred from SAM to glycine, forming sarcosine. Those
carbons may then be recovered as 5,10-THF to sustain
the single carbon pool during overnight fasting. Genetic
polymorphisms in a key enzyme, sarcosine dehydrogenase, can prevent the transfer of the sarcosine N-methyl
group, resulting in sarcosinemia that can be related to
low methylation capacity. Moderately elevated plasma
sarcosine can be an indicator of polymorphisms for this
enzyme. Adequate methylation is important for gene
regulation, detoxification and neurotransmitter formation. Therefore, identification of individuals with such
difficulties can have clinical significance.
On most metabolic pathway charts the only route to
sarcosine originates with choline and proceeds through
betaine (trimethylglycine) and dimethylglycine to yield
sarcosine. The conversion of sarcosine to glycine is
the final methyl group removal step (right to left in
Figure 4.24). This pathway is a principal source of single
carbon units as the dehydrogenase enzymes convert the
methyl groups to 5,10-methylene-THF. However, when
SAM and glycine are in abundance, the reverse reaction,
N-methylation of glycine, also produces sarcosine (left
to right in Figure 4.24).451 The enzyme that catalyzes
this reaction, glycine-N-methyltransferase, plays an

important role in the overall economy of total-body
methyl group supply. See Figure 2.12 in Chapter 2,
“Vitamins,” to review the single carbon forms of folate.
During postprandial periods of high glycine clearance,
the rate of 5,10-methylene-THF formation can easily
exceed the rate of single carbon utilization, resulting in
folate trapping. Postprandial methionine flow encourages hepatic formation of SAM that also might accumulate because its rate of utilization is strongly regulated.
Clearing of SAM by glycine methylation stores excess
methyl groups as sarcosine.452 The advantage to the cell
is in providing a temporary methyl group storage site
in sarcosine. Up to 14% of dietary methionine may be
converted to sarcosine by this pathway.453
Clinical Relevance and Treatment: Since the involvement of sarcosine in methyl-group conservation is
a relatively new discovery, clinical associations are tentative. Elevated plasma or urinary sarcosine may become a
part of the metabolic pattern analysis that allows methylation status assessment. The glycine N-methylation
pathway can become important as a means of maintaining methylation status in conditions like autism, where a
block has been demonstrated in cycling of homocysteine
to methionine.386 This block tends to produce relative
excesses of SAMe, which is relieved by normal glycine
methylation. In autistic patients, elevated sarcosine is a
sign of exacerbation of methylation difficulties due to
blockage in release of homocysteine. Similarly, individuals with SNPs affecting tetrahydrofolate reductase may
have exacerbation of symptoms if there is concurrent
difficulty with the sarcosine methyl buffering system.
Figure 4.25 shows the distribution of plasma sarcosine
in a set of 599 sequentially accessioned outpatient specimens.550 Sarcosinemia is clearly present in a significant
Choline

SAMe

COOH

H2N

SAH

Glycine-Nmethyltransferase
Sacosine dehydrogenase

Glycine

Fe2+ B2
5,10-Methylene-THF

THF

Betaine
H3C
N
H

COOH

Sarcosine
(N-Methylglycine)

H3C

Dimethylglycine
dehydrogenase

Fe2+ B2
5,10-Methylene-THF

N

COOH

H3C

THF

Dimethylglycine

Figure 4.24 — Methylglycine Conversions
Sarcosine (N-methylglycine) is formed largely by single carbon transfer from dimethylglycine via dimethylglycine
dehydrogenase. A similar reaction converts sarcosine into glycine. A small amount of sarcosine may be formed by transfer
of a methyl group from SAMe to glycine.

Alanine (Ala)
N = 599

H3C

COOH

Plasma Sarcosine (microM)
NH2
ALANINE
115 (19%) > 5.0
Undetectable
83 124 165 206 247 288 329 370 411 452 493 534 575

Case

Figure 4.25 — Plasma Sarcosine Distribution of a

Large Outpatient Population

Sarcosine was measured by the standard ion exchange
chromatographic method. The detection limit for this
method was 2.0 µM, so much of this typical sampling
of an outpatient population is shown below this level.
One hundred and fifteen individuals, or 19% of the
population is above the 5th quintile cutoff of 5.0,
indicating slow clearance of sarcosine. Many patients
had levels above 15 µM consistent with more severe
clearance issues.

portion of this patient population. Sarcosinemia due to
defects in the enzyme, sarcosine dehydrogenase, which
catalyzes the conversion of sarcosine to glycine, has been
extensively reviewed.453 Sarcosinemia can also result
from folate deficiency because of the folate requirement for the sarcosine-to-glycine reaction. Sarcosine
is one of the amino acids found elevated in plasma for
patients with Parkinson’s disease.95 Since several amino
acids show CSF-plasma ratios lower than controls,
Parkinson’s disease appears to involve a disruption of
amino acid transport. Sarcosine has also been found
helpful as adjunct therapy for schizophrenia because it
delivers glycine to the brain, where it activates NMDA
receptor glutamatergic response, modulating dopamine
release.454–456

During strenuous exercise, muscle protein is degraded to amino acids that must be recovered to prevent
loss of energy. Alanine transaminase (AT) enzymes are
highly active in muscle. They provide a mechanism for
the removal of ammonia by transferring amine groups
from a variety of amino acids to pyruvate, forming
alanine. Thus, alanine is the major carrier of amino acid
nitrogen from muscle to liver where its carbon skeleton
is converted to glucose (via glucogenesis). This carrier
role of alanine is significant because the metabolism of
amino acids in skeletal muscle is a major contributor to
overall protein metabolism.
Sustained exercise requires that glucose be constantly supplied to muscle tissue. The alanine that flows from
muscle serves as substrate for hepatic alanine aminotransferase (ALT) that catalyzes the reverse of the muscle
reaction. Alanine is deaminated so that pyruvate is made
available for gluconeogenesis and the amine group is
used in formation of glutamate or glutamine. Glutamine
may then carry the amine group into the urea cycle for
final disposal as urea. The vitamin B6-dependent enzyme
ALT is one of the most abundant enzymes in hepatic
tissue, which has led to measurement of plasma ALT as a
standard marker for liver disease.457
Glutamine is the dominant regulator of blood
glucose via renal gluconeogenesis (see Glutamine).
Hepatic alanine clearance assists glutamine production
by transamination where the alanine carbon skeleton
becomes pyruvate while glutamate (and thus glutamine)
is formed, drawing α-ketoglutarate away from mitochondrial compartments.
Clinical Relevance and Treatment: The transaminase enzymes require pyridoxal-5-phosphate derived
from vitamin B6. In vitamin B6 deficiency, transaminase
activity falls. Because of the strong dependence on

Notes:

Ethanolamine (EtN)

NH2

HO

ETHANOLAMINE

H2O3P

O

PHOSPHOETHANOLAMINE
NH2

Phosphoserine (PS)

NH2

O

Phosphoethanolamine (PE)
H2O3P

COOH

These three amino acids are closely related structurally and they share principal roles in phospholipid
metabolism (Figure 4.26). Methylation of ethanolamine
by three SAM transfers yields phosphatidyl choline, also
known as lecithin. Metabolism of dietary lecithin can
also produce choline for acetylcholine synthesis. High
plasma ethanolamine levels may reflect reduced synthesis of choline due to poor methylation status.
Brain: Human tissues (especially the brain) contain
another form of lipid ethanolamine compound called
plasmalogen, where an unsaturated fatty acid is attached
to the first carbon of glycerol by an ether linkage. Recent
studies have shown that ethanolamine plasmalogens
confer special antioxidant properties on membranes.461
Phosphoethanolamine is a precursor to acetaldehyde,462
which can exert metabolic poisoning effects by irreversible binding to coenzyme A, especially in an individual
with restricted intake of pantothenic acid (vitamin B5).
Mitochondrial inhibition by both ethanolamine and PE
in vitro suggests that altered brain phospholipid metabolism may initiate depression and bipolar disorder.463
Parkinson’s disease patients have elevated plasma
phosphoserine and the CSF-plasma ratio of many amino
acids is significantly lower in patients than those of
controls. In contrast, Alzheimer’s disease patients had
lower CSF levels of phosphoserine than controls.96 Both
of these disorders may have origins in the dysfunction
of transport of neutral and basic amino acids across the
blood-brain barrier.95
DNA, Wound Healing and Tissue Regeneration:
Ethanolamine is converted to phosphoethanolamine
via a magnesium- and manganese-dependent reaction.
High levels of ethanolamine combined with low levels of
phosphoethanolamine may reflect functional deficiency
of these elements. Ethanolamine exerts significant effects
on DNA synthesis, which are independent of phosphoethanolamine utilization in membrane lipid formation.464
At high concentrations, ethanolamine exerts inhibition
of insulin-induced DNA synthesis. Patients with diseases
that produce increased requirements for tissue replacement have increased demands for DNA synthesis. Assuring adequate cofactor status to prevent chronic elevated
ethanolamine should assist such patients, such as those
with chronic inflammatory bowel conditions.
In addition to possible physiological effects, high
ethanolamine can be due to environmental exposure,
shown in Table 4.15. Other names for ethanolamine that
might appear on labels for chemicals are ethylolamine,
monoethanolamine, β-aminoethyl alcohol, aminoethanol and 2-hydroxyethylamine. Although no data
is available for effects of chronic exposure in humans,
ethanolamine is irritating to the skin, eyes and lungs. At

transamination reactions for alanine clearance, high
alanine levels can indicate vitamin B6 need. Similar to
the response of glutamine, plasma alanine may actually
rise when dietary protein is restricted, due to increased
de novo synthesis.458
A pattern of low alanine and other amino acids in
plasma or urine can be a sign of need for supplementation
of alanine, especially if symptoms of easy fatigability between meals are present. In hypoglycemic adults, infusion
of alanine to raise plasma alanine from 138 to 1,481 µmol/
L improved some aspects of cognitive performance.459
Huntington’s disease seems to be characterized by a
defect in cellular uptake or metabolism of neutral amino
acids resulting in low plasma alanine. Genetic polymorphism of the genes that control cell uptake of alanine in
non-Huntington’s patients may account for variability
seen in plasma alanine.460

Table 4.15 — Environmental Sources

of Ethanolamine

Agricultural chemicals

Cleansers

Corrosion inhibitors

Cosmetics

Detergents

Dry cleaning

Electroplating

Emulsifiers

Emulsion paints

Fuel oil additives

Hair-waving solutions

Pharmaceuticals

Polishes

Soaps

Wool treatment

Ethanolamine
Mg2+
Mn2+

Phosphoethanolamine
Mg2+

Ethanolamine cytidyl transferase

CH3+

O
H

H+

CO2

NH3+

R
O

3 SAM

3 SAH

+

N

R
O

H H

COO-

Phosphatidyl
ethanolamine

CH3+
CH3+

Phosphatidyl
choline

Figure 4.26 — Metabolism of Phosphatidyl Ethanolamine

Phosphatidyl
serine

H H

NH3+

R

The “R” group in these structures represents the diacylglycerol phosphate group. These derivatives of the amino acids are
major components of cell membranes and they are present in virtually all whole foods. Recent evidence indicates that human
tissues do not have the enzyme for direct phosphatidyl serine decarboxylation. The absence of this reaction suggests that
dietary intake of phosphatidyl ethanolamine is of more importance to supply the large demand for cell membrane formation.

Notes:

high concentrations, it causes central nervous system
depression in exposed animals. Further information on
the toxicity of ethanolamine may be found at the U.S.
Occupational Safety & Health Administration Web site
(www.osha.gov).
Interpretation and Treatment: Cytosolic phosphoethanolamine and ethanolamine have been shown
to provide prognostic factors in breast cancer. Phosphoethanolamine is elevated in patients with high rates
of breast tumor growth.465 As the stage of the disease
progresses, the values for phosphoethanolamine plus
ethanolamine become higher. Increased plasma and urinary phosphoethanolamine is found in individuals with
osteopenia associated with “adult” hypophosphatasia,
along with subnormal circulating total alkaline phosphatase activity.466
High PE may indicate functional impairment
of acetylcholine synthesis. Functional vitamin B12
or folic acid deficiency, or disordered methionine
metabolism (i.e., inhibition of methyl group transfer),
may account for high PE levels. Therefore, high
phosphoethanolamine may indicate a need for SAMe,
vitamin B12, folate and betaine.

Bone Collagen-Specific
Hydroxyproline (HPro)
HO

Collagen, the protein of bone, tendons, ligaments
and basement membranes is the most abundant protein
in the human body. Its unique structural properties are
due to the recurrence of proline and glycine residues
and its great strength and stability are due to cross-linking afforded by lysine side chains. Cells that are dedicated to collagen synthesis make large demands on proline
and glycine supply.

H
HYDROXYPROLINE

Proline (Pro)
COOH

High levels in 24-hour urine or plasma correlate
with the increased osteocalcin secretion that is characteristic of high bone turnover.472 This marker may be as
sensitive as the measurement of bone collagen-specific
peptides.473 Free plasma hydroxyproline in multiple
myeloma is closely related to the extension of skeletal
lesions at diagnosis and is useful in the follow-up of
bone disease.474 Plasma hydroxyproline also is highly
correlated with serum alkaline phosphatase,475 another
marker of bone resorption.
Hydroxyproline, a component of collagen, is
synthesized from proline using vitamin C and iron as
cofactors. Vitamin C has been used to successfully treat
certain types of collagen disorders and to stimulate collagen synthesis.476

N

Hydroxylysine (HLys)

Proline is found in virtually every dietary protein
except lactalbumin. Although proline is not classified as
an essential amino acid, proline levels in plasma are dramatically reduced with a proline-free diet.467,468 Proline is
a major constituent of collagen and can be metabolized
to α-KG, which is important in ammonia detoxification
and citric acid cycle.
Proline is universally required for protein synthesis
and is metabolized to hydroxyproline, an important
component in connective tissue. Therefore, high levels
may reflect inadequate connective tissue synthesis.
Proline can also be oxidized to glutamic acid, requiring
niacin as a cofactor precursor.
Interpretation and Treatment: Low plasma or urine
levels of proline reflect low tissue supply of this amino
acid and α-KG could be used to normalize the value.
Low proline levels can indicate a low-protein diet and
may prevent optimal connective tissue maintenance. Hyperprolinemia is a recognized genetic disorder characterized by renal and central nervous system dysfunction.26
Following on the earliest nutritional interventions
for scurvy, vitamin C and iron are known cofactors in
the conversion to hydroxyproline and may be useful
if connective tissue symptoms are present. Acute or
chronic deficiency of vitamin C produces a significant
increase in the proline/hydroxyproline ratio in urine.469
The relationship between proline and hydroxyproline
urinary excretion has been used as an index of collagen
catabolism.470 In conclusion, high levels of proline and
hydroxyproline may be lowered by supplementing vitamin C and iron.471

PROLINE

H
COOH

N

NH2
H2N

COOH
OH

HYDROXYLYSINE

A portion of the lysine of collagen is modified to
hydroxylysine, which provides a marker for bone loss
due to the turnover of collagen during bone resorption.
Both hydroxylysine and hydroxyproline are indicators of
liver disease. However, hydroxylysine has the strongest
correlation, possibly because dietary intake of collagen
can influence hydroxyproline levels.477 Changes in
hydroxylysine excretion with cadmium loading in
experimental animals indicate that cadmium interferes
with collagen synthesis.478
Urinary hydroxylysine provides a marker of
response to growth hormone in GH-deficient children.479
The hydroxylysine group of bone collagen is glycated
and elevated urinary concentrations of galactosylhydroxylysine (GHYL) provides a specific indicator of
bone metastases because of the greatly increased rate
of degradation of bone collagen.480 Glycosylation of
hydroxylysine in bone collagen and has been proposed

to explain the higher urinary GHYL in osteoporotic
women.481
High plasma levels are indicative of connective
tissue breakdown. Collagen is synthesized using the
cofactors iron, α-ketoglutaric acid and vitamin C.
Supplementation of these nutrients as well as chondroitin sulfate and manganese may be useful in reversing
this condition.482

β-Amino Acids

NH2

BETA-ALANINE

HOOC

β-Alanine

β-Alanine is released from skeletal muscle during
strenuous exercise and it occurs in food mainly as carnosine in red meats or anserine in poultry. The pyrimidines
cytosine and uracil from DNA and RNA are degraded to
β-alanine.
β-Alanine can become elevated in plasma or urine
due to enzyme deficiency, dietary intake, intestinal
Notes:

β-Amino acids are so named because their amino
groups are attached to the beta carbon. These compounds are not found in proteins. They serve physiological functions ranging from bile acid precursor and
antioxidant to neurotransmitter and metabolic control.
They can be acquired from the diet or synthesized de
novo. Taurine is a β-amino acid, but was also discussed
under the sulfur amino acids. Taurine and the other
β-amino acids use the same carrier-mediated active
transport into cells.

microbial overgrowth, or high turnover of muscle tissue
(Figure 4.27). β-Alanine has been used as an index of
carnosine catabolism.259
Deficient activity of the enzyme β-alanyl-α-ketoglutarate transaminase in a 4-year-old girl was corrected
by oral pyridoxine therapy in one reported case.483
Intermittent seizures and lethargy were reduced. The
biochemical pathway involved in this case is the conversion of β-alanine to α-ketoglutarate (not shown in
Figure 4.27).
Vitamin B6 deficiency generally causes lowered
activity of the enzymes that degrade β-alanine, resulting
in high urinary excretion.484 High β-alanine is frequently
associated with generalized β-aminoaciduria and
concomitant loss of other amino acids such as taurine,
due to impairment of renal tubular resorption. Low
taurine levels may indicate taurine depletion by this
mechanism. High levels of β-alanine are frequently
accompanied by increases in 1- and 3-methyl-histidine,
carnosine and anserine.79
Uptake of taurine occurs by a carrier-mediated
active transport process specific for β-amino acids.485 Because there is transporter competition for β-amino acid
entry into cells, excessive taurine administration may
cause elevated carnosine (resulting in muscle weakness)
or elevated β-alanine.486 Therefore, monitoring β-alanine
levels can help the clinician appropriately adjust taurine
supplementation. Use of taurine should be decreased
when β-alanine is elevated. Excess excretion of taurine
may indicate β-aminoaciduria. β-Alanine impairs renal
tubular resorption of a variety of amino acids, including taurine, thus propagating amino acid deficiencies.

DNA

Zn++ Enzyme

Cytosine
Liver

Carnosine
(plasma)

β-ALANINE
(plasma)

Strenuous
Exercise

Dietary Sources of β-Alanine

β-Alanine
(muscle)

Histidine
or 1-MHis
Gut microbes

Activate myosin ATPase
α-KG
P-5-P

Aspartic acid

O

ATP

HO—CH2—C—C—C—NH—CH2—CH2—C—OH

Coenzyme A

CH OH
Pantoic acid

Pantothenic acid

Figure 4.27 — β-Amino Acid Pathways

• Fatty acid biosynthesis
• Fatty acid oxidation (β-oxidation)
• Carrier for acetate (TCA)

β-Alanine

CO + H 0

O

Acetate

Malonate

Glutamate

CO2
CH3

Carnosine
(muscle)

Carnosine (red meat)
β-Alanylhistine
or
Anserine (poultry)
β-Alanyl-1-methylhistidine

The origins and dispositions for β-alanine are quite different from those for alanine discussed previously. At cell death, DNA
catabolism releases β-alanine from breakdown of cytosine. Dietary carnosine and anserine are normally hydrolyzed rapidly
with release of β-alanine. β-Alanine is used for synthesis of muscle carnosine and for ubiquitously distributed coenzyme A that
is required for multiple central energy pathways. Excess β-alanine is oxidized via conversion to acetate.

Epileptic patient treatment with the GABA transaminase
inhibitor, vigabatrin, produces elevated β-alanine because the drug also blocks its breakdown.487
Intestinal bacteria and/or Candida albicans can
also make β-alanine, which can raise plasma levels of
β-alanine. With high β-alanine, check urinary indican or
other dysbiosis markers as a measure of bowel dysbiosis. A bowel detoxification program may be appropriate
with supplementation of a high-potency Lactobacillus
acidophilus and L. bifidus products along with pre-biotics
and a high-fiber diet to support growth of the favorable
organisms (see Chapter 7, “GI Function”). Because of the
competition of β-alanine for the taurine transporter, a
bowel detoxification program to remove a major source
(microbial overgrowth) of β-alanine can help to raise
the kidney threshold to taurine spill and, therefore, help
raise plasma taurine levels.
β-Aminoisobutyric Acid
HOOC

NH2
CH2
BETA-AMINOISOBUTYRIC ACID

Thymine, released when RNA and DNA are degraded, enters a catabolic pathway that leads to β-aminoisobutyric acid (β-AIB). High β-AIB in urine is a
benign metabolic polymorphism present in some human
populations due to deficiency of hepatic β-AIB-pyruvate
transaminase. Over 40% of some asian populations have
this condition.79 Excretion of β-AIB increases in cases
of leukemia and x-ray radiation-induced destruction of
DNA.488 Parenteral administration of excessive folic acid
also stimulates cell turnover that results in increased
β-AIB.489 If this amino acid is high, it may indicate a
vitamin B6 insufficiency.

Carnosine
ß-Alanine

Histidine

H2N

H

H

N

N
COOH

O

N

Anserine
ß-Alanine
H
H 2N

1-Methylhistidine
CH3
N

N
O

COOH

N

Carnosine and anserine are involved in muscle
function through the regulation of muscle phosphorylase activity.490 Carnosine and anserine are formed in
skeletal muscle, where they activate the myosin ATPase
enzyme.491 Carnosine is a dipeptide containing histidine
and β-alanine. There is an active turnover of carnosine normally, with exchange between muscle, plasma
and liver. Anserine is structurally like carnosine except
that the histidine ring contains a methyl group in the
1 position (see 1-methylhistidine). It has been shown
that testosterone increases carnosine synthesis, whereas
anserine synthesis increases with age, indicating the role
of these amino acids in androgen-modulated changes in
skeletal muscle.492
Both compounds are present in the muscle tissue
of animals. Their concentrations are lower in humans
than in most animals. Anserine predominates in poultry
(especially hens) and carnosine is highest in pork.493
Carnosine and anserine are hydrolyzed by carnosinase
in human tissues, releasing histidine and 1-methylhistidine, respectively and β-alanine (Figure 4.27).
Dietary carnosine forms a tight complex with zinc,
which greatly assists in the absorption of zinc494 and acts
as an antioxidant in ischemia495 and in ethanol-induced
injury.496 Through this tight binding complex, carnosine
can rescue neurons from zinc- and copper-mediated
neurotoxicity and may be an endogenous neuroprotective agent.497
In mammalian mitochondria, anserine activates and
carnosine inhibits Ca(2+) uptake.498 Both anserine and
carnosine increase the respiratory burst and interleukin1 beta production of human neutrophils. They suppress
apoptosis of human neutrophils in vitro, showing that

ANSERINE

carnosine and anserine have the capacity to modulate
the immune response.499 It has been shown that they
potentiate the carcinogenic effects of Ni(II) by increasing
the formation of oxidized nucleotides into DNA.500 However, carnosine provides protection of rat brain endothelial cells against degenerative affects of β-amyloid501 and
against malondialdehyde-induced toxicity.502
Genetic variants with deficient carnosinase activity in plasma show greatly increased urinary carnosine,
but no detectable increase in plasma carnosine. Genetic
carnosinase deficiency is a variable phenotype with
presentations ranging from normal to severe psychomotor retardation, hypotonia and myoclonic seizures in
the first year of life. Affected individuals excrete high
amounts of carnosine and anserine.503 The condition
was found in a 12-year-old male with profound mental
retardation, severe athetoid spastic quadriparesis, optic
atrophy, sensory peripheral neuropathy and suprabulbar signs.504 Reduced serum carnosinase activity is
also found in patients with Parkinson’s disease and MS
and in patients following a cerebrovascular accident.
Chronic high carnosine in plasma or urine is associated
with mental retardation.505 Inherited traits producing
a deficiency of carnosinase, the enzyme that converts
carnosine back to histidine plus β-alanine is associated
with progressive neurological problems and sensory
polyneuropathy.504,506
Zinc is the cofactor for carnosinase and elevations of
carnosine or anserine may be one effect of zinc deficiency. A patient with zinc deficiency who consumes a
high-poultry diet would tend to show increased anserine
excretion because of low carnosinase activity.
Notes:

The Methylhistidines

In cases of mild elevation of 3-methylhistidine, the
contribution of dietary meat intake can be accounted for
by checking 1-methylhistidine. Significant 1-methylhistidine excretion confirms high-meat intake.507 This method
has been used to achieve greater accuracy in the assessment of the catabolic effects of infection.516 Hypothyroidism and reduced dietary protein can result in decreased
urinary 3-MHis.517 Twenty-four-hour urinary 3-MHis
excretions can be applied for estimating skeletal muscle
mass (SM) in healthy adults on a meat-free diet.518
Excessive muscle tissue breakdown can be associated
with inadequate antioxidant protection in the muscle.
Supplementation of the natural antioxidants—vitamins
A, C, E and B2 and selenium, β-carotene, lipoic acid and
coenzyme Q10 (CoQ10)—may be useful in preventing
excessive free radical pathology associated with this problem.519 BCAAs have also been indicated to lower plasma
levels of 3-MHis by preventing muscle proteolysis.520

1-Methylhistidine (1-MHis)
NH2

N

COOH
N
CH3

1-METHYLHISTIDINE

NH2
COOH

3-METHYLHISTIDINE

Enzymes in skeletal muscle carry out the post-translational methylation of protein histidine residues forming 3-methylhistidine. High urinary excretion of 3-MHis
indicates active catabolism of muscle and is a marker
for skeletal muscle breakdown as in strenuous exercise.510 The catabolic effects of cortisol and the opposing
anabolic effects of testosterone on muscle catabolism are
reflected in the level of 3-MHis in urine. Excretion of 3MHis rises with cortisol and falls with administration of
testosterone when cortisol is normal.511
3-MHis has been used as a marker in studies of
clinical conditions associated with nitrogen loss, including trauma, infection,512 and in uncontrolled diabetes.513
The ratio of urinary 3-MHis to creatinine is increased
in severe injury, thyrotoxicosis, neoplastic disease,
prednisolone administration and sometimes Duchenne
muscular dystrophy. In myxedema, osteomalacia and
hypothermia, the ratio of 3-MHis to creatinine in urine
was decreased.514 Hypervitaminosis A in rats causes acceleration in myofibrillar protein breakdown revealed by
increased urinary 3-methylhistidine.515

N

There is a relative paucity of information about
clinical interventions to correct polyamine abnormalities, partly because laboratory evaluations of polyamines
have not been routinely available. The greater availability
of instrumental methods for their analysis and the key
physiological roles of polyamines, however, make their
inclusion in profiles used to screen for metabolic issues a
likely eventuality.
Since they posses no carboxylic acid group, the
polyamines are not considered amino acids. They will
be discussed here, however, because they are derived
from amino acids and are likely to be reported in amino
acid profiles. The biologically active polyamines contain
two (putrescene and cadaverine), three (spermidine), or
four (spermine) amine groups. This means that they are
highly basic molecules that become positively charged
at neutral pH. Their special charge characteristics lead
to their participation in ionic transfer phenomena,
especially calcium ion (Ca++) movements that are widely
used for cellular regulation. The amine groups also
make these compounds highly odiferous, producing the
characteristic odor of putrefaction. Salivary cadaverine
is associated with oral malodor independent of sulfur
compound presence.521
Polyamine levels have not been available as routine
assays from clinical laboratories, so little information is
available on abnormal levels. Availability of precursor
amino acids and pathway cofactors may be presumed

H3C
N

The Polyamines

3-Methylhistidine (3MHis)

1-Methylhistidine is derived mainly from hydrolysis of the anserine of dietary meat, especially poultry.
Carnosinase splits anserine into β-alanine and 1-methylhistidine (Figure 4.27) and since 1-methylhistidine is
not normally metabolized in human tissues, most of it
rapidly appears in urine.507 Urinary excretion of 1-methylhistidine has been used as a marker to distinguish
meat-eating individuals from vegetarians.508 Vitamin
E deficiency can lead to 1-methylhistidinuria from increased oxidative effects in skeletal muscle.509

to have effects that could lead to lowered polyamine
synthesis. Genetic polymorphic changes in the enzymes
of the pathways also have potential to reduce rates of
synthesis.

Arginine

H3N+—CH2—CH2—CH2—CH—COOH

Putrescene

Ornthine
B6

CO2

H3N+
N+H3

H3N+—(CH2)4—NH3+
Putrescine

Putrescene

SAM
5'Methylthioadenosine
H3N —(CH2)4—NH—(CH2)3—NH3+
+

NH

NH

NH3+

Spermine

Spermine is abundant in seminal plasma and brain
tissue. Polyamines have long been known to be associated with male reproductive function and, in the
mouse, growth and fertility require normal spermine
synthesis.527 Modulation of synaptic transmission by
polyamines has been proposed as a reason for high brain
levels of spermine. Uptake of choline and dopamine is
inhibited by spermine.528
Spermine oxidation by copper-containing serum
amine oxidase enzymes causes a necrotizing cytotoxic
effect, in which phosphatidyl serine participates via its

SAM
5'Methylthioadenosine

H3N —(CH2)3—NH—(CH2)4—NH—(CH2)3—NH3+

+

Spermine

Figure 4.28 — Biosynthesis of Spermine from

Arginine or Ornithine and SAM

H3+N

Spermine
Spermidine

Putrescene is an intermediate in the formation of
spermine. The conversion of putrescene into spermine
consumes two SAM molecules in reactions that transfer
propylamine groups (-(CH2) 3 -NH2 ) rather than the
methyl group from the methionine sulfur atom as occurs
in methyl transfer pathways (Figure 4.28). Thus, the formation of spermine from putrescene results in a net loss
of methionine. Putrescene accumulation can alter chromatin structure.522 Cancer of blood and solid tissues,
including stomach tumors induced by N-methyl-N-nitro-N’-nitrosoguanidine are associated with significant
elevations of putrescine, spermidine and spermine.523
However, the production of spermine from putrescene
may be why it is required in cell culture growth media
for mammalian cells.524 Other evidence links putrascene
with regulatoin of cell proliferation. Human HL-60 cells
grown in culture show rapidly declining putrescene
(but not spermine or spermidine) during apoptosis,525
whereas proliferation due to chemically induced carcinogenesis is associated with increased putrescene.526

Arginine decarboxylase or ornithine decarboxylase
initiates the conversion of arginine or ornithine to
putrescine, respectively. Two molecules of SAM are
then required to transfer –(CH2)3-NH2 groups from
methionine, forming spermidine and spermine.

ability to signal phagocytic engulfment.529 Oxidation of
spermine is the mechanism that makes seminal plasma
immunosuppressive.530 Spermine also has been shown
to be responsible for the T-lymphocyte suppressive effect
of seminal fluid.531
In myometrium cell plasma membranes, spermine
has a relaxing effect on smooth muscle cells. The effect is
mediated by increasing Ca++ concentration.532 Activity of
Ca2+, Mg(2+)-ATPase was stimulated at very low concentrations (0.1–0.5 µM), but an inhibitory effect became
dominant at higher concentrations.
In women, plasma spermine concentrations undergo distinct cyclic changes during the menstrual cycle.
Peak spermine concentrations coincide with the first
estradiol increase and the follicular phase, just prior
to ovulation, during the period of rapid endometrial
growth.533 Since the biosynthesis of spermine results
in net loss of methionine, the availability of this essential amino acid for methylation functions may drop as
spermine rises.

Cadaverine

H2N

H2N

COOH

NH2

Lysine
Cadaverine

CO2

The percentages of amino acids in a free-form amino
acid base formula are set according to studies estimating
optimum intake for maintenance and growth.539 For the
indispensable amino acids with reported levels below
their low reference limits, additional amounts are added
as calculated by formulas like that shown below, where
the constant is adjusted to provide safe and effective
increments to the base.The cofactors α-ketoglutarate and
vitamin B6 are added to assure interconversions leading
to non-essential amino acids.
Added amount (g) =
(Low limit − Reported level) ÷ Low limit × Constant

Notes:
NH2

Cadaverine
Figure 4.29 — Conversion of Lysine

to Cadaverine

This reaction does not occur in human tissues, but
bacteria expressing lysine decarboxylase can produce
cadaverine from lysine in a single step.

Because of their free (non-peptide linked) form, the
amino acids are very efficiently absorbed, even in the
absence of stomach acid and pancreatic secretions. Some
patients prefer encapsulation to avoid contact with taste
buds, but in most cases, mixing with flavorful juices
or food is sufficient. Effective adult dosage is 10 to 30
grams of the mixture daily.
The biochemistry, physiology and clinical impact
for individual amino acids that have been covered in this
chapter explain the extreme variety of favorable clinical
responses to improved amino acid status. A common
hypothesis among practitioners is that many cell functions can be restored by providing amino acids to assist
neurotransmitter and hormone synthesis. The physical
and immunologic barriers in the gut can be restored as
the rate of secretory and structural protein production is
increased. Blood glucose can be stabilized through better
gluconeogenesis, whereas utilization of fatty acids for
energy is enhanced by better lipoprotein synthesis and
mitochondrial performance. Hepatic and gastrointestinal detoxification reactions are improved when amino
acids required for conjugation reactions are available
and the oxidative damage from such activity is reduced
when sulfur amino acid supply is adequate to maintain
glutathione.

Free-Form Amino Acid
Supplement Formulas

Lysine decarboxylase

H2N

Lysine decarboxylase is not present in human
tissues, but some bacterial species possess the gene
that allows the formation of cadaverine from lysine.
(Figure 4.29) The production of cadaverine by Escherichia coli allows the organism to survive acid stress via
inhibition of outer membrane proteins called porins.534
Cadaverine induces compartmentalization of Shigella
species to the phagolysosome of polymorphonuclear
leukocytes. This response appears to be protective,
contributing to the diminished ability of polymorphonuclear leukocytes to transmigrate across intestinal epithelia, carrying the infection to the tissues of the host.535
Putrescine and cadaverine are the most concentrated
polyamines in saliva, having highest concentrations of
33 and 18 µg/mL, respectively, immediately after awakening.536 The growth of anaerobic organisms in bacterial
vaginosis is accompanied by higher levels of putrescene
and cadaverine that generate the fishy odor.537,538

NH2

Correction of Abnormal
Amino Acid Levels

low arginine and lysine, relative to leucine. Likewise,
phenylalanine is only moderately low relative to tyrosine, which is severely depressed. The rate of fall for
individual amino acids depends on specific non-protein
demands, whereas urea and blood protein synthesis
change uniformly as they represent processes involving
all 20 protein-building amino acids.

Fasting plasma amino acid profiles reflect amino
acid status in humans, as shown in the case of an 81year-old female with maldigestion and muscle wasting.
A serum chemistry profile revealed frank protein and
amino acid deficiency as simultaneous low albumin and
total serum protein in the presence of normal BUN-Creatinine ratio (Figure 4.30A). The protein deficiency state
was evident in her plasma amino acid profile, which
showed abnormally low values for all essential amino acids as well as the 4 non-essential amino acids reported.
Thus, not only does she show signs of reduced rates of
major protein synthesis, but there is also evidence that
she is unable to sustain plasma amino acid concentrations for all anabolic or energy-yielding processes. The
added dimension of relative concentrations from the
amino acid profile is seen in the disproportionately

BUN/Creatinine

15.6 g/dl

12.0–20.0

Protein, Total

5.1

L

6.4–8.4

Albumin

2.9

L

3.0–5.5

Reference Limit

Results
Essential Amino Acids

Plasma Amino Acid Profile

Essential Amino Acids

Arginine

Results

Reference Limit
50–160

Histidine
Isoleucine
L

Leucine
L

Reference Limit

Example of an Individual Plasma Amino Acid Profile

Lysine
Methionine
Phenylalanine
Threonine
Tryptophan
Valine
L

170–420

Taurine
L

50–250

Result

Conditions that manifest due to impaired protein
synthesis, poor detoxification activity or low neurotransmitter status may improve with optimized amino acid
supply. Low levels of EAAs in plasma provide the most

Serum Chem-Screen

Free-Form Amino Acid
Supplementation

70–140
50–160
90–200
150–300
25–50
L

45–140
100–250
35–60

Example of an Individualized Amino Acid Supplement
Grams Added

L

50–160

Valine

11.1 +

11 gm
L

70–140

Leucine

12.9 +

14 gm
L

50–160

Isoleucine

9.4 +

9 gm
L

90–200

Phenylalanine

12.9 +

5 gm
L

150–300

Tryptophan

2.0 +

0 gm
L

25–50

Methionine

7.7 +

0 gm
L

45–140

Threonine

8.1 +

0 gm

Threonine
L

100–250

Lysine

9.4 +

0 gm

Tryptophan
L

35–60

Histidine

10.1 +

0 gm

Valine
L

170–420

Arginine

9.4 +

0 gm

Taurine

3.3 +

8 gm

Glycine
L

200–450

Pyridoxal-5-Phosphate

.30 +

0 gm

Serine
L

80–200

Alpha-ketoglutaric acid

8.5 +

0 gm

Taurine
L

50–250

Tyrosine
L

140–360

Histidine
Isoleucine
Leucine
Lysine
Methionine
Phenylalanine

% of Base
Arginine

Essential Amino Acid Derivatives

Figure 4.30A — Laboratory Results in

Amino Acid Deficiency

Chronic deficiency of amino acids produces low albumin
and total protein with normal blood urea nitrogen (BUNCreatinine) and concurrently lowered plasma amino acid
concentrations. These markers show different aspects of
the failure to supply nitrogen and essential amino acids.

Base Formula Amount: 253 gm

Figure 4.30B — Amino Acid Supplement

Formula Based on Plasma Amino
Acid Profile Results

The laboratory results shown are used to design a
customized formula of essential amino acids and
cofactors to assure metabolic utilization. In order to
more closely approximate the most effective individual
balance, a calculation is used to adjust amounts of
individual amino acids in the supplemental formula.

Leucine Concentration (uM)
0.0

1.0

2.0

3.0

4.0

Time (hr.)

clinical responses to amino acid supplementation
customized according to plasma levels in the manner
described in this chapter was initially surprising. Since
protein intake was generally near levels corresponding
to nitrogen balance, the effects may be best explained
by considering effects of transient elevated blood levels
rather than total daily increase of amino acid intake.
An algorithm can be used to individually customize formulations based on fractional reductions of
each amino acid below reference limits. Compounding pharmacies can produce the custom formulations.
Figure 4.30B (top) shows an example of laboratory
results from which the customized amino acid formula
in Figure 4.30B (bottom) is designed. The variable
(Patient Result – Low Reference Limit), is applied with
appropriate multipliers to yield the values in the column
labeled “Grams Added.” The supplement formula is
designed to yield 300 grams of blended powder. The
supply normally lasts for 30 days, at the usual adult
dosage of 1.5 tsp (5.0 g) twice daily, before meals. A
base mixture is used as the starting point to which extra
amounts of individual amino acids are added. The “% of
Base” column shows the fixed composition of the base.
To the 253 grams of base mixture shown in the example,
additional amino acids are added in amounts shown in
the “Grams Added” column. The resulting formula is
enriched in those amino acids that the individual has the
most difficulty sustaining. In this case the effect is to enhance primarily the branched-chain and aromatic amino
acids. Critical cofactors, α-ketoglutarate and pyridoxal5-phosphate helps to assure hepatic interconversions so
that NEAAs may be formed as needed.
One explanation for the clinical improvements
from such therapy is the breaking of vicious cycles
formed when patients develop homeostatic set points
of amino acid utilization that limit processes such as
protein synthesis for formation of new healthy tissue,
neurotransmitter synthesis, detoxification functions, or
nuclear regulatory controls. After consumption of a 10 g
oral dose of EAAs, plasma levels quickly rise, peaking
at concentrations approximately twice the upper limit
of fasting levels within 30 to 60 minutes (Figure 4.31).
Figure 4.32 shows a hypothetical curve representing
daily amino acid excursions following meals overlaid
with the shorter duration supraphysiologic rises
from oral doses of free-form amino acids. One
hypothesis explaining the high percentage of patients
reporting clinical improvements after starting such

Figure 4.31 — Blood Spot Amino Acid

Concentrations after Oral Dosing

Three healthy adult fasting males submitted blood
spot specimens at the intervals shown after consuming
a 10 g bolus of free-form amino acids containing 1.3 g
of L-leucine. The three different symbols show an
individual subject’s results from the eight dried blood
spot specimens collected over the 4-hour interval.
Leucine concentrations were determined by quantitative
LC-MS/MS analysis.

direct information regarding candidacy for amino acid
therapy. Retesting after administration of an amino acid
mixture allows assessment of efficacy.
There is abundant evidence from the medical literature to demonstrate a wide range of clinical responses to
amino acid supplementation. Since no digestive function
is needed for free-form amino acids and absorption is efficient, their assimilation is much quicker than for amino
acids released from dietary protein. Oral amino acid
supplementation attenuates the extent of ischemia-reperfusion injury.540 Daily dosing of elderly adults with 18
grams of essential amino acids stimulates muscle protein
anabolism.541 The positive effect of arginine and lysine
on osteoblast proliferation, activation and differentiation
suggests a benefit of amino acids in prevention of osteoporosis.542 Supplementation of a mixture of essential
amino acids lowered blood sugar and reduced cataract
incidence in rats with streptozotocin-induced diabetes.295
Symptom improvements have been reported after
administration of amino acids in a large number of
patients who presented with a broad range of chronic
illnesses and children with developmental or behavioral
problems.550 The frequency and magnitude of favorable

Plasma Concentrations

Individual Free-form
AA’s Peaking at
Supraphysiological Levels

Amino Acids from
Dietary Protein

Noon

6 AM

6 PM

Figure 4.32 — Representation of Daily Plasma Amino Acid Levels

slow down the rate of interchange of many amino acids,
producing higher levels in plasma due to lower utilization rates. Table 4.16 summarizes some specific nutrient
indications from amino acid profile results.
If blood amino acids are initially in the low-normal
ranges and micronutrients are added, then follow-up
testing may show even lower amino acid concentrations
because the rates of utilization have increased. Extra
zinc and B-complex vitamins, for example, can increase
the rate of protein synthesis in multiple tissues. Such responses can result in plasma amino acid concentrations
being lower on follow-up testing, even though amino
acids are being supplemented. Thus, multiple factors
must be considered for interpretation changes seen on
follow-up testing of amino acids.

supplementation routines is that free-form amino
acids twice daily stimulate metabolism by significantly
increasing plasma levels.

Schematic approximations are shown for plasma concentrations of essential amino acids from three meals of dietary protein
compared with twice daily oral dosing with 5 grams of a free-form essential amino mixture. Although the supplement
supplies only a fraction of total daily intake, the immediate delivery to absorptive mechanisms without need for protein
digestion means that assimilation is rapid. Each amino acid (represented by colored lines) is delivered to the tissues at mild
supraphysiologic concentration, allowing greater saturation of multiple biosynthetic and energetic processes.

Cofactors

A major reason for impaired utilization of amino
acids generating elevated fasting plasma levels is dietary
deficiency of micronutrients such as zinc and B-complex vitamins. For example, plasma serine, threonine,
glycine, alanine, tyrosine, lysine and histidine levels
increase in vitamin B12 deficiency.543 Restriction of flux
out of plasma results from lowered utilization due to restricted vitamin B12 supply. Activities of the major transminase enzymes discussed under glutamine and alanine
are lowered by zinc deficiency.544 This effect tends to

Table 4.16 — Vitamin and Mineral Indications from Amino Acid Reports

Specimen

High/Low

Nutrient

Reference

Multiple High EAAs

Plasma or whole blood

High

Vitamin B6

545, 546

His

Plasma

Low

Folic acid
Zinc
Lys

Plasma

Low

Carnitine
Pro/HPro

Urine

High

Vitamin C
Sarcosine, Gly

Plasma

High

Vitamin B12, Folate
Phe/Tyr

Plasma

High

Tetrahydrobiopterin
Iron

Case Illustrations
CASE ILLUSTRATION 4.1 —

Metabolic Fragility from Insufficient Glu & Gln

CASE ILLUSTRATION 4.2 —

The amino acid profile was measured on a plasma
History: Four years prior to the testing date, this 30-yearspecimen. The results show concurrent low Glu and Gln.
old clinician had recurrent urinary tract infections for several
Although neither amino acid is below the 95th percentile
months, treated with antibiotics. She says, “Then suddenly
ranges, the dependent nature of this pair makes the results
my body just broke down. My immune system just collapsed
quite unusual. The physiological state might be described as
and I had infections everywhere: lungs, ears, nose, bladder,
one of metabolic fragility because of difficulty in responding
etc. I got allergic to everything I ate.”
to systemic pH and ammonia production shifts.
Current diagnosis and symptoms: Interstitial cystitis,
She reports that her bladder and general body pain is much
frequent upper respiratory infections, constipation
worse
and
bloating.
Case Illustration 4.1 Metabolic fragility from insufficient Glu & Glnin the morning, a time when systemic pH is under
stress from cortisol-stimulated organic acid and
Methodology: ION Exchange HPLC
Amino Acid Analysis - 20 Plasma
ammonia formation.
The most common amino acid-based treatPercentile Ranking by Quintile
95%
ment
in such cases is to use customized free1st
2nd
3rd
4th
5th
Results
Reference
umol/L
Interval
form
essential
amino acid mixtures formulated
80%
60%
20%
40%
as described in this chapter. Such low glutamic
Essential Amino Acids
acid and glutamine patterns are very frequently
19 - 153
Glutamic Acid
31 L
accompanied by multiple imbalances in utiliza303 - 626
Glutamine
321 L
tion of EAA. v

High Glu/Gln Ratio in a Patient with Autism
Case Illustration 4.2 High Glu/Gln Ratio in an autistic

A routine amino acid profile was orderd
Methodology: ION Exchange HPLC
Amino Acid Analysis - 20 Plasma
along with other metabolic testing on a
severely autistic 3-year-old girl. Her plasma
Percentile Ranking by Quintile
95%
glutamate was very elevated, 383 µM
1st
2nd
3rd
4th
5th
Results
Reference
umol/L
Interval
(19–153), while glutamine was only 35 µM
80%
60%
20%
40%
(303–626).
Essential Amino Acids
Extreme elevations of multiple organic
19 - 153
Glutamic Acid
383 H
acids were found in urine, consistent with
303 - 626
Glutamine
35 L
acidemia and calcium was very high in
erythrocytes, indicating difficulty mainThis case has multiple metabolic disturbances that can
taining the membrane calcium pumping
be affecting systemic pH and brain chemistry. Her situasystem. Her plasma fatty acid profile showed an extremely
tion is exacerbated by the loss of control over conversion of
high AA/EPA ratio that is associated with the pro-inflammaglutamate to glutamine. There is the possibility of genetic
tory state and her urine contained very high quinolinate and
impairment of hepatic glutamine synthetase, but correction
kynurenate levels, indicating interferon-γ-stimulated macroof potential dependent metabolic issues could be undertaken
phage inflammatory response. Since her urinary p-hydroxybefore attempting to confirm such diagnosis. v
benzoate was very elevated, one area of suspected etiology
is a severe overgrowth of bacteria or parasites producing an
inflammatory response in the gut.

CASE ILLUSTRATION 4.3 —

Apparent Ornithine Transcarbamylase Deficiency

Case Illustration 4.3 Apparent Ornithine Carbamoyl Transferase Deficiency
Methodology: ION Exchange HPLC

Amino Acid Analysis - 40 Urine
Results
umol/L

95%
Reference
Interval

Arginine
10 - 70

Histidine

2,182 H

Isoleucine
10 - 70

Leucine
15 - 110

Lysine
75 - 600

Methionine
15 - 95

Phenylalanine
30 - 190

Threonine
90 - 490

Tryptophan
30 - 150

Valine
10 - 70

This 62-year-old male exhibits manifestations of ornithine transcarbamylase (OCT)
deficiency, one of the most prevalent inherited
disorders. Estimates of urea cycle polymorphmism incidence, including those beyond the
childhood years are as high as 1 in 20,000.
A urine amino acid pattern reveals very
high ornithine with low-normal citrulline (see
arrows). In addition, the amine-transporting amino acids, glutamine and aspartic acid,
are extremely elevated, indicating a general
metabolic acidosis with nitrogen transport impairment. These products may spill into urine
to reduce the nitrogen (ammonia) load on the
urea cycle (see Figure 4.9). Urinary histidine
has one of the highest upper reference limits,
indicating the ease of histidine loss.

Essential Amino Acids

<= 30

H

1,099

500 - 2,000

Serine
160 - 710

Taurine
350 - 1,850

Tyrosine
40 - 290
Asparagine
Aspartic Acid
Glutamic Acid
Glutamine

Ornithine

30 - 85

70 - 500

H

Citrulline

H

α-Aminoadipic Acid

Ammonia/Energy Metabolism

Glycine

Essential Amino Acid Derivatives
Neuroendocrine Metabolism
Gamma-Aminobutyric Acid

460 - 2,100

135 - 275
<= 30
20- 95

1,266

H

300- 800
H

10 - 100

The follow-up blood spot amino acid pattern supports the
conclusion that this patient is exhibiting an OCT deficiency.
Ornithine is extremely elevated as is the urea cycle
intermediate, arginine, further indicating a metabolic backup
due to lack of urea cycle activity. Many other amino acids
are in their high-normal or moderately elevated ranges. The
passage of histidine, glutamine and aspartic acid into urine
keeps their blood levels within normal limits.

Continued on following page…

Case Ill

ustrati

Amino

on 4.3

a App

arent O

Acid An

alysis -

rnithin

20 Bloo

e Carb

dspot

amoyl

Transfe
r

Method

ology:

Essenti
Alanine

Result
s
umol/
L

al Amin

o Acids

Anserin

e
β-Alan

ine

734 H

β-Amin

ric Acid

ine

amine
lysine

681 H

proline

<1

ylhistid

<1

ylhistid

2,016

3-Meth
Phosph

ine

ine

oethan

Phosph

oserine

Proline

olamin

e

e

<1

a-Amin

o-N-Bu

5.9 H

d

111 H

<= 300
<= 150
100 - 40
<= 20

572 H
tyric Aci
<= 60

H

212 H

Sarcosin

95%
Referen
ce
Interval
130 - 63

H

Hydroxy
1-Meth

PLC

<= 20

1,136

Ethanol
Hydroxy

ficienc

hange H

<= 160

<1

oisobuty

Camos

ase De

ION Exc

100 - 80
30 - 30
20 - 95
50 - 20
<= 1.0
<= 1.0
5 - 50
y

CASE ILLUSTRATION 4.3 (continued) —

Apparent Ornithine Carbamoyl Transferase Deficiency
Case Illustration 4.3b Apparent Ornithine Carbamoyl Transferase Deficiency
Amino Acid Analysis - 20 Bloodspot

Methodology: High Pressure Liquid chromotagraphy
Iscleucine
Leucine

189 H

Lysine

293 H

Methionine
Phenylalanine

107 H

Threonine
Tryptophan
Valine
Glysine
Serine

159 H

Taurine
Tyrosine

175 H

Asparagine
Aspartic Acid
Citruline
Glutamic Acid
Clutamine
Omithine

329 H

40%

4th
60%

5th
80%
18 - 101
19 - 102
33 -118
62 -186
72 - 232
8 - 27
38 - 97
51 - 203
21 - 59
110 - 329
209 - 574
84 - 383
133 - 355
39 - 116
40 - 95
35 - 250

Notes:
95%
Reference
Interval

These profiles provide evidence that blood
spot amino acid analyses are well suited for
monitoring amino acid status in this condition.
The organic acid pattern should reveal an ammonia overload pattern. For instance, orotate
should be elevated (see Chapter 6, “Organic
Acids”) and could be used to monitor resolution
of the problem.
The patient may need a carefully controlled
low-protein diet to reduce ammonemia and the
symptoms may largely stem from ammonemia.
A blood ammonia evaluation could be used to
confirm. The value of supplemental arginine
depends on the degree of structural impairment
of the enzyme. v

108 H

20%

3rd

Arginine
Histidine

2nd

Essential Amino Acids

1st

Percentile Ranking by Quintile
Results
umol/L

17 - 53
108 - 272
196 - 600
56 - 194

CASE ILLUSTRATION 4.4 —

Plasma Histidine in Major Cognitive Failure
Case Illustration 4.4 Plasma histidine in major cognitive failure

This profile was found in a 66-year-old
female with very poor short-term memory and
Amino Acid Analysis - 20 Plasma
difficulty following simple action sequences.
Results
She indicates a sense of enhanced well-being
umol/L
on high doses of 5-hydroxytryptophan. Her
Essential Amino Acids
plasma amino acid profile reveals normal EAA
except a for low histidine level.
Arginine
Chronic stimulation of histidine conversion
Histidine
55 L
to histamine can lead to depleted total-body
Isoleucine
histidine. In addition to reduced histamine
Leucine
production capacity having effects on brain
Lysine
and immune responses, her hematopoietic
Methionine
system may be under metabolic stress due
Phenylalanine
to histidine insufficiency. Low hematocrit
Threonine
and hemoglobin would confirm such effects.
Tryptophan
The obvious action of using supplemental
Valine
histidine should be effective. As ususal, using
an essential amino acid formula enhanced
with histidine can prevent induced imbalances and assist
histidine utilization. v

Methodology: ION Exchange HPLC
Percentile Ranking by Quintile
1st

2nd
20%

3rd

4th
60%

40%

5th
80%
42 - 130
53 - 101
37 - 98
73 - 161
109 - 235

15 - 32
43 - 81

67 - 166
34 - 70
134 - 305

CASE ILLUSTRATION 4.5 —

95%
Reference
Interval

Indication of Impaired SN1-SN2 Transporter

Case Illustration 4.6 Indication of impaired SN1 - SN2 Transporter

A portion of the plasma
Amino Acid Analysis - 20 Plasma
amino acid profile report from
a 15-year-old boy with severe
Results
behavioral problems and addiction
umol/L
to marijuana is shown.
The results of concurrent 5th
Histidine
quintile levels for histidine, asAsparagine
paragine and glutamine indicate
Glutamine
a possible defect in the SN1-SN2
transporter system. This system is
required for transport of these three
amino acids away from blood in liver and brain, preventing
circulating levels in fasting plasma from being elevated. v

Methodology: ION Exchange HPLC
Percentile Ranking by Quintile
1st

2nd
20%
3rd
40%

4th
60%

5th
80%

95%
Reference
Interval

53 - 101
30 - 60
387 - 641

Notes:

CASE ILLUSTRATION 4.6 —

Essential Amino Acid Support in Schizophrenia
data is presented not to explain the mental disturbance, but
rather that the essential amino acid insufficiency often resulting from such disorders is identified by laboratory testing.
Case Illustration 4.7 Essential amino acid support in schizophrenia
Her plasma amino acid profile shows very
low lysine along with low values for the
Methodology: ION Exchange HPLC
Amino Acid Analysis - 20 Plasma
BCAA. A urinary organic acid profile done at
Percentile Ranking by Quintile
95%
the same time showed positive biochemical
1st
2nd
3rd
4th
5th
Results
Reference
umol/L
Interval
markers for carnitine insufficiency.
80%
60%
20%
40%
The results justify essential amino acid
Essential Amino Acids
therapy
with a custom formula that enhances
Arginine
42 - 130
lysine
and
BCAA levels. Initial use of carnitine
Histidine
53 - 101
can
help
to
assure metabolic demand for
Isoleucine
39 L
37 - 98
energy production from fatty acid oxidation is
Leucine
59 L
73 - 161
met while lysine status is enhanced gradually
Lysine
77 L
109 - 235
by twice daily dosing of free-form amino
Methionine
15 - 32
acids. v
Phenylalanine
38 L
43 - 81

This data is from a woman who had her first psychotic episode at 21-years-old. She presented for this metabolic profile
12 years later, exhibiting a severe form of schizophrenia. This
Tryptophan

40 L

Valine

140 L

67 - 166
34 - 70

134 - 305

CASE ILLUSTRATION 4.7 —

Threonine

Case Illustration 4.7 Anxiety correction by lysine

Patient Population Ranking Quintile

2nd

3rd

4th

5th

95% Reference
Interval
(For adults 13 and over)

Essential Amino Acids
Arginine
43 - 129

Histidine
55 - 124

Isoleucine
33 - 93

Leucine
72 - 165

Lysine

130 L

114 - 253

Methionine
14 - 42

Phenylalanine

52 L

45 - 87

Threonine
70 - 204

Tryptophan
34 - 74

Valine
125 - 325

Essential Amino Acid Derivatives
Neuroendocrine Metabolism
Glycine
145 - 442

Serine
60 - 133

Taurine
24 - 95

Tyrosine
34 - 88

Asparagine
24 - 60

Aspartic Acid
5 - 17

Citrulline
21 - 52

Glutamic Acid
27 - 217

Glutamine
Ornithine
Ammonia/Energy Metabolism

Homocysteine - Plasma

Homocysteine
1st

Results
umol/L

Anxiety Correction by Lysine

This patient presented with various physical complaints
and significant anxiety and sleep disturbance. Test Results: Although most of the essential amino acids were in
healthy range, lysine was very low, along with 1st quintile
phenylalanine.
Recommendations: In cases of anxiety, sleep disturbance,
or irritable bowel, consider lysine deficiency as a possible
moderator for serotonin hypersensitivity. Lysine at several
hundred mg/d is the normal dosing.
Comments: In follow-up discussions the testing physician
indicated a remarkable, immediate reduction in severity
and frequency of anxiety after supplementing lysine and
phenylalanine. v

Methodology: ION Exchange HPLC

Amino Acid Analysis - 20 Plasma

302- 605
31 - 125

L

Methodology: High Preformance Liquid Chromotography

Results

Reference
limits
nmol/mL
<= 8

CASE ILLUSTRATION 4.8 —

Tyrosine Utilization Cofactors in Bronchospasms
Methodology: ION Exchange HPLC

Amino Acid Analysis - 20 Plasma

Percentile Ranking by Quintile
1st

Results
umol/L

2nd
20%

Essential Amino Acids

3rd
40%

4th
60%

5th
80%
Arginine

96 L

Histidine

66 L

Isoleucine
42 - 130
53 - 101
37 - 98
Leucine
Lysine
Methionine
Phenylalanine
73 - 161
109 - 235

15 - 32
43 - 81
Threonine
Tryptophan
Valine
67 - 166

Plasma amino acid analysis revealed
elevated tyrosine in a man suffering from
adult-onset, cold-induced bronchospams.
The cofactors converting tyrosine to
epinephrine, a bronchodilator, include
vitamin C and copper, among others. The
patient tested low for copper.
When copper was added to his nutrient
supplementation regimen, the bronchospams ceased to occur, giving clinical
evidence that tyrosine metabolism to
catecholamines had been restored. v

34 - 70

Essential Amino Acid Derivatives
Neuroendocrine Metabolism

Taurine

L
L
H
138 - 430
60 - 133
26 - 103
37 - 89

Tyrosine

Serine

Glycine

134 - 305

Notes:

CASE ILLUSTRATION 4.9 —

Apparent Diet-Induced Taurine deficiency
with Cardiovascular Consequences

A 59-year-old female physician who had been vegetarian
for several years presented with hypertension and paroxysCase
mal supraventricular tachycardia. She had started taking
theIllustration 4.9 Apparent diet-induced taurine deficiency
with cardiovaschlar consequences
usual multiple supplemental nutrients
Methodology: ION Exchange HPLC
Amino Acid Analysis - 20 Plasma
with little effect.
The plasma amino acid laboratory
Percentile Ranking by Quintile
report revealed extremely low taurine in
1st
2nd
3rd
4th
5th
Results
umol/L
80%
60%
20%
40%
the presence of upper-normal meEssential Amino Acids
thionine, indicating a problem with the
42 - 130
Arginine
pathway from homocysteine to taurine.
53 - 101
Histidine
The multiple amino acid levels in the
37 - 98
Isoleucine
46 L
5th quintile suggest an insufficiency of
73 - 161
Leucine
vitamin B6, possibly exacerbated by iron
109 - 235
Lysine
deficiency that is common in vegetarians.
15 - 32
Methionine
Further testing can help identify these
43 - 81
Phenylalanine
deficiencies. If correction of micronutri90
67 - 166
Threonine
ent insufficiencies does not resolve the
34 - 70
Tryptophan
low taurine, genetic impairment may
134 - 305
Valine
be present, requiring sustained taurine
Essential Amino Acid Derivatives
supplementation. v
Neuroendocrine Metabolism
Glycine
Serine

Notes:

Taurine

Tyrosine
L
138 - 430
60 - 133
26 - 103
37 - 89

6.

7.

8.

9.
10.

11.

27.

28.
29.

30.

31.
32.
33.

34.

14.
15.

16.

17.
18.
19.

20.

21.

35.
36.
37.

13.

12.

26.

5.

25.

4.

24.

Patel DK, Ogunbona A, Notarianni LJ, Bennett PN. Depletion of plasma
glycine and effect of glycine by mouth on salicylate metabolism during
aspirin overdose. Hum Exp Toxicol. 1990;9(6):389-395.
Kelly GS. L-Carnitine: therapeutic applications of a conditionally-essential
amino acid. Altern Med Rev. 1998;3(5):345-360.
Mauri MC, Ferrara A, Boscati L, et al. Plasma and platelet amino acid
concentrations in patients affected by major depression and under
fluvoxamine treatment. Neuropsychobiology. 1998;37(3):124-129.
Leung KC, Waters MJ, Markus I, Baumbach WR, Ho KK. Insulin and insulinlike growth factor-I acutely inhibit surface translocation of growth hormone
receptors in osteoblasts: a novel mechanism of growth hormone receptor
regulation. Proc Natl Acad Sci U S A. Oct 14 1997;94(21):11381-11386.
Scriver C, Rosenberg L. Amino Acid Metabolism and It’s Disorders. Vol X.
Philadelphia: W. B. Saunders; 1973.
Roiser JP, McLean A, Ogilvie AD, et al. The subjective and cognitive effects
of acute phenylalanine and tyrosine depletion in patients recovered from
depression. Neuropsychopharmacology. Apr 2005;30(4):775-785.
Chao HM, Richardson MA. Aromatic amino acid hydroxylase genes and
schizophrenia. Am J Med Genet. Aug 8 2002;114(6):626-630.
Wessler S, Hocker M, Fischer W, et al. Helicobacter pylori activates the
histidine decarboxylase promoter through a mitogen-activated protein
kinase pathway independent of pathogenicity island-encoded virulence
factors. J Biol Chem. Feb 4 2000;275(5):3629-3636.
Ohning GV, Song M, Wong HC, Wu SV, Walsh JH. Immunolocalization of
gastrin-dependent histidine decarboxylase activity in rat gastric mucosa
during feeding. Am J Physiol. Oct 1998;275(4 Pt 1):G660-667.
Maeda K, Taniguchi H, Ohno I, et al. Induction of L-histidine decarboxylase
in a human mast cell line, HMC-1. Exp Hematol. Apr 1998;26(4):325-331.
Neumeister A. Tryptophan depletion, serotonin, and depression: where do
we stand? Psychopharmacol Bull. 2003;37(4):99-115.
Gershon MD. Review article: serotonin receptors and transporters—roles in
normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther. Nov
2004;20 Suppl 7:3-14.
Schaeffer MC, Rogers QR, Leung PM, Wolfe BM, Strombeck DR. Changes
in cerebrospinal fluid and plasma amino acid concentrations with elevated
dietary protein concentration in dogs with portacaval shunts. Life Sci.
1991;48(23):2215-2223.
Johnson A. Newborn Genetic and Metabolic Disease Screening; 2005.
Bureau MaCH, Genetics ACoM. Newborn Screening: Toward a Uniform
Screening Panel and System 2005.
Henriquez H, el Din A, Ozand PT, Subramanyam SB, al Gain SI. Emergency
presentations of patients with methylmalonic acidemia, propionic acidemia
and branched chain amino acidemia (MSUD). Brain Dev. Nov 1994;16
Suppl:86-93.
Muntau AC, Roschinger W, Habich M, et al. Tetrahydrobiopterin as an
alternative treatment for mild phenylketonuria. N Engl J Med. Dec 26
2002;347(26):2122-2132.
McMullen S, Langley-Evans SC. Maternal low-protein diet in rat pregnancy
programs blood pressure through sex-specific mechanisms. Am J Physiol
Regul Integr Comp Physiol. Jan 2005;288(1):R85-90.
Lepage N, McDonald N, Dallaire L, Lambert M. Age-specific distribution of
plasma amino acid concentrations in a healthy pediatric population. Clin
Chem. 1997;43(12):2397-2402.
Chih-Kuang C, Shuan-Pei L, Shyue-Jye L, Tuan-Jen W. Plasma free amino
acids in Taiwan Chinese: the effect of age. Clin Chem Lab Med. Apr
2002;40(4):378-382.
Sakai R, Miura M, Amao M, et al. Potential approaches to the assessment
of amino acid adequacy in rats: a progress report. J Nutr. Jun 2004;134(6
Suppl):1651S-1655S; discussion 1664S-1666S, 1667S-1672S.
Caldwell J. Pharmacogenetics and individual variation in the range of amino
acid adequacy: the biological aspects. J Nutr. Jun 2004;134(6 Suppl):1600S1604S; discussion 1630S-1632S, 1667S-1672S.

3.

23.

2.

Zhang F, Warskulat U, Wettstein M, et al. Hyperosmolarity stimulates
prostaglandin synthesis and cyclooxygenase-2 expression in activated rat
liver macrophages. Biochem J. Nov 15 1995;312 (Pt 1):135-143.
Braverman ER, Pfeiffer CC, Blum K, Smayda R. The Healing Nutrients
Within: Facts, Findings, and New Research on Amino Acids. 3rd ed. North
Bergen, NJ: Basic Health Publications; 2003.
Shapira E, Blitzer M, Miller J, Africk D. Biochemical Genetics. A Laboratory
Manual. New York: Oxford U Press; 1989.
Moughan PJ, Butts CA, Rowan AM, Deglaire A. Dietary peptides increase
endogenous amino acid losses from the gut in adults. Am J Clin Nutr. Jun
2005;81(6):1359-1365.
Bellinger L, Lilley C, Langley-Evans SC. Prenatal exposure to a maternal
low-protein diet programmes a preference for high-fat foods in the young
adult rat. Br J Nutr. Sep 2004;92(3):513-520.
Su Y, Pitot HC. Identification of regions in the rat serine dehydratase gene
responsible for regulation by cyclic AMP alone and in the presence of
glucocorticoids. Mol Cell Endocrinol. Dec 1992;90(1):141-146.
Singewald N, Kouvelas D, Chen F, Philippu A. The release of inhibitory
amino acids in the hypothalamus is tonically modified by impulses from
aortic baroreceptors as a consequence of blood pressure fluctuations.
Naunyn Schmiedebergs Arch Pharmacol. Sep 1997;356(3):348-355.
Brooks VL, Freeman KL, Clow KA. Excitatory amino acids in rostral
ventrolateral medulla support blood pressure during water deprivation in
rats. Am J Physiol Heart Circ Physiol. May 2004;286(5):H1642-1648.
Scriver CR. The Metabolic and Molecular Bases of Inherited Disease. 8th ed.
New York: McGraw-Hill; 2001.
Gaspari R, Arcangeli A, Mensi S, et al. Late-onset presentation of ornithine
transcarbamylase deficiency in a young woman with hyperammonemic
coma. Ann Emerg Med. Jan 2003;41(1):104-109.
Cylwik D, Mogielnicki A, Buczko W. L-arginine and cardiovascular system.
Pharmacol Rep. Jan-Feb 2005;57(1):14-22.
Bello E, Caramelo C. [Increase of tubular secretion of creatinine by
L-arginine: mechanism of practical significance in the assessment of
renal function based on creatinine clearance]. Nefrologia. Nov-Dec
2000;20(6):517-522.
Yatsunami K, Fukui T, Ichikawa A. [Molecular biology of L-histidine
decarboxylase]. Yakugaku Zasshi. Nov 1994;114(11):803-822.
Cooperman JM, Lopez R. The role of histidine in the anemia of folate
deficiency. Exp Biol Med (Maywood). Dec 2002;227(11):998-1000.
Chen Z, Li WD, Zhu LJ, Shen YJ, Wei EQ. Effects of histidine, a precursor of
histamine, on pentylenetetrazole-induced seizures in rats. Acta Pharmacol
Sin. Apr 2002;23(4):361-366.
Chen Z, Li Z, Sakurai E, et al. Chemical kindling induced by
pentylenetetrazol in histamine H(1) receptor gene knockout mice
(H(1)KO), histidine decarboxylase-deficient mice (HDC(-/-)) and mast celldeficient W/W(v) mice. Brain Res. Apr 4 2003;968(1):162-166.
Murray RK, Granner DK, Mayes PA, Rodwell VW, eds. Harper’s Illustrated
Biochemistry. New York: Lange Medical Books/McGraw-Hill; 2003.
Radin NS, Rittenberg D, Shemin D. The role of glycine in the biosynthesis
of heme. J Biol Chem. Jun 1950;184(2):745-753.
Pui YM, Fisher H. Factorial supplementation with arginine and glycine on
nitrogen retention and body weight gain in the traumatized rat. J Nutr. Feb
1979;109(2):240-246.
Altamura C, Maes M, Dai J, Meltzer HY. Plasma concentrations of excitatory
amino acids, serine, glycine, taurine and histidine in major depression. Eur
Neuropsychopharmacol. 1995;5 Suppl:71-75.
Altamura CA, Mauri MC, Ferrara A, Moro AR, D’Andrea G, Zamberlan F.
Plasma and platelet excitatory amino acids in psychiatric disorders. Am J
Psychiatry. Nov 1993;150(11):1731-1733.

1.

22.

References

38.

39.

40.

41.

42.

43.

50.

51.

52.
53.

54.

55.

71.
72.

73.

74.
75.

76.

77.

58.

59.

60.
61.

62.
63.
64.

65.

57.

56.

70.

49.

69.

48.

68.

47.

67.

Butler LE, Dauterman WC. The effect of dietary protein levels on xenobiotic
biotransformations in F344 male rats. Toxicol Appl Pharmacol. Sep 15
1988;95(2):301-310.
Adekunle AA, Hayes JR, Campbell TC. Effect of protein deficiency on the
hepatic microsomal mixed function oxidase. III-Influence on aflatoxin B1
metabolism and epoxide hydrase activity. Biochem Exp Biol. 1978;14(1):45-53.
Magee EA, Curno R, Edmond LM, Cummings JH. Contribution of dietary
protein and inorganic sulfur to urinary sulfate: toward a biomarker of
inorganic sulfur intake. Am J Clin Nutr. Jul 2004;80(1):137-142.
Anderson PA, Alster JM, Clinton SK, et al. Plasma amino acids and excretion
of protein end products by mice fed 10 or 40% soybean protein diets with
or without dietary benzo[a]pyrene or 1,2-dimethylhydrazine. J Nutr. Nov
1985;115(11):1515-1527.
Holland A. Dietary intake and nitrogen balance in athletes with and
without consumption of a protein supplement. Hum Nutr Appl Nutr. Oct
1987;41(5):367-372.
Phillips SM. Protein requirements and supplementation in strength sports.
Nutrition. Jul-Aug 2004;20(7-8):689-695.
Borsheim E, Tipton KD, Wolf SE, Wolfe RR. Essential amino acids and
muscle protein recovery from resistance exercise. Am J Physiol Endocrinol
Metab. Oct 2002;283(4):E648-657.
Borsheim E, Cree MG, Tipton KD, Elliott TA, Aarsland A, Wolfe RR. Effect
of carbohydrate intake on net muscle protein synthesis during recovery
from resistance exercise. J Appl Physiol. Feb 2004;96(2):674-678.
Askanazi J, Elwyn DH, Kinney JM, et al. Muscle and plasma amino acids
after injury: the role of inactivity. Ann Surg. 1978;188(6):797-803.
Wilmore DW. The effect of glutamine supplementation in patients following
elective surgery and accidental injury. J Nutr. Sep 2001;131(9 Suppl):2543S2549S; discussion 2550S-2541S.
Ganapathy V, Inoue K, Prasad P, Ganapathy M. Cellular uptake of amino
acids: systems and regulation. In: Cynober L, ed. Metabolic and Therapeutic
Aspects of Amino Acids in Clinical Nutrition. 2nd ed. Boca Raton: CRC
Press; 2004:63-78.
Miyamoto K, Nakanishi H, Moriguchi S, et al. Involvement of enhanced
sensitivity of N-methyl-D-aspartate receptors in vulnerability of developing
cortical neurons to methylmercury neurotoxicity. Brain Res. May 18
2001;901(1-2):252-258.
Gu S, Roderick HL, Camacho P, Jiang JX. Identification and characterization
of an amino acid transporter expressed differentially in liver. Proc Natl Acad
Sci U S A. Mar 28 2000;97(7):3230-3235.
Scriver CR. The Metabolic and Molecular Bases of Inherited Disease. 7th ed.
New York: McGraw-Hill, Health Professions Division; 1995.
Closs EI, Graf P. Cationic amino acid transporters (CATs). Targets for the
manipulation of NO-synthase activity? Pharm Biotechnol. 1999;12:229-249.
McGivan JD, Nicholson B. Regulation of high-affinity glutamate transport
by amino acid deprivation and hyperosmotic stress. Am J Physiol. Oct
1999;277(4 Pt 2):F498-500.
Burrows CF, Kronfeld DS, Banta CA, Merritt AM. Effects of fiber on
digestibility and transit time in dogs. J Nutr. Sep 1982;112(9):1726-1732.
Aoki TT, Assal JP, Manzano FM, Kozak GP, Cahill GF. Plasma and
cerebrosponal fluid amino acid levels in diabetic ketoacidosis before and
after corrective therapy. Diabetes. May 1975;24(5):463-467.
Maes M, Verkerk R, Vandoolaeghe E, Lin A, Scharpe S. Serum levels of
excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine
and arginine in treatment-resistant depression: modulation by treatment
with antidepressants and prediction of clinical responsivity. Acta Psychiatr
Scand. Apr 1998;97(4):302-308.
Moller SE, Honore P, Larsen OB. Tryptophan and tyrosine ratios to neutral
amino acids in endogenous depression. Relation to antidepressant response
to amitriptyline and lithium + L-tryptophan. J Affect Disord. 1983;5(1):67-79.

46.

66.

45.

Millward DJ. Macronutrient intakes as determinants of dietary protein and
amino acid adequacy. J Nutr. Jun 2004;134(6 Suppl):1588S-1596S.
Soeters PB, van de Poll MC, van Gemert WG, Dejong CH. Amino
acid adequacy in pathophysiological states. J Nutr. Jun 2004;134(6
Suppl):1575S-1582S.
Noguchi Y, Sakai R, Kimura T. Metabolomics and its potential for
assessment of adequacy and safety of amino acid intake. J Nutr. Jun
2003;133(6 Suppl 1):2097S-2100S.
Irwin MI, Hegsted DM. A conspectus of research on protein requirements of
man. J Nutr. 1971;101(3):387-429.
Irwin MI, Hegsted DM. A conspectus of research on amino acid
requirements of man. J Nutr. 1971;101(4):539-566.
Kilberg MS, Pan YX, Chen H, Leung-Pineda V. Nutritional control of gene
expression: how mammalian cells respond to amino acid limitation. Annu
Rev Nutr. 2005;25:59-85.
Hatzoglou M, Fernandez J, Yaman I, Closs E. Regulation of cationic
amino acid transport: the story of the CAT-1 transporter. Annu Rev Nutr.
2004;24:377-399.
Filho JC, Hazel SJ, Anderstam B, Bergstrom J, Lewitt M, Hall K. Effect of
protein intake on plasma and erythrocyte free amino acids and serum IGF-I
and IGFBP-1 levels in rats. Am J Physiol. 1999;277(4 Pt 1):E693-701.
Yoshida A, Leung PM, Rogers QR, Harper AE. Effect of amino acid imbalance
on the fate of the limiting amino acid. J Nutr. May 1966;89(1):80-90.
Cosen-Binker LI, Binker MG, Negri G, Tiscornia O. Influence of stress
in acute pancreatitis and correlation with stress-induced gastric ulcer.
Pancreatology. 2004;4(5):470-484.
Kwiecien S, Brzozowski T, Konturek PC, et al. Gastroprotection by
pentoxyfilline against stress-induced gastric damage. Role of lipid
peroxidation, antioxidizing enzymes and proinflammatory cytokines. J
Physiol Pharmacol. Jun 2004;55(2):337-355.
Ohta Y, Nishida K. Protective effect of coadministered superoxide dismutase
and catalase against stress-induced gastric mucosal lesions. Clin Exp
Pharmacol Physiol. Aug 2003;30(8):545-550.
Brzozowski T, Konturek PC, Konturek SJ, et al. Implications of reactive
oxygen species and cytokines in gastroprotection against stress-induced
gastric damage by nitric oxide releasing aspirin. Int J Colorectal Dis. Jul
2003;18(4):320-329.
Nagahashi S, Suzuki H, Miyazawa M, et al. Ammonia aggravates stressinduced gastric mucosal oxidative injury through the cancellation of
cytoprotective heat shock protein 70. Free Radic Biol Med. Oct 15
2002;33(8):1073-1081.
Brillon DJ, Zheng B, Campbell RG, Matthews DE. Effect of cortisol on
energy expenditure and amino acid metabolism in humans. Am J Physiol.
1995;268(3 Pt 1):E501-513.
Nobels F, Rillaerts E, D’Hollander M, Van Gaal L, De Leeuw I. Plasma zinc
levels in diabetes mellitus: relation to plasma albumin and amino acids.
Biomed Pharmacother. 1986;40(2):57-60.
Riley DR, Harrill I, Gifford ED. Influence of zinc and vitamin D on plasma
amino acids and liver xanthine oxidase in rats. J Nutr. 1969;98(3):351-355.
Dai XH, Sun BG. Changes in serum free amino acid level in patients with
spleen deficiency syndrome. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih.
1994;14(7):403-405.
Jahoor F, Abramson S, Heird WC. The protein metabolic response to HIV
infection in young children. Am J Clin Nutr. Jul 2003;78(1):182-189.
Hortin GL, Landt M, Powderly WG. Changes in plasma amino acid
concentrations in response to HIV-1 infection. Clin Chem. 1994;40(5):785-789.
Maddison JE, Leong DK, Dodd PR, Johnston GA. Plasma GABA-like
activity in rats with hepatic encephalopathy is due to GABA and taurine.
Hepatology. 1990;11(1):105-110.
Campbell TC, Campbell TM. The China Study: The Most Comprehensive Study
of Nutrition Ever Conducted and The Startling Implications for Diet, Weight Loss
and Long-term Health. 1st BenBella Books ed. Dallas, TX: BenBella Books; 2005.

44.

78.

79.
80.
81.

82.
83.

84.

85.

94.

95.

96.

97.
98.

99.

100.

101.
102.
103.

104.

105.

106.
107.

93.

92.

91.

108. Nissim I. Newer aspects of glutamine/glutamate metabolism: the role of
acute pH changes. Am J Physiol. Oct 1999;277(4 Pt 2):F493-497.
109. Savoie L, Agudelo RA, Gauthier SF, Marin J, Pouliot Y. In vitro
determination of the release kinetics of peptides and free amino acids during
the digestion of food proteins. J AOAC Int. May-Jun 2005;88(3):935-948.
110. Gotoh Y, Ishida M, Shinozaki H. Excitatory amino acids control the gastric
function in the rat. In: Lubec G, Rosenthal G, eds. Amino Acids. Leiden:
ESCOM; 1990:1195.
111. Meldrum BS. Glutamate as a neurotransmitter in the brain: review of
physiology and pathology. J Nutr. 2000;130(4S Suppl):1007S-1015S.
112. Eck HP, Mertens T, Rosokat H, et al. T4+ cell numbers are correlated with
plasma glutamate and cystine levels: association of hyperglutamataemia
with immunodeficiency in diseases with different aetiologies. Int Immunol.
1992;4(1):7-13.
113. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA.
Neuroglial activation and neuroinflammation in the brain of patients with
autism. Ann Neurol. Jan 2005;57(1):67-81.
114. Nurjhan N, Bucci A, Perriello G, et al. Glutamine: a major gluconeogenic
precursor and vehicle for interorgan carbon transport in man. J Clin Invest.
Jan 1995;95(1):272-277.
115. Battezzati A, Simonson DC, Luzi L, Matthews DE. Glucagon increases
glutamine uptake without affecting glutamine release in humans.
Metabolism. Jun 1998;47(6):713-723.
116. Stumvoll M, Meyer C, Kreider M, Perriello G, Gerich J. Effects of glucagon
on renal and hepatic glutamine gluconeogenesis in normal postabsorptive
humans. Metabolism. Oct 1998;47(10):1227-1232.
117. Stumvoll M, Perriello G, Nurjhan N, et al. Glutamine and alanine
metabolism in NIDDM. Diabetes. Jul 1996;45(7):863-868.
118. Stumvoll M, Perriello G, Meyer C, Gerich J. Role of glutamine in human
carbohydrate metabolism in kidney and other tissues. Kidney Int. Mar
1999;55(3):778-792.
119. Weigert C, Thamer C, Brodbeck K, et al. The -913 G/A glutamine:fructose6-phosphate aminotransferase gene polymorphism is associated with
measures of obesity and intramyocellular lipid content in nondiabetic
subjects. J Clin Endocrinol Metab. Mar 2005;90(3):1639-1643.
120. James LR, Fantus IG, Goldberg H, Ly H, Scholey JW. Overexpression of
GFAT activates PAI-1 promoter in mesangial cells. Am J Physiol Renal
Physiol. Oct 2000;279(4):F718-727.
121. James LR, Ingram A, Ly H, Thai K, Cai L, Scholey JW. Angiotensin II
activates the GFAT promoter in mesangial cells. Am J Physiol Renal Physiol.
Jul 2001;281(1):F151-162.
122. Matthews DE, Campbell RG. The effect of dietary protein intake on
glutamine and glutamate nitrogen metabolism in humans. Am J Clin Nutr.
1992;55(5):963-970.
123. Forslund AH, Hambraeus L, van Beurden H, et al. Inverse relationship
between protein intake and plasma free amino acids in healthy men at
physical exercise. Am J Physiol Endocrinol Metab. 2000;278(5):E857-867.
124. Mitani H, Shirayama Y, Yamada T, Kawahara R. Plasma levels of
homovanillic acid, 5-hydroxyindoleacetic acid and cortisol, and serotonin
turnover in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry.
Jan 12 2006.
125. D’Souza R, Powell-Tuck J. Glutamine supplements in the critically ill. J R
Soc Med. Sep 2004;97(9):425-427.
126. Haberle J, Gorg B, Rutsch F, et al. Congenital glutamine deficiency with
glutamine synthetase mutations. N Engl J Med. Nov 3 2005;353(18):19261933.
127. Boelens PG, Fonk JC, Houdijk AP, et al. Primary immune response to
keyhole limpet haemocyanin following trauma in relation to low plasma
glutamine. Clin Exp Immunol. May 2004;136(2):356-364.
128. Askanazi J, Furst P, Michelsen CB, et al. Muscle and plasma amino acids
after injury: hypocaloric glucose vs. amino acid infusion. Ann Surg.
1980;191(4):465-472.

90.

89.

88.

87.

Prior RL, Crim MC, Castaneda C, et al. Conditions altering plasma
concentrations of urea cycle and other amino acids in elderly human
subjects. J Am Coll Nutr. Jun 1996;15(3):237-247.
Ravaglia G, Forti P, Maioli F, et al. Plasma amino acid concentrations in
patients with amnestic mild cognitive impairment or Alzheimer disease. Am
J Clin Nutr. Aug 2004;80(2):483-488.
Price SR, Reaich D, Marinovic AC, et al. Mechanisms contributing to
muscle-wasting in acute uremia: activation of amino acid catabolism. J Am
Soc Nephrol. Mar 1998;9(3):439-443.
Poon RT, Yu WC, Fan ST, Wong J. Long-term oral branched chain amino
acids in patients undergoing chemoembolization for hepatocellular
carcinoma: a randomized trial. Aliment Pharmacol Ther. Apr 1
2004;19(7):779-788.
Saito A, Noguchi Y, Yoshikawa T, et al. Gastrectomized patients are
in a state of chronic protein malnutrition analyses of 23 amino acids.
Hepatogastroenterology. Mar-Apr 2001;48(38):585-589.
Rudman D, Mattson DE, Feller AG, Cotter R, Johnson RC. Fasting plasma
amino acids in elderly men. Am J Clin Nutr. 1989;49(3):559-566.
Schmeisser DD, Kummerow FA, Baker DH. Effect of excess dietary lysine on
plasma lipids of the chick. J Nutr. Sep 1983;113(9):1777-1783.
Sanchez A, Hubbard RW. Plasma amino acids and the insulin/glucagon ratio
as an explanation for the dietary protein modulation of atherosclerosis. Med
Hypotheses. Sep 1991;36(1):27-32.
Sugiyama K, Ohkawa S, Muramatsu K. Relationship between amino acid
composition of diet and plasma cholesterol level in growing rats fed a high
cholesterol diet. J Nutr Sci Vitaminol (Tokyo). Aug 1986;32(4):413-423.
Molina JA, Jimenez-Jimenez FJ, Gomez P, et al. Decreased cerebrospinal
fluid levels of neutral and basic amino acids in patients with Parkinson’s
disease. J Neurol Sci. 1997;150(2):123-127.
Molina JA, Jimenez-Jimenez FJ, Vargas C, et al. Cerebrospinal fluid levels
of non-neurotransmitter amino acids in patients with Alzheimer’s disease. J
Neural Transm. 1998;105(2-3):279-286.
Bralley J, Lord R. Treatment of chronic fatigue syndrome with specific amino
acid supplementation. J App Nutr. 1994;46(3):74-78.
Gempel K, Gerbitz KD, Casetta B, Bauer MF. Rapid determination of total
homocysteine in blood spots by liquid chromatography-electrospray
ionization-tandem mass spectrometry. Clin Chem. 2000;46(1):122-123.
Pokhrel PK, Lau-Cam CA. Protection by taurine and structurally related
sulfur-containing compounds against erythrocyte membrane damage by
hydrogen peroxide. Adv Exp Med Biol. 2000;483:411-429.
Garde AH, Hansen AM, Kristiansen J, Knudsen LE. Comparison of
uncertainties related to standardization of urine samples with volume and
creatinine concentration. Ann Occup Hyg. Mar 2004;48(2):171-179.
Bellows CF, Jaffe BM. Glutamine is essential for nitric oxide synthesis by
murine macrophages. J Surg Res. 1999;86(2):213-219.
Roth E. L-argine-nitric oxide metabolism. Glutamine: a new player in this
metabolic game? Clin Nutr. 1998;17(1):1-2.
Oba M, Baldwin RLt, Bequette BJ. Oxidation of glucose, glutamate, and
glutamine by isolated ovine enterocytes in vitro is decreased by the presence
of other metabolic fuels. J Anim Sci. Feb 2004;82(2):479-486.
Zhu LH, Armentano LE, Bremmer DR, Grummer RR, Bertics SJ. Plasma
concentration of urea, ammonia, glutamine around calving, and the relation
of hepatic triglyceride, to plasma ammonia removal and blood acid-base
balance. J Dairy Sci. Apr 2000;83(4):734-740.
Sawara K, Kato A, Yoshioka Y, Suzuki K. Brain glutamine and glutamate
levels in patients with liver cirrhosis: assessed by 3.0-T MRS. Hepatol Res.
Sep 2004;30(1):18-23.
Cunningham CC, Van Horn CG. Energy availability and alcohol-related
liver pathology. Alcohol Res Health. 2003;27(4):291-299.
Haussinger D. Nitrogen metabolism in liver: structural and functional
organization and physiological relevance. Biochem J. Apr 15
1990;267(2):281-290.

86.

150. Plaitakis A, Constantakakis E. Altered metabolism of excitatory amino acids,
N-acetyl-aspartate and N-acetyl-aspartyl-glutamate in amyotrophic lateral
sclerosis. Brain Res Bull. 1993;30(3-4):381-386.
151. Moghaddam B. Recent basic findings in support of excitatory amino acid
hypotheses of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry.
1994;18(5):859-870.
152. Monaco F, Gianelli M, Schiavella MP, et al. Plasma amino acid alterations in
idiopathic generalized epilepsy: an investigation in probands and their firstdegree relatives. Ital J Neurol Sci. 1994;15(3):137-144.
153. Gillessen T, Budd S, Lipton S. Excitatory Amino Acid Neurotoxicity. In:
Alzheimer C, ed. Neurodegenerative Disease. Georgetown, TX: Eureka
Bioscience; 2002.
154. Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved
in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004;27:723749.
155. Droge W, Eck HP, Betzler M, Naher H. Elevated plasma glutamate
levels in colorectal carcinoma patients and in patients with acquired
immunodeficiency syndrome (AIDS). Immunobiology. Aug 1987;174(45):473-479.
156. Summar ML, Barr F, Dawling S, et al. Unmasked adult-onset urea cycle
disorders in the critical care setting. Crit Care Clin. Oct 2005;21(4 Suppl):
S1-8.
157. Ma CL, Zhu CG, Fan M, Liu SH, Liu QY, Cong B. Screening for glutamateinduced and dexamethasone-downregulated epilepsy-related genes in rats
by mRNA differential display. Chin Med J (Engl). Mar 20 2006;119(6):488495.
158. Zhou BG, Norenberg MD. Ammonia downregulates GLAST mRNA
glutamate transporter in rat astrocyte cultures. Neurosci Lett. Dec 10
1999;276(3):145-148.
159. Hack V, Gross A, Kinscherf R, et al. Abnormal glutathione and sulfate levels
after interleukin 6 treatment and in tumor-induced cachexia. Faseb J. Aug
1996;10(10):1219-1226.
160. Brusilow S, Horwich A. Urea cycle enzymes. In: CR S, AL B, D V, WS S, eds.
The Metabolic and Molecular Bases of Inherited Disease. Vol II. 8th ed. New
York: McGraw-Hill, Health Professions Division; 2001:1909-1963.
161. Peters H, Noble NA. Dietary L-arginine in renal disease. Semin Nephrol.
1996;16(6):567-575.
162. Milner JA. Metabolic aberrations associated with arginine deficiency. J Nutr.
1985;115(4):516-523.
163. Wheatley DN, Scott L, Lamb J, Smith S. Single amino acid (arginine)
restriction: growth and death of cultured HeLa and human diploid
fibroblasts. Cell Physiol Biochem. 2000;10(1-2):37-55.
164. Algert SJ, Stubblefield NE, Grasse BJ, Shragg GP, Connor JD. Assessment of
dietary intake of lysine and arginine in patients with herpes simplex. J Am
Diet Assoc. 1987;87(11):1560-1561.
165. Shen LJ, Beloussow K, Shen WC. Modulation of arginine metabolic
pathways as the potential anti-tumor mechanism of recombinant arginine
deiminase. Cancer Lett. Jan 8 2006;231(1):30-35.
166. Lind DS. Arginine and cancer. J Nutr. Oct 2004;134(10 Suppl):2837S2841S; discussion 2853S.
167. Wakabayashi Y. Tissue-selective expression of enzymes of arginine synthesis.
Curr Opin Clin Nutr Metab Care. Jul 1998;1(4):335-339.
168. Baumgartner MR, Hu CA, Almashanu S, et al. Hyperammonemia with
reduced ornithine, citrulline, arginine and proline: a new inborn error
caused by a mutation in the gene encoding delta(1)-pyrroline-5-carboxylate
synthase. Hum Mol Genet. 2000;9(19):2853-2858.
169. Wakabayashi Y, Yamada E, Yoshida T, Takahashi N. Effect of intestinal
resection and arginine-free diet on rat physiology. Am J Physiol. Aug
1995;269(2 Pt 1):G313-318.

129. Andrews FJ, Griffiths RD. Glutamine: essential for immune nutrition in the
critically ill. Br J Nutr. Jan 2002;87 Suppl 1:S3-8.
130. Kinscherf R, Hack V, Fischbach T, et al. Low plasma glutamine in
combination with high glutamate levels indicate risk for loss of body cell
mass in healthy individuals: the effect of N- acetyl-cysteine. J Mol Med.
1996;74(7):393-400.
131. Souba WW. Nutritional support. N Engl J Med. Jan 2 1997;336(1):41-48.
132. Flaring UB, Rooyackers OE, Wernerman J, Hammarqvist F. Glutamine
attenuates post-traumatic glutathione depletion in human muscle. Clin Sci
(Lond). Mar 2003;104(3):275-282.
133. Coeffier M, Miralles-Barrachina O, Le Pessot F, et al. Influence of
glutamine on cytokine production by human gut in vitro. Cytokine. Feb 7
2001;13(3):148-154.
134. Cao Y, Feng Z, Hoos A, Klimberg VS. Glutamine enhances gut glutathione
production. JPEN J Parenter Enteral Nutr. Jul-Aug 1998;22(4):224-227.
135. Honda S, Yamamoto K, Sekizuka M, et al. Successful treatment of severe
hyperammonemia using sodium phenylacetate powder prepared in hospital
pharmacy. Biol Pharm Bull. Sep 2002;25(9):1244-1246.
136. Rudman D, Akgun S, Galambos JT, et al. Observations on the nitrogen
metabolism of patients with portal cirrhosis. Am J Clin Nutr. Sep
1970;23(9):1203-1211.
137. Gupta SV, Yamada N, Fungwe TV, Khosla P. Replacing 40% of dietary animal
fat with vegetable oil is associated with lower HDL cholesterol and higher
cholesterol ester transfer protein in cynomolgus monkeys fed sufficient
linoleic acid. J Nutr. Aug 2003;133(8):2600-2606.
138. Goldman HI, Freudenthal R, Holland B, Karelitz S. Clinical effects of two
different levels of protein intake on low-birth-weight infants. J Pediatr. Jun
1969;74(6):881-889.
139. Goldman HI, Goldman J, Kaufman I, Liebman OB. Late effects of
early dietary protein intake on low-birth-weight infants. J Pediatr. Dec
1974;85(6):764-769.
140. Garlick PJ. Assessment of the safety of glutamine and other amino acids. J
Nutr. Sep 2001;131(9 Suppl):2556S-2561S.
141. Buchman AL. Glutamine: commercially essential or conditionally essential?
A critical appraisal of the human data. Am J Clin Nutr. Jul 2001;74(1):25-32.
142. Lowe DK, Benfell K, Smith RJ, et al. Safety of glutamine-enriched parenteral
nutrient solutions in humans. Am J Clin Nutr. Dec 1990;52(6):1101-1106.
143. Houdijk AP, Visser JJ, Rijnsburger ER, Teerlink T, van Leeuwen PA. Dietary
glutamine supplementation reduces plasma nitrate levels in rats. Clin Nutr.
1998;17(1):11-14.
144. Zorad S, Jezova D, Szabova L, Macho L, Tybitanclova K. Low number of
insulin receptors but high receptor protein content in adipose tissue of rats
with monosodium glutamate-induced obesity. Gen Physiol Biophys. Dec
2003;22(4):557-560.
145. Farombi EO, Onyema OO. Monosodium glutamate-induced oxidative
damage and genotoxicity in the rat: modulatory role of vitamin C, vitamin E
and quercetin. Hum Exp Toxicol. May 2006;25(5):251-259.
146. Ortiz GG, Bitzer-Quintero OK, Zarate CB, et al. Monosodium glutamateinduced damage in liver and kidney: a morphological and biochemical
approach. Biomed Pharmacother. Feb 2006;60(2):86-91.
147. Macho L, Fickova M, Jezova, Zorad S. Late effects of postnatal
administration of monosodium glutamate on insulin action in adult rats.
Physiol Res. 2000;49 Suppl 1:S79-85.
148. Schoelch C, Hubschle T, Schmidt I, Nuesslein-Hildesheim B. MSG lesions
decrease body mass of suckling-age rats by attenuating circadian decreases
of energy expenditure. Am J Physiol Endocrinol Metab. Sep 2002;283(3):
E604-611.
149. Vermeiren C, Hemptinne I, Vanhoutte N, Tilleux S, Maloteaux JM,
Hermans E. Loss of metabotropic glutamate receptor-mediated regulation
of glutamate transport in chemically activated astrocytes in a rat model of
amyotrophic lateral sclerosis. J Neurochem. Feb 2006;96(3):719-731.

190. Wahbi N, Dalton RN, Turner C, Denton M, Abbs I, Swaminathan
R. Dimethylarginines in chronic renal failure. J Clin Pathol. Jun
2001;54(6):470-473.
191. Achan V, Tran CT, Arrigoni F, Whitley GS, Leiper JM, Vallance P. All-transRetinoic acid increases nitric oxide synthesis by endothelial cells: a role for
the induction of dimethylarginine dimethylaminohydrolase. Circ Res. Apr
19 2002;90(7):764-769.
192. Cardounel AJ, Zweier JL. Endogenous methyl-arginines regulate neuronal
nitric oxide synthase and prevent excitotoxic injury. J Biol Chem. Jun 28
2002.
193. Boger RH, Bode-Boger SM, Thiele W, Creutzig A, Alexander K, Frolich
JC. Restoring vascular nitric oxide formation by L-arginine improves the
symptoms of intermittent claudication in patients with peripheral arterial
occlusive disease. J Am Coll Cardiol. 1998;32(5):1336-1344.
194. Al Banchaabouchi M, Marescau B, Possemiers I, D’Hooge R, Levillain O, De
Deyn PP. NG, NG-dimethylarginine and NG, NG-dimethylarginine in renal
insufficiency. Pflugers Arch. 2000;439(5):524-531.
195. Kielstein JT, Boger RH, Bode-Boger SM, et al. Asymmetric dimethylarginine
plasma concentrations differ in patients with end-stage renal disease:
relationship to treatment method and atherosclerotic disease. J Am Soc
Nephrol. 1999;10(3):594-600.
196. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine
(ADMA): a novel risk factor for endothelial dysfunction: its role in
hypercholesterolemia. Circulation. 1998;98(18):1842-1847.
197. Fard A, Tuck CH, Donis JA, et al. Acute elevations of plasma asymmetric
dimethylarginine and impaired endothelial function in response to a highfat meal in patients with type 2 diabetes [In Process Citation]. Arterioscler
Thromb Vasc Biol. 2000;20(9):2039-2044.
198. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC.
Biochemical evidence for impaired nitric oxide synthesis in patients with
peripheral arterial occlusive disease. Circulation. 1997;95(8):2068-2074.
199. Creager MA, Cooke JP, Mendelsohn ME, et al. Impaired vasodilation of
forearm resistance vessels in hypercholesterolemic humans. J Clin Invest.
1990;86(1):228-234.
200. Boger RH, Bode-Boger SM, Matsuoka H, et al. Is asymmetric
dimethylarginine a novel marker of atherosclerosis? [letter; comment].
Circulation. 2000;101(14):E160-161.
201. Bode-Boger SM, Boger RH, Alfke H, et al. L-arginine induces nitric
oxide-dependent vasodilation in patients with critical limb ischemia. A
randomized, controlled study. Circulation. Jan 1 1996;93(1):85-90.
202. Valenti S, Cuttica CM, Giusti M, Giordano G. Nitric oxide modulates
Leydig cell function in vitro: is this a way of communication between the
immune and endocrine system in the testis? Ann N Y Acad Sci. Jun 22
1999;876:298-300.
203. Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M. In vivo and
in vitro antitumor effect of ascorbic acid, lysine, proline, arginine, and
green tea extract on human fibrosarcoma cells HT-1080. Med Oncol.
2006;23(1):105-111.
204. Uneda S, Hata H, Matsuno F, et al. A nitric oxide synthase inhibitor,
N(G)-nitro-l-arginine-methyl-ester, exerts potent antiangiogenic effects on
plasmacytoma in a newly established multiple myeloma severe combined
immunodeficient mouse model. Br J Haematol. Feb 2003;120(3):396-404.
205. Surdacki A, Nowicki M, Sandmann J, et al. Reduced urinary excretion
of nitric oxide metabolites and increased plasma levels of asymmetric
dimethylarginine in men with essential hypertension. J Cardiovasc
Pharmacol. 1999;33(4):652-658.
206. Sato J, Masuda H, Tamaoki S, et al. Endogenous asymmetrical
dimethylarginine and hypertension associated with puromycin nephrosis in
the rat. Br J Pharmacol. 1998;125(3):469-476.
207. Nagase S, Takemura K, Ueda A, et al. A novel nonenzymatic pathway for
the generation of nitric oxide by the reaction of hydrogen peroxide and Dor L-arginine. Biochem Biophys Res Commun. 1997;233(1):150-153.

170. Pita AM, Fernandez-Bustos A, Rodes M, et al. Orotic aciduria and plasma
urea cycle-related amino acid alterations in short bowel syndrome,
evoked by an arginine-free diet. JPEN J Parenter Enteral Nutr. Sep-Oct
2004;28(5):315-323.
171. Molderings GJ, Burian M, Homann J, Nilius M, Gothert M. Potential
relevance of agmatine as a virulence factor of Helicobacter pylori. Dig Dis
Sci. 1999;44(12):2397-2404.
172. Galea E, Regunathan S, Eliopoulos V, Feinstein DL, Reis DJ. Inhibition of
mammalian nitric oxide synthases by agmatine, an endogenous polyamine
formed by decarboxylation of arginine. Biochem J. 1996;316(Pt 1):247-249.
173. Reis DJ, Regunathan S. Is agmatine a novel neurotransmitter in brain?
Trends Pharmacol Sci. 2000;21(5):187-193.
174. Tousoulis D, Davies GJ, Tentolouris C, et al. Effects of changing the
availability of the substrate for nitric oxide synthase by L-arginine
administration on coronary vasomotor tone in angina patients with
angiographically narrowed and in patients with normal coronary arteries.
Am J Cardiol. 1998;82(9):1110-1113, A1116.
175. Kaleli B, Ozden A, Aybek Z, Bostanci B. The effect of L-arginine and
pentoxifylline on postoperative adhesion formation. Acta Obstet Gynecol
Scand. 1998;77(4):377-380.
176. Giroux I, Kurowska EM, Carroll KK. Role of dietary lysine, methionine,
and arginine in the regulation of hypercholesterolemia in rabbits. J Nutr
Biochem. Mar 1999;10(3):166-171.
177. Kato T, Sano M, Mizutani N. Inhibitory effect of intravenous lysine infusion
on urea cycle metabolism. Eur J Pediatr. Jan 1987;146(1):56-58.
178. Perez-Amador MA, Leon J, Green PJ, Carbonell J. Induction of the arginine
decarboxylase ADC2 gene provides evidence for the involvement of
polyamines in the wound response in Arabidopsis. Plant Physiol. Nov
2002;130(3):1454-1463.
179. Angele MK, Smail N, Ayala A, Cioffi WG, Bland KI, Chaudry IH. L-arginine:
a unique amino acid for restoring the depressed macrophage functions after
trauma-hemorrhage. J Trauma. 1999;46(1):34-41.
180. Aydin S, Inci O, Alagol B. The role of arginine, indomethacin and kallikrein in
the treatment of oligoasthenospermia. Int Urol Nephrol. 1995;27(2):199-202.
181. Castillo L, Sanchez M, Vogt J, et al. Plasma arginine, citrulline, and ornithine
kinetics in adults, with observations on nitric oxide synthesis. Am J Physiol.
1995;268(2 Pt 1):E360-367.
182. Brock AA, Chapman SA, Ulman EA, Wu G. Dietary manganese deficiency
decreases rat hepatic arginase activity. J Nutr. Mar 1994;124(3):340-344.
183. O’Quinn PR, Knabe DA, Wu G. Arginine catabolism in lactating porcine
mammary tissue. J Anim Sci. Feb 2002;80(2):467-474.
184. Castellano MA, Rojas-Diaz D, Martin F, et al. Opposite effects of low and
high doses of arginine on glutamate-induced nitric oxide formation in rat
substantia nigra. Neurosci Lett. Nov 16 2001;314(3):127-130.
185. Dillon BJ, Prieto VG, Curley SA, et al. Incidence and distribution of
argininosuccinate synthetase deficiency in human cancers: a method
for identifying cancers sensitive to arginine deprivation. Cancer. Feb 15
2004;100(4):826-833.
186. Jang JJ, Ho HK, Kwan HH, Fajardo LF, Cooke JP. Angiogenesis is impaired
by hypercholesterolemia: role of asymmetric dimethylarginine. Circulation.
2000;102(12):1414-1419.
187. Boger RH, Lentz SR, Bode-Boger SM, Knapp HR, Haynes WG. Elevation of
asymmetrical dimethylarginine may mediate endothelial dysfunction during
experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Colch).
2001;100(2):161-167.
188. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes
WG. Role of oxidant stress in endothelial dysfunction produced by
experimental hyperhomocyst(e)inemia in humans. Circulation. Sep 14
1999;100(11):1161-1168.
189. Nijveldt RJ, Teerlink T, Siroen MP, Van Lambalgen AA, Rauwerda JA,
Van Leeuwen PA. The liver is an important organ in the metabolism of
asymmetrical dimethylarginine (ADMA). Clin Nutr. Feb 2003;22(1):17-22.

227. Campistron G, Guiraud R, Cros J, Pontagnier H. Pharmacokinetics of
arginine and aspartic acid administered simultaneously in the rat—III:
Changes in the levels of amino acids in the plasma, liver and brain after
simultaneous administration of arginine and aspartic acid. Eur J Drug Metab
Pharmacokinet. 1983;8(3):281-286.
228. Rotondo G, De Angelis AM. [On the use of acetyl-aspartic acid and of
citrulline in the treatment and prevention of flight fatigue]. Riv Med
Aeronaut Spaz. 1966;29(1):85-105.
229. Hawkins DS, Park JR, Thomson BG, et al. Asparaginase pharmacokinetics
after intensive polyethylene glycol-conjugated L-asparaginase therapy for
children with relapsed acute lymphoblastic leukemia. Clin Cancer Res. Aug
15 2004;10(16):5335-5341.
230. Garnick MB, Larsen PR. Acute deficiency of thyroxine-binding globulin
during L-asparaginase therapy. N Engl J Med. Aug 2 1979;301(5):252-253.
231. Buchanan GR, Holtkamp CA. Reduced antithrombin III levels during Lasparaginase therapy. Med Pediatr Oncol. 1980;8(1):7-14.
232. Gentili D, Conter V, Rizzari C, et al. L-Asparagine depletion in plasma and
cerebro-spinal fluid of children with acute lymphoblastic leukemia during
subsequent exposures to Erwinia L-asparaginase [see comments]. Ann
Oncol. 1996;7(7):725-730.
233. Hammarqvist F, von der Decken A, Vinnars E, Wernerman J. Stress
hormone and amino acid infusion in healthy volunteers: short-term
effects on protein synthesis and amino acid metabolism in skeletal muscle.
Metabolism. 1994;43(9):1158-1163.
234. Eiduson S, Yuwiler A, Eberle ED. The effect of pyridoxine deficiency on
L-aromatic amino acid decarboxylase and tyrosine aminotransferase in
developing brain. Adv Biochem Psychopharmacol. 1972;4:63-80.
235. Cynober LA. Amino Acid Metabolism and Therapy in Health and Nutritional
Disease. Boca Raton: CRC Press; 1995.
236. Harris RA, Zhang B, Goodwin GW, et al. Regulation of the branched-chain
alpha-ketoacid dehydrogenase and elucidation of a molecular basis for
maple syrup urine disease. Adv Enzyme Regul. 1990;30:245-263.
237. Slyshenkov VS, Dymkowska D, Wojtczak L. Pantothenic acid and
pantothenol increase biosynthesis of glutathione by boosting cell energetics.
FEBS Lett. Jul 2 2004;569(1-3):169-172.
238. Wang X, Price SR. Differential regulation of branched-chain alpha-ketoacid
dehydrogenase kinase expression by glucocorticoids and acidification in
LLC-PK1-GR101 cells. Am J Physiol Renal Physiol. Mar 2004;286(3):F504508.
239. Obayashi M, Shimomura Y, Nakai N, et al. Estrogen controls branchedchain amino acid catabolism in female rats. J Nutr. Oct 2004;134(10):26282633.
240. Ferrando AA, Sheffield-Moore M, Paddon-Jones D, Wolfe RR, Urban RJ.
Differential anabolic effects of testosterone and amino acid feeding in older
men. J Clin Endocrinol Metab. Jan 2003;88(1):358-362.
241. Ferrando AA, Tipton KD, Doyle D, Phillips SM, Cortiella J, Wolfe RR.
Testosterone injection stimulates net protein synthesis but not tissue amino
acid transport. Am J Physiol. Nov 1998;275(5 Pt 1):E864-871.
242. Chennaoui M, Gomez-Marino D, Drogou C, Bourrilhon C, Sautivet S,
Guezennec CY. Hormonal and metabolic adaptation in professional cyclists
during training. Can J Appl Physiol. Dec 2004;29(6):714-730.
243. Lucke T, Perez-Cerda C, Baumgartner M, et al. Propionic acidemia: unusual
course with late onset and fatal outcome. Metabolism. Jun 2004;53(6):809810.
244. van der Meer SB, Poggi F, Spada M, et al. Clinical outcome and long-term
management of 17 patients with propionic acidaemia. Eur J Pediatr. Mar
1996;155(3):205-210.
245. Matsuishi T, Stumpf DA, Chrislip K. The effect of malate on propionate
mitochondrial toxicity. Biochem Med Metab Biol. Oct 1991;46(2):177-184.
246. Matsuishi T, Stumpf DA, Seliem M, Eguren LA, Chrislip K. Propionate
mitochondrial toxicity in liver and skeletal muscle: acyl CoA levels. Biochem
Med Metab Biol. Apr 1991;45(2):244-253.

208. Blum A, Miller H, Blum A, Miller H. The effects of L-arginine on
atherosclerosis and heart disease. Int J Cardiovasc Intervent. 1999;2(2):97100.
209. Venho B, Voutilainen S, Valkonen VP, et al. Arginine intake, blood pressure,
and the incidence of acute coronary events in men: the Kuopio Ischaemic
Heart Disease Risk Factor Study. Am J Clin Nutr. Aug 2002;76(2):359-364.
210. Crenn P, Coudray-Lucas C, Cynober L, Messing B. Post-absorptive plasma
citrulline concentration: a marker of intestinal failure in humans. Transplant
Proc. 1998;30(6):2528.
211. Pappas PA, Tzakis AG, Saudubray JM, et al. Trends in serum citrulline and
acute rejection among recipients of small bowel transplants. Transplant
Proc. Mar 2004;36(2):345-347.
212. Lagerwerf FM, Wever RM, van Rijn HJ, et al. Assessment of nitric oxide
production by measurement of [15N]citrulline enrichment in human
plasma using high-performance liquid chromatography- mass spectrometry.
Anal Biochem. 1998;257(1):45-52.
213. Iafolla AK, Kahler SG, Chen YT. Low plasma citrulline concentrations
during protein restriction in an unaffected infant at risk for ornithine
transcarbamylase deficiency. J Pediatr. 1992;120(3):496-497.
214. Kamoun P, Rabier D, Bardet J, Parvy P. Citrulline concentrations in human
plasma after arginine load. Clin Chem. 1991;37(7):1287.
215. Yamaguchi S, Brailey LL, Morizono H, Bale AE, Tuchman M. Mutations and
polymorphisms in the human ornithine transcarbamylase (OTC) gene. Hum
Mutat. Jul 2006;27(7):626-632.
216. Harada E, Nishiyori A, Tokunaga Y, et al. Late-onset ornithine
transcarbamylase deficiency in male patients: prognostic factors
and characteristics of plasma amino acid profile. Pediatr Int. Apr
2006;48(2):105-111.
217. Hommes FA, Roesel RA, Metoki K, Hartlage PL, Dyken PR. Studies
on a case of HHH-syndrome (hyperammonemia, hyperornithinemia,
homocitrullinuria). Neuropediatrics. Feb 1986;17(1):48-52.
218. Arn PH, Hauser ER, Thomas GH, Herman G, Hess D, Brusilow
SW. Hyperammonemia in women with a mutation at the ornithine
carbamoyltransferase locus. A cause of postpartum coma. N Engl J Med. Jun
7 1990;322(23):1652-1655.
219. Solaini G, Mazziotti A, Solaini L, Cacciari G, Cavallari A. [Variations in
the plasma concentration of ornithine, citrulline and arginine in acute
experimental liver failure]. Boll Soc Ital Biol Sper. 1981;57(7):705-710.
220. Salerno F, Abbiati R, Fici F. Effect of pyridoxine alpha-ketoglutarate (PAK)
on ammonia and pyruvic and lactic acid blood levels in patients with
cirrhosis. Int J Clin Pharmacol Res. 1983;3(1):21-25.
221. Holtta E, Pohjanpelto P. Control of ornithine decarboxylase in Chinese
hamster ovary cells by polyamines. Translational inhibition of synthesis and
acceleration of degradation of the enzyme by putrescine, spermidine, and
spermine. J Biol Chem. 1986;261(20):9502-9508.
222. Krassowski J, Rousselle J, Maeder E, Felber JP. The effect of ornithine alphaketoglutarate on growth hormone (GH) and prolactin (PRL) release in
normal subjects. Endokrynol Pol. 1986;37(1):11-15.
223. Lecointre C, Mallet E. [Study of tall stature in children. Low paradoxically
low answer of growth hormone to stimulation with ornithine (letter)]. Arch
Fr Pediatr. 1990;47(10):763.
224. Feoli-Fonseca JC, Lambert M, Mitchell G, et al. Chronic sodium benzoate
therapy in children with inborn errors of urea synthesis: effect on carnitine
metabolism and ammonia nitrogen removal. Biochem Mol Med. Feb
1996;57(1):31-36.
225. Barshop BA, Breuer J, Holm J, Leslie J, Nyhan WL. Excretion of hippuric
acid during sodium benzoate therapy in patients with hyperglycinaemia or
hyperammonaemia. J Inherit Metab Dis. 1989;12(1):72-79.
226. Campistron G, Guiraud R, Cros J, Prat G. Pharmacokinetics of arginine and
aspartic acid administered simultaneously in the rat: II. Tissue distribution.
Eur J Drug Metab Pharmacokinet. 1982;7(4):315-322.

267. Gerber DA. Low free serum histidine concentration in rheumatoid arthritis.
A measure of disease activity. J Clin Invest. 1975;55(6):1164-1173.
268. Ngo TM, Winchell HS. Alterations in histidine catabolism in normal rats
given pharmacological doses of folic acid and cyanocobalamin. Proc Soc Exp
Biol Med. 1969;132(1):168-170.
269. Buehring KU, Batra KK, Stokstad EL. The effect of methionine on folic
acid and histidine metabolism in perfused rat liver. Biochim Biophys Acta.
1972;279(3):498-512.
270. Lee YT, Hsu CC, Lin MH, Liu KS, Yin MC. Histidine and carnosine delay
diabetic deterioration in mice and protect human low density lipoprotein
against oxidation and glycation. Eur J Pharmacol. Apr 18 2005;513(12):145-150.
271. Wagner W, Fogel WA. Mammary histidine decarboxylase vulnerability to
enzyme antisense oligonucleotides: histamine and polyamine systems crosstalk. Amino Acids. Jul 2004;26(4):311-316.
272. Hitomi-Ohmura E, Amano N, Aoyama Y, Yoshida A. The effect of a
histidine-excess diet on cholesterol synthesis and degradation in rats. Lipids.
Oct 1992;27(10):755-760.
273. Aoyama Y, Tsuda T, Hitomi-Ohmura E, Yoshida A. Activities of some
regulatory enzymes of carbohydrate metabolism in the liver of rats
fed a histidine-excess diet. Comp Biochem Physiol Comp Physiol. Feb
1993;104(2):381-388.
274. Henkin RI. Comments to the editor concerning the paper entitled “Histidine
suppresses food intake through its conversion into neuronal histamine” by
Yoshimatsu et al. Exp Biol Med (Maywood). Sep 2002;227(8):559; author
reply 560.
275. Yoshimatsu H, Chiba S, Tajima D, Akehi Y, Sakata T. Histidine suppresses
food intake through its conversion into neuronal histamine. Exp Biol Med
(Maywood). Jan 2002;227(1):63-68.
276. Aoyama Y, Kato C. Suppressive effect of excess dietary histidine on the
expression of hepatic metallothionein-1 in rats. Biosci Biotechnol Biochem.
Mar 2000;64(3):588-591.
277. Manders AJ, von Oostrom CG, Trijbels JM, Rutten FJ, Kleijer WJ.
alpha-Aminoadipic aciduria and persistence of fetal haemoglobin in an
oligophrenic child. Eur J Pediatr. 1981;136(1):51-55.
278. Kamoun P, Richard V, Rabier D, Saudubray JM. Plasma lysine concentration
and availability of 2-ketoglutarate in liver mitochondria. J Inherit Metab Dis.
Feb 2002;25(1):1-6.
279. Shaw S, Lieber CS. Increased hepatic production of alpha-amino-nbutyric acid after chronic alcohol consumption in rats and baboons.
Gastroenterology. 1980;78(1):108-113.
280. Krajcovicova-Kudlackova M, Simoncic R, Bederova A, Babinska K, Beder I.
Correlation of carnitine levels to methionine and lysine intake. Physiol Res.
2000;49(3):399-402.
281. Katsumata M, Kawakami S, Kaji Y, Takada R, Dauncey MJ. Differential
regulation of porcine hepatic IGF-I mRNA expression and plasma IGF-I
concentration by a low lysine diet. J Nutr. Apr 2002;132(4):688-692.
282. Takada G, Goto A, Komatsu K, Goto R. Carnitine deficiency in lysinuric
protein intolerance: lysine-sparing effect of carnitine. Tohoku J Exp Med.
1987;153(4):331-334.
283. Fernandez Ortega MF. Effect of dietary lysine level and protein restriction on
the lipids and carnitine levels in the liver of pregnant rats. Ann Nutr Metab.
1989;33(3):162-169.
284. Smriga M, Kameishi M, Uneyama H, Torii K. Dietary L-lysine deficiency
increases stress-induced anxiety and fecal excretion in rats. J Nutr. Dec
2002;132(12):3744-3746.
285. Srinongkote S, Smriga M, Nakagawa K, Toride Y. A diet fortified with
L-lysine and L-arginine reduces plasma cortisol and blocks anxiogenic
response to transportation in pigs. Nutr Neurosci. Oct 2003;6(5):283-289.

247. Glasgow AM, Chase HP. Effect of propionic acid on fatty acid oxidation and
ureagenesis. Pediatr Res. Jul 1976;10(7):683-686.
248. Rosenlund BL. Effects of insulin on free amino acids in plasma and the role
of the amino acid metabolism in the etiology of diabetic microangiopathy.
Biochem Med Metab Biol. 1993;49(3):375-391.
249. Fryburg DA, Jahn LA, Hill SA, Oliveras DM, Barrett EJ. Insulin and insulinlike growth factor-I enhance human skeletal muscle protein anabolism
during hyperaminoacidemia by different mechanisms. J Clin Invest.
1995;96(4):1722-1729.
250. Kirvela O, Thorpy M, Takala J, Askanazi J, Singer P, Kvetan V. Respiratory
and sleep patterns during nocturnal infusions of branched chain amino
acids. Acta Anaesthesiol Scand. 1990;34(8):645-648.
251. Gil KM, Skeie B, Kvetan V, Friedman MI, Askanazi J. Parenteral nutrition
and oral intake: effect of branched-chain amino acids. Nutrition.
1990;6(4):291-295.
252. Nair KS, Schwartz RG, Welle S. Leucine as a regulator of whole body and
skeletal muscle protein metabolism in humans. Am J Physiol. 1992;263(5 Pt
1):E928-934.
253. Edgar AJ. Mice have a transcribed L-threonine aldolase/GLY1 gene, but the
human GLY1 gene is a non-processed pseudogene. BMC Genomics. Mar 9
2005;6(1):32.
254. Tews JK, Greenwood J, Pratt OE, Harper AE. Threonine entry into rat
brain after diet-induced changes in plasma amino acids. J Neurochem. Jun
1987;48(6):1879-1886.
255. Tews JK, Kim YW, Harper AE. Induction of threonine imbalance by
dispensable amino acids: relation to competition for amino acid transport
into brain. J Nutr. Feb 1979;109(2):304-315.
256. King N, Suleiman MS. Effect of regular training on the myocardial and
plasma concentrations of taurine and alpha-amino acids in thoroughbred
horses. Amino Acids. 1998;15(3):241-251.
257. LaFranchi S, Buist NR, Jhaveri B, Klevit H. Amino acids as substrates in
children with growth hormone deficiency and hypoglycemia. Pediatrics.
1981;68(2):260-264.
258. Hauser SL, Doolittle TH, Lopez-Bresnahan M, et al. An antispasticity effect
of threonine in multiple sclerosis. Arch Neurol. 1992;49(9):923-926.
259. Kriengsinyos W, Rafii M, Wykes LJ, Ball RO, Pencharz PB. Long-term effects
of histidine depletion on whole-body protein metabolism in healthy adults.
J Nutr. Nov 2002;132(11):3340-3348.
260. Roon-Djordjevic Bv, Cerfontain-van S. Urinary excretion of histidine
metabolites as an indication for folic acid and vitamin B12 deficiency. Clin
Chim Acta. 1972;41:55-65.
261. Schalinske KL, Steele RD. Quantification of the carbon flow through
the folate-dependent one-carbon pool using radiolabeled histidine:
effect of altered thyroid and folate status. Arch Biochem Biophys. Apr 1
1996;328(1):93-100.
262. Celanire S, Wijtmans M, Talaga P, Leurs R, de Esch IJ. Keynote review:
Histamine H(3) receptor antagonists reach out for the clinic. Drug Discov
Today. Dec 2005;10(23-24):1613-1627.
263. Kaminski RM, Zolkowska D, Kozicka M, Kleinrok Z, Czuczwar SJ. Lhistidine is a beneficial adjuvant for antiepileptic drugs against maximal
electroshock-induced seizures in mice. Amino Acids. Feb 2004;26(1):85-89.
264. Parmentier R, Ohtsu H, Djebbara-Hannas Z, Valatx JL, Watanabe T, Lin JS.
Anatomical, physiological, and pharmacological characteristics of histidine
decarboxylase knock-out mice: evidence for the role of brain histamine in
behavioral and sleep-wake control. J Neurosci. Sep 1 2002;22(17):7695-7711.
265. Tamaddonfard E, Rahimi S. Central effect of histamine and peripheral
effect of histidine on the formalin-induced pain response in mice. Clin Exp
Pharmacol Physiol. Aug 2004;31(8):518-522.
266. Lozeva V, Tarhanen J, Attila M, Mannisto PT, Tuomisto L. Brain histamine
and histamine H3 receptors following repeated L-histidine administration in
rats. Life Sci. Aug 8 2003;73(12):1491-1503.

307. Trijbels JM, Monnens LA, Bakkeren JA, Van Raay-Selten AH, Corstiaensen
JM. Biochemical studies in the cerebro-hepato-renal syndrome of Zellweger:
a disturbance in the metabolism of pipecolic acid. J Inherit Metab Dis.
1980;2(2):39-42.
308. Heggarty HJ, Ball R, Smith M, Henderson MJ. Amino acid profile in Down’s
syndrome. Arch Dis Child. Apr 1996;74(4):347-349.
309. Torrents D, Mykkanen J, Pineda M, et al. Identification of SLC7A7,
encoding y+LAT-1, as the lysinuric protein intolerance gene. Nat Genet. Mar
1999;21(3):293-296.
310. Lukkarinen M, Nanto-Salonen K, Pulkki K, Aalto M, Simell O. Oral
supplementation corrects plasma lysine concentrations in lysinuric protein
intolerance. Metabolism. Jul 2003;52(7):935-938.
311. Berner YN, Larchian WA, Lowry SF, Nicroa RR, Brennan MF, Shike M.
Low plasma carnitine in patients on prolonged total parenteral nutrition:
association with low plasma lysine. JPEN J Parenter Enteral Nutr.
1990;14(3):255-258.
312. Gershoff SN, McGandy RB, Suttapreyasri D, et al. Nutrition studied in
Thailand. II. Effects of fortification of rice with lysine, threonine, thiamin,
riboflavin, vitamin A, and iron on preschool children. Am J Clin Nutr. Jul
1977;30(7):1185-1195.
313. Olszewski AJ, Szostak WB. Homocysteine content of plasma proteins in
ischemic heart disease [published erratum appears in Atherosclerosis 1991
May;88(1):97-8]. Atherosclerosis. 1991;69(2-3):109-113.
314. Tane N, Takeda T, Shioji T, Ohyama H, Itoh H. Effect of vitamin B6
deficiency on collagen metabolism in rats. J Nutr Sci Vitaminol (Tokyo).
1976;22(2):105-114.
315. Lo JC, Chertow GM, Rennke H, Seifter JL. Fanconi’s syndrome and
tubulointerstitial nephritis in association with L-lysine ingestion. Am J
Kidney Dis. 1996;28(4):614-617.
316. Institute of Medicine (U.S.). Panel on Macronutrients., Institute of Medicine
(U.S.). Standing Committee on the Scientific Evaluation of Dietary
Reference Intakes. Dietary Reference Intakes for Energy, Carbohydrate, Fiber,
Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.:
National Academies Press; 2005.
317. Erlandsen H, Stevens RC. A structural hypothesis for BH4 responsiveness in
patients with mild forms of hyperphenylalaninaemia and phenylketonuria. J
Inherit Metab Dis. Apr 2001;24(2):213-230.
318. Boulos M, Boulat O, Van Melle G, Guignard JP, Matthieu JM. Correlation
between plasma and urine phenylalanine concentrations. Biol Neonate.
2004;86(1):6-9.
319. Dale Y, Mackey V, Mushi R, Nyanda A, Maleque M, Ike J. Simultaneous
measurement of phenylalanine and tyrosine in phenylketonuric plasma and
dried blood by high-performance liquid chromatography. J Chromatogr B
Analyt Technol Biomed Life Sci. May 5 2003;788(1):1-8.
320. Reilly AA, Bellisario R, Pass KA. Multivariate discrimination for
phenylketonuria (PKU) and non-PKU hyperphenylalaninemia after analysis
of newborns’ dried blood-spot specimens for six amino acids by ionexchange chromatography. Clin Chem. Feb 1998;44(2):317-326.
321. Mallolas J, Mila M, Lambruschini N, Cambra FJ, Campistol J, Vilaseca
MA. Biochemical phenotype and its relationship with genotype
in hyperphenylalaninemia heterozygotes. Mol Genet Metab. Jun
1999;67(2):156-161.
322. Lehmann WD, Heinrich HC. Impaired phenylalanine-tyrosine conversion
in patients with iron- deficiency anemia studied by a L-(2H5)phenylalanineloading test. Am J Clin Nutr. 1986;44(4):468-474.
323. Verduci E, Riva E, Agostoni C, et al. Phenylalanine hydroxylase mutations
and phenylalanine-tyrosine metabolism in heterozygotes for phenylalanine
hydroxylase deficiency. Acta Paediatr. 2002;91(7):805-810.
324. Hoffmann GF, Assmann B, Brautigam C, et al. Tyrosine hydroxylase
deficiency causes progressive encephalopathy and dopa-nonresponsive
dystonia. Ann Neurol. 2003;54 Suppl 6:S56-65.

286. Smriga M, Ghosh S, Mouneimne Y, Pellett PL, Scrimshaw NS. Lysine
fortification reduces anxiety and lessens stress in family members in
economically weak communities in Northwest Syria. Proc Natl Acad Sci U S
A. Jun 1 2004;101(22):8285-8288.
287. Smriga M, Torii K. L-Lysine acts like a partial serotonin receptor 4 antagonist
and inhibits serotonin-mediated intestinal pathologies and anxiety in rats.
Proc Natl Acad Sci U S A. Dec 23 2003;100(26):15370-15375.
288. Maron E, Toru I, Vasar V, Shlik J. The effect of 5-hydroxytryptophan
on cholecystokinin-4-induced panic attacks in healthy volunteers. J
Psychopharmacol. Jun 2004;18(2):194-199.
289. Griebel G, Rodgers RJ, Perrault G, Sanger DJ. The effects of compounds
varying in selectivity as 5-HT(1A) receptor antagonists in three rat models
of anxiety. Neuropharmacology. Jul 24 2000;39(10):1848-1857.
290. Smriga M, Torii K. Metabolic interactions between restraint stress
and L-lysine: the effect on urea cycle components. Amino Acids. Jun
2003;24(4):435-437.
291. Flodin NW. The metabolic roles, pharmacology, and toxicology of lysine. J
Am Coll Nutr. 1997;16(1):7-21.
292. Ruyechan WT, Olson JW. Surface lysine and tyrosine residues are required
for interaction of the major herpes simplex virus type 1 DNA-binding
protein with single- stranded DNA. J Virol. 1992;66(11):6273-6279.
293. Thein DJ, Hurt WC. Lysine as a prophylactic agent in the treatment
of recurrent herpes simplex labialis. Oral Surg Oral Med Oral Pathol.
1984;58(6):659-666.
294. Jyothirmayi GN, Modak R, Reddi AS. L-lysine reduces nonenzymatic
glycation of glomerular basement membrane collagen and albuminuria in
diabetic rats. Nephron. Feb 2001;87(2):148-154.
295. Sulochana KN, Punitham R, Ramakrishnan S. Beneficial effect of lysine and
amino acids on cataractogenesis in experimental diabetes through possible
antiglycation of lens proteins. Exp Eye Res. Nov 1998;67(5):597-601.
296. Sulochana KN, Rajesh M, Ramakrishnan S. Insulin receptor tyrosine kinase
activity in monocytes of type 2 diabetes mellitus patients receiving oral Llysine. Indian J Biochem Biophys. Oct 2001;38(5):331-334.
297. Bernasconi R, Jones RS, Bittiger H, et al. Dose pipecolic acid interact with
the central GABA-ergic system? J Neural Transm. 1986;67(3-4):175-189.
298. Takahama K, Miyata T, Okano Y, Kataoka M, Hitoshi T, Kase Y. Potentiation
of phenobarbital-induced anticonvulsant activity by pipecolic acid. Eur J
Pharmacol. Jul 9 1982;81(2):327-331.
299. Gutierrez J, Liebana J. Immunological methods for the detection of
structural components and metabolites of bacteria and fungi in blood. Ann
Biol Clin (Paris). 1993;51(2):83-90.
300. Charles AK. Pipecolic acid receptors in rat cerebral cortex. Neurochem Res.
Apr 1986;11(4):521-525.
301. Beitz AJ, Larson AA. Inhibition of intrathecally administered picrotoxin- and
bicuculline-induced convulsions in mice by pipecolic acid or GABA. Eur J
Pharmacol. Aug 15 1985;114(2):181-187.
302. Takahama K, Hashimoto T, Wang MW, et al. Pipecolic acid enhancement
of GABA response in single neurons of rat brain. Neuropharmacology. Mar
1986;25(3):339-342.
303. Gutierrez MC, Delgado-Coello BA. Influence of pipecolic acid on the
release and uptake of [3H]GABA from brain slices of mouse cerebral cortex.
Neurochem Res. May 1989;14(5):405-408.
304. Matsuda Y, Fujita T, Hada T, Higashino K. Comparative study on the
correlation of plasma gamma-aminobutyric acid and pipecolic acid
with liver function in patients with liver cirrhosis. Hepatol Res. Aug
2000;18(2):132-140.
305. Takagi T, Ando R, Ohgushi A, et al. Intracerebroventricular injection of
pipecolic acid inhibits food intake and induces sleeping-like behaviors in
the neonatal chick. Neurosci Lett. Sep 14 2001;310(2-3):97-100.
306. Feigenbaum P, Chang YF. Pipecolic acid antagonizes barbiturateenhanced GABA binding to bovine brain membranes. Brain Res. Apr 30
1986;372(1):176-179.

345. Herrera R, Manjarrez G, Nishimura E, Hernandez J. Serotonin-related
tryptophan in children with insulin-dependent diabetes. Pediatr Neurol. Jan
2003;28(1):20-23.
346. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC. Plasma tryptophan and
other amino acids in primary fibromyalgia: a controlled study. J Rheumatol.
Jan 1992;19(1):90-94.
347. Neumeister A, Praschak-Rieder N, Hesselmann B, et al. Effects of
tryptophan depletion in drug-free depressed patients who responded to
total sleep deprivation. Arch Gen Psychiatry. 1998;55(2):167-172.
348. Kuhn E, Rysanek K, Brodan V, Spankova H. Changes in blood tryptophan
level during sleep deprivation. Experientia. 1976;32(9):1117-1118.
349. Lanoir J, Ternaux JP, Pons C, Lagarde JM. Long-term effects of a tryptophanfree diet on serotonin metabolism and sleep-waking balance in rats. Exp
Brain Res. 1981;41(3-4):346-357.
350. Bellodi L, Erzegovesi S, Bianchi L, Lucini V, Conca R, Lucca A. Plasma
tryptophan levels and tryptophan/neutral amino acid ratios in obsessivecompulsive patients with and without depression. Psychiatry Res.
1997;69(1):9-15.
351. Anderson IM, Parry-Billings M, Newsholme EA, Poortmans JR,
Cowen PJ. Decreased plasma tryptophan concentration in major
depression: relationship to melancholia and weight loss. J Affect Disord.
1990;20(3):185-191.
352. Thomson J, Rankin H, Ashcroft GW, Yates CM, McQueen JK, Cummings
SW. The treatment of depression in general practice: a comparison of
L- tryptophan, amitriptyline, and a combination of L-tryptophan and
amitriptyline with placebo. Psychol Med. 1982;12(4):741-751.
353. Hagberg GE, Torstenson R, Marteinsdottir I, Fredrikson M, Langstrom
B, Blomqvist G. Kinetic compartment modeling of [11C]-5-hydroxyL-tryptophan for positron emission tomography assessment of
serotonin synthesis in human brain. J Cereb Blood Flow Metab. Nov
2002;22(11):1352-1366.
354. Bengtsson F, Bugge M, Johansen KH, Butterworth RF. Brain tryptophan
hydroxylation in the portacaval shunted rat: a hypothesis for the regulation
of serotonin turnover in vivo. J Neurochem. Mar 1991;56(3):1069-1074.
355. Herneth AM, Steindl P, Ferenci P, Roth E, Hortnagl H. Role of tryptophan in
the elevated serotonin-turnover in hepatic encephalopathy. J Neural Transm.
1998;105(8-9):975-986.
356. PDR for Nutritional Supplements. Montvale, NJ: Medical Economics,
Thomson Healthcare; 2001.
357. Tamarappoo BK, Raizada MK, Kilberg MS. Identification of a system Nlike Na(+)-dependent glutamine transport activity in rat brain neurons. J
Neurochem. Mar 1997;68(3):954-960.
358. Chaouloff F, Kennett GA, Serrurrier B, Merino D, Curzon G. Amino acid
analysis demonstrates that increased plasma free tryptophan causes the
increase of brain tryptophan during exercise in the rat. J Neurochem. May
1986;46(5):1647-1650.
359. Stanko RT, Morse EL, Adibi SA. Prevention of effects of ethanol on amino
acid concentrations in plasma and tissues by hepatic lipotropic factors in
rats. Gastroenterology. Jan 1979;76(1):132-138.
360. Stanko RT, Mendelow H, Shinozuka H, Adibi SA. Prevention of alcoholinduced fatty liver by natural metabolites and riboflavin. J Lab Clin Med.
Feb 1978;91(2):228-235.
361. Hilderbrand RL, Hervig LK, Conway TL, Ward HW, Markland FS.
Alcohol intake, ratio of plasma alpha-amino-n-butyric acid to leucine,
and gamma-glutamyl transpeptidase in nonalcoholics. J Stud Alcohol. Sep
1979;40(9):902-905.
362. Chick J, Longstaff M, Kreitman N, Plant M, Thatcher D, Waite J. Plasma
alpha-amino-n-butyric acid: leucine ratio and alcohol consumption in
working men and in alcoholics. J Stud Alcohol. May 1982;43(5):583-587.
363. Dienstag JL, Carter EA, Wands JR, Isselbacher KJ, Fischer JE. Plasma
alpha-amino-n-butyric acid to leucine ratio: nonspecificity as a marker for
alcoholism. Gastroenterology. Oct 1978;75(4):561-565.

325. Gropper SS, Yannicelli S, White BD, Medeiros DM. Plasma phenylalanine
concentrations are associated with hepatic iron content in a murine model
for phenylketonuria. Mol Genet Metab. May 2004;82(1):76-82.
326. Yannicelli S, Medeiros DM. Elevated plasma phenylalanine concentrations
may adversely affect bone status of phenylketonuric mice. J Inherit Metab
Dis. Sep 2002;25(5):347-361.
327. Colome C, Artuch R, Lambruschini N, Cambra FJ, Campistol J, Vilaseca
M. Is there a relationship between plasma phenylalanine and cholesterol
in phenylketonuric patients under dietary treatment? Clin Biochem. Jul
2001;34(5):373-376.
328. Artuch R, Colome C, Vilaseca MA, et al. Plasma phenylalanine is associated
with decreased serum ubiquinone-10 concentrations in phenylketonuria. J
Inherit Metab Dis. Jun 2001;24(3):359-366.
329. Scriver CR, Kaufman S. Hyperphenylalaninemia: Phenylalanine hydroxylase
deficiency. In: Scriver C, Beaudet A, Sly W, Valle D, eds. The Metabolic and
Molecular Bases of Inherited Disease. Vol II. New York: McGraw-Hill, Health
Professions Division; 1995:1667 - 1724.
330. Merrick J, Aspler S, Schwarz G. Phenylalanine-restricted diet should be life
long. A case report on long-term follow-up of an adolescent with untreated
phenylketonuria. Int J Adolesc Med Health. Apr-Jun 2003;15(2):165-168.
331. Sawabe K, Wakasugi KO, Hasegawa H. Tetrahydrobiopterin uptake in
supplemental administration: elevation of tissue tetrahydrobiopterin in mice
following uptake of the exogenously oxidized product 7,8-dihydrobiopterin
and subsequent reduction by an anti-folate-sensitive process. J Pharmacol
Sci. Oct 2004;96(2):124-133.
332. Blau N, Thöny B. Possible impact of tetrahydrobiopterin and sepiapterin on
endothelial dysfunction. Arterioscler, Thromb, Vasc Biol. 2003;23:913.
333. Sanjurjo P, Aldamiz L, Georgi G, Jelinek J, Ruiz JI, Boehm G. Dietary
threonine reduces plasma phenylalanine levels in patients with
hyperphenylalaninemia. J Pediatr Gastroenterol Nutr. Jan 2003;36(1):23-26.
334. van Spronsen FJ, Smit PG, Koch R. Phenylketonuria: tyrosine beyond the
phenylalanine-restricted diet. J Inherit Metab Dis. Feb 2001;24(1):1-4.
335. Easton EJ, Simpson I, Martin JK, Campbell M. Tyrosinemia induced by a
pyridoxine antagonist, desoxypyridoxine. Clin Chem. Feb 1972;18(2):161163.
336. Gelenberg AJ, D. WJ, H. GJ, et al. Tyrosine for the treatment of depression.
American Journal Psychiatry. 1980;137:5(May):622-623.
337. Wurtman R. Nutrition and the brain. Vol 6. Philadelphia: Raven Press; 1983.
338. Huisman TH, Jonxis JH. Some investigations on the metabolism of
phenylalanine and tyrosine in children with vitamin C deficiency. Arch Dis
Child. Apr 1957;32(162):77-81.
339. Siersbaek-Nielsen K. Determination of the plasma tyrosine in
thyroid disorders. A new test of thyroid function. Acta Med Scand.
1966;179(4):417-426.
340. Belanger R, Chandramohan N, Misbin R, Rivlin RS. Tyrosine and glutamic
acid in plasma and urine of patients with altered thyroid function.
Metabolism. 1972;21(9):855-865.
341. Boirie Y, Albright R, Bigelow M, Nair KS. Impairment of phenylalanine
conversion to tyrosine in end-stage renal disease causing tyrosine deficiency.
Kidney Int. Aug 2004;66(2):591-596.
342. Salomon RM, Miller HL, Delgado PL, Charney D. The use of tryptophan
depletion to evaluate central serotonin function in depression and other
neuropsychiatric disorders. Int Clin Psychopharmacol. Nov 1993;8 Suppl
2:41-46.
343. Manjarrez G, Contreras JL, Chagoya G, Hernandez RJ. Free tryptophan
as an indicator of brain serotonin synthesis in infants. Pediatr Neurol.
1998;18(1):57-62.
344. Walderhaug E, Lunde H, Nordvik JE, Landro NI, Refsum H, Magnusson
A. Lowering of serotonin by rapid tryptophan depletion increases
impulsiveness in normal individuals. Psychopharmacology (Berl). Dec
2002;164(4):385-391.

385. Martensson J, Sjodahl R, Tobiasson P. Effect of gastrointestinal surgery and
bacterial overgrowth on the urinary excretion of sulfur amino acids and their
main degradation products. Scand J Gastroenterol. 1984;19(4):507-514.
386. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased
oxidative stress and impaired methylation capacity in children with autism.
Am J Clin Nutr. Dec 2004;80(6):1611-1617.
387. Fukagawa NK, Ajami AM, Young VR. Plasma methionine and cysteine
kinetics in response to an intravenous glutathione infusion in adult humans.
Am J Physiol. 1996;270(2 Pt 1):E209-214.
388. White CW, Stabler SP, Allen RH, Moreland S, Rosenberg AA. Plasma
cysteine concentrations in infants with respiratory distress. J Pediatr.
1994;125(5 Pt 1):769-777.
389. Davies MH, Klovrza L, Waring RH, Elias E. Plasma cysteine and
sulphate levels in patients with cirrhosis of the liver. Clin Sci (Colch).
1994;87(3):357-362.
390. Serougne C, Felgines C, Ferezou J, Hajri T, Bertin C, Mazur A.
Hypercholesterolemia induced by cholesterol- or cystine-enriched diets
is characterized by different plasma lipoprotein and apolipoprotein
concentrations in rats. J Nutr. 1995;125(1):35-41.
391. Yoshida K, Yahiro M, Ahiko K. Effects of addition of arginine, cystine,
and glycine to the bovine milk-simulated amino acid mixture on the
level of plasma and liver cholesterol in rats. J Nutr Sci Vitaminol (Tokyo).
1988;34(6):567-576.
392. Bernhard MC, Junker E, Hettinger A, Lauterburg BH. Time course of total
cysteine, glutathione and homocysteine in plasma of patients with chronic
hepatitis C treated with interferon-alpha with and without supplementation
with N-acetylcysteine. J Hepatol. 1998;28(5):751-755.
393. Jacobson SH, Moldeus P. Whole blood-, plasma- and red blood cell
glutathione and cysteine in patients with kidney disease and during
hemodialysis. Clin Nephrol. 1994;42(3):189-192.
394. Brattstrom L, Lindgren A, Israelsson B, Andersson A, Hultberg B.
Homocysteine and cysteine: determinants of plasma levels in middle-aged
and elderly subjects. J Intern Med. 1994;236(6):633-641.
395. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, Berne C.
Plasma total homocysteine and cysteine in relation to glomerular filtration
rate in diabetes mellitus [In Process Citation]. Kidney Int. 1999;55(3):10281035.
396. Del Bianco A, Maruotti G, Fulgieri AM, et al. Recurrent spontaneous
miscarriages and hyperhomocysteinemia. Minerva Ginecol. Oct
2004;56(5):379-383.
397. Abbott MH, Folstein SE, Abbey H, Pyeritz RE. Psychiatric manifestations of
homocystinuria due to cystathionine beta- synthase deficiency: prevalence,
natural history, and relationship to neurologic impairment and vitamin B6responsiveness. Am J Med Genet. 1987;26(4):959-969.
398. Lubec B, Fang-Kircher S, Lubec T, Blom HJ, Boers GH. Evidence for
McKusick’s hypothesis of deficient collagen cross-linking in patients with
homocystinuria. Biochim Biophys Acta. 1996;1315(3):159-162.
399. Finkelstein JD, Martin JJ, Harris BJ, Kyle WE. Regulation of hepatic
betaine-homocysteine methyltransferase by dietary betaine. J Nutr.
1983;113(3):519-521.
400. Melse-Boonstra A, Holm PI, Ueland PM, Olthof M, Clarke R, Verhoef
P. Betaine concentration as a determinant of fasting total homocysteine
concentrations and the effect of folic acid supplementation on betaine
concentrations. Am J Clin Nutr. Jun 2005;81(6):1378-1382.
401. Pullin CH, Bonham JR, McDowell IF, et al. Vitamin C therapy ameliorates
vascular endothelial dysfunction in treated patients with homocystinuria. J
Inherit Metab Dis. May 2002;25(2):107-118.
402. Lang CA, Mills BJ, Mastropaolo W, Liu MC. Blood glutathione decreases in
chronic diseases. J Lab Clin Med. May 2000;135(5):402-405.
403. Steullet P, Neijt HC, Cuenod M, Do KQ. Synaptic plasticity impairment and
hypofunction of NMDA receptors induced by glutathione deficit: Relevance
to schizophrenia. Neuroscience. Dec 1 2005.

364. Steele RD. Transaminative metabolism of alpha-amino-n-butyrate in rats.
Metabolism. Apr 1982;31(4):318-325.
365. Richerson GB. Looking for GABA in all the wrong places: the relevance
of extrasynaptic GABA(A) receptors to epilepsy. Epilepsy Curr. Nov-Dec
2004;4(6):239-242.
366. Gutierrez R, Heinemann U. Co-existence of GABA and Glu in the
hippocampal granule cells: implications for epilepsy. Curr Top Med Chem.
2006;6(10):975-978.
367. Lernmark A. Glutamic acid decarboxylase—gene to antigen to disease. J
Intern Med. Nov 1996;240(5):259-277.
368. Petty F, Kramer GL, Fulton M, Davis L, Rush AJ. Stability of plasma GABA
at four-year follow-up in patients with primary unipolar depression. Biol
Psychiatry. 1995;37(11):806-810.
369. Reynolds GP, Pearson SJ. Neurochemical-clinical correlates in Huntington’s
disease—applications of brain banking techniques. J Neural Transm Suppl.
1993;39:207-214.
370. Rajeswari TS, Radha E. Age-related effects of nutritional vitamin B6
deficiency on B6-dependent enzymes of glutamate, gamma-aminobutyrate
and glutamine systems in the rat brain. Exp Gerontol. 1984;19(2):87-93.
371. Chang YF, Hargest V, Chen JS. Modulation of benzodiazepine by lysine
and pipecolic acid on pentylenetetrazol-induced seizures. Life Sci.
1988;43(15):1177-1188.
372. Gibson K, Jakobs C. Disorders of β- and γ-amino acids in free and peptidelinked forms. The Metabolic and Molecular Bases of Inherited Disease. 8th
ed. New York: McGraw-Hill; 2001:2079-2105.
373. Wang Y, Waghorn GC, Barry TN, Shelton ID. The effect of condensed
tannins in Lotus corniculatus on plasma metabolism of methionine, cystine
and inorganic sulphate by sheep. Br J Nutr. 1994;72(6):923-925.
374. Lakshmanan FL, Perera WD, Scrimshaw NS, Young VR. Plasma and urinary
amino acids and selected sulfur metabolites in young men fed a diet devoid
of methionine and cystine. Am J Clin Nutr. 1976;29(12):1367-1371.
375. Regina M, Korhonen VP, Smith TK, Alakuijala L, Eloranta TO.
Methionine toxicity in the rat in relation to hepatic accumulation of Sadenosylmethionine: prevention by dietary stimulation of the hepatic
transsulfuration pathway. Arch Biochem Biophys. Feb 1 1993;300(2):598607.
376. Kachru DN, Khandelwal S, Tandon SK. Influence of methionine
supplementation in chelation of lead in rats. Biomed Environ Sci.
1989;2(3):265-270.
377. Domingo JL, Llobet JM. Treatment of acute cobalt intoxication in rats with
L-methionine. Rev Esp Fisiol. 1984;40(4):443-448.
378. Toue S, Kodama R, Amao M, Kawamata Y, Kimura T, Sakai R. Screening of
toxicity biomarkers for methionine excess in rats. J Nutr. Jun 2006;136(6
Suppl):1716S-1721S.
379. Lieber CS, Packer L. S-Adenosylmethionine: molecular, biological, and
clinical aspects—an introduction. Am J Clin Nutr. Nov 2002;76(5):1148S1150S.
380. Bottiglieri T. S-Adenosyl-L-methionine (SAMe): from the bench to the
bedside—molecular basis of a pleiotrophic molecule. Am J Clin Nutr. Nov
2002;76(5):1151S-1157S.
381. Lieber CS. S-adenosyl-L-methionine: its role in the treatment of liver
disorders. Am J Clin Nutr. Nov 2002;76(5):1183S-1187S.
382. Lieber CS. S-Adenosyl-L-methionine and alcoholic liver disease in animal
models: implications for early intervention in human beings. Alcohol. Jul
2002;27(3):173-177.
383. Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk
of myocardial infarction: relation with vitamins B6, B12, and folate. Am J
Epidemiol. 1996;143(9):845-859.
384. Chawla RK, Lewis FW, Kutner MH, Bate DM, Roy RG, Rudman D.
Plasma cysteine, cystine, and glutathione in cirrhosis. Gastroenterology.
1984;87(4):770-776.

424. Kopple JD, Vinton NE, Laidlaw SA, Ament ME. Effect of intravenous taurine
supplementation on plasma, blood cell, and urine taurine concentrations
in adults undergoing long-term parenteral nutrition. Am J Clin Nutr.
1990;52(5):846-853.
425. Boelens PG, Houdijk AP, de Thouars HN, et al. Plasma taurine
concentrations increase after enteral glutamine supplementation in trauma
patients and stressed rats. Am J Clin Nutr. Jan 2003;77(1):250-256.
426. Di Leo MA, Ghirlanda G, Gentiloni Silveri N, Giardina B, Franconi F, Santini
SA. Potential therapeutic effect of antioxidants in experimental diabetic
retina: a comparison between chronic taurine and vitamin E plus selenium
supplementations. Free Radic Res. Mar 2003;37(3):323-330.
427. Nakamura T, Ushiyama C, Suzuki S, et al. Effects of taurine and vitamin
E on microalbuminuria, plasma metalloproteinase-9, and serum type IV
collagen concentrations in patients with diabetic nephropathy. Nephron.
1999;83(4):361-362.
428. Hsu JM, Anthony WL. Zinc deficiency and urinary excretion of taurine-35S
and inorganic sulfate-35S following cystine-35S injecion in rats. J Nutr. Oct
1970;100(10):1189-1195.
429. Milakofsky L, Harris N, Vogel WH. Effect of repeated stress on plasma
catecholamines and taurine in young and old rats. Neurobiol Aging.
1993;14(4):359-366.
430. Hashiguchi Y, Fukushima R, Saito H, et al. Interleukin-1 and tumor necrosis
factor alter plasma concentration and interorgan fluxes of taurine in dogs.
Shock. 1997;7(2):147-153.
431. Azuma J, Hasegawa H, Sawamura A, et al. Taurine for treatment of
congestive heart failure. Int J Cardiol. 1982;2(2):303-304.
432. Huxtable, Bardeau. Taurine in Nutrition and Neurology. Plenum; 1982.
433. Waterfield CJ, Carvalho F, Timbrell JA. Effect of treatment with beta-agonists
on tissue and urinary taurine levels in rats. Mechanism and implications for
protection. Adv Exp Med Biol. 1996;403:233-245.
434. Hayes KC, Pronczuk A, Addesa AE, Stephan ZF. Taurine modulates platelet
aggregation in cats and humans. Am J Clin Nutr. 1989;49(6):1211-1216.
435. Sanderson SL, Gross KL, Ogburn PN, et al. Effects of dietary fat and Lcarnitine on plasma and whole blood taurine concentrations and cardiac
function in healthy dogs fed protein-restricted diets. Am J Vet Res. Oct
2001;62(10):1616-1623.
436. Bruinvels J, Pepplinkhuizen L. Impaired glycine-serine conversion and
increased plasma taurine levels in episodic psychotic patients with
psychedelic symptoms. J Psychiatr Res. 1984;18(3):307-318.
437. Houdijk AP, Oosterling SJ, Siroen MP, et al. Hypertaurinemia in bile
duct-ligated rats after surgery: the effect of gut endotoxin restriction on
organ fluxes and oxidative status. JPEN J Parenter Enteral Nutr. May-Jun
2006;30(3):186-193.
438. Backus RC, Rogers QR, Rosenquist GL, Calam J, Morris JG. Diets causing
taurine depletion in cats substantially elevate postprandial plasma
cholecystokinin concentration. J Nutr. 1995;125(10):2650-2657.
439. Park T, Lee K. Dietary taurine supplementation reduces plasma and
liver cholesterol and triglyceride levels in rats fed a high-cholesterol or a
cholesterol-free diet. Adv Exp Med Biol. 1998;442:319-325.
440. Inoue M, Arias IM. Taurine transport across hepatocyte plasma membranes:
analysis in isolated rat liver sinusoidal plasma membrane vesicles. J Biochem
(Tokyo). 1988;104(1):155-158.
441. Lake N, Wright ED, Lapp WS. Effects of taurine deficiency on immune
function in mice. Adv Exp Med Biol. 1992;315:241-243.
442. Jackson AA, Badaloo AV, Forrester T, Hibbert JM, Persaud C. Urinary
excretion of 5-oxoproline (pyroglutamic aciduria) as an index of glycine
insufficiency in normal man. Br J Nutr. 1987;58(2):207-214.
443. Riedel E, Nundel M, Algermissen B, Hampl H, Scigalla P, Stabell U. Changes
in the concentrations of hydroxyproline, glycine and serine in the plasma of
haemodialysis patients undergoing erythropoietin therapy. J Clin Chem Clin
Biochem. 1989;27(11):851-856.

404. Yorbik O, Sayal A, Akay C, Akbiyik DI, Sohmen T. Investigation of
antioxidant enzymes in children with autistic disorder. Prostaglandins
Leukot Essent Fatty Acids. Nov 2002;67(5):341-343.
405. Truscott RJ. Age-related nuclear cataract-oxidation is the key. Exp Eye Res.
May 2005;80(5):709-725.
406. Kretschmar M, Felk A, Staib P, et al. Individual acid aspartic proteinases
(Saps) 1-6 of Candida albicans are not essential for invasion and
colonization of the gastrointestinal tract in mice. Microb Pathog. Feb
2002;32(2):61-70.
407. Kaviarasan K, Arjunan MM, Pugalendi KV. Lipid profile, oxidant-antioxidant
status and glycoprotein components in hyperlipidemic patients with/
without diabetes. Clin Chim Acta. Dec 2005;362(1-2):49-56.
408. Pemberton PW, Smith A, Warnes TW. Non-invasive monitoring of oxidant
stress in alcoholic liver disease. Scand J Gastroenterol. Sep 2005;40(9):11021108.
409. Salem TA, El-Refaei MF, Badra GA. Study of antioxidant enzymes level
and phagocytic activity in chronic liver disease patients. Egypt J Immunol.
2003;10(1):37-45.
410. Sbrana E, Paladini A, Bramanti E, Spinetti MC, Raspi G. Quantitation of
reduced glutathione and cysteine in human immunodeficiency virusinfected patients. Electrophoresis. Jun 2004;25(10-11):1522-1529.
411. Bernard GR, Wheeler AP, Arons MM, et al. A trial of antioxidants Nacetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study
Group. Chest. Jul 1997;112(1):164-172.
412. Forrester TE, Badaloo V, Bennett FI, Jackson AA. Excessive excretion of
5-oxoproline and decreased levels of blood glutathione in type II diabetes
mellitus. Eur J Clin Nutr. 1990;44(11):847-850.
413. Harris C, Dixon M, Hansen JM. Glutathione depletion modulates methanol,
formaldehyde and formate toxicity in cultured rat conceptuses. Cell Biol
Toxicol. May 2004;20(3):133-145.
414. Vitvitsky V, Mosharov E, Tritt M, Ataullakhanov F, Banerjee R. Redox
regulation of homocysteine-dependent glutathione synthesis. Redox Rep.
2003;8(1):57-63.
415. Jung YS, Kwak HE, Choi KH, Kim YC. Effect of acute ethanol
administration on S-amino acid metabolism: increased utilization of
cysteine for synthesis of taurine rather than glutathione. Adv Exp Med Biol.
2003;526:245-252.
416. Liu L, Klaassen CD. Different mechanism of saturation of acetaminophen
sulfate conjugation in mice and rats. Toxicol Appl Pharmacol.
1996;139(1):128-134.
417. Zhang J, Sugahara K, Sagara Y, Fontana M, Dupre S, Kodama H. Effect of
cystathionine ketimine on the stimulus coupled responses of neutrophils
and their modulation by various protein kinase inhibitors. Biochem Biophys
Res Commun. 1996;218(1):371-376.
418. National Research Council (U.S.). Subcommittee on Cat Nutrition. Nutrient
requirements of cats. Rev. ed. Washington, DC: National Academy Press; 1986.
419. Helms RA, Storm MC, Christensen ML, Hak EB, Chesney RW. Cysteine
supplementation results in normalization of plasma taurine concentrations in
children receiving home parenteral nutrition. J Pediatr. 1999;134(3):358-361.
420. Turner O, Phoenix J, Wray S. Developmental and gestational changes of
phosphoethanolamine and taurine in rat brain, striated and smooth muscle.
Exp Physiol. 1994;79(5):681-689.
421. Lima L, Obregon F, Rousso T, Quintal M, Benzo Z, Auladell C. Content
and concentration of taurine, hypotaurine, and zinc in the retina, the
hippocampus, and the dentate gyrus of the rat at various postnatal days.
Neurochem Res. Jan 2004;29(1):247-255.
422. Barabas P, Kovacs I, Kardos J, Schousboe A. Exogenous glutamate and
taurine exert differential actions on light-induced release of two endogenous
amino acids in isolated rat retina. J Neurosci Res. Sep 1 2003;73(5):731-736.
423. Trautwein EA, Hayes KC. Plasma and whole blood taurine concentrations
respond differently to taurine supplementation (humans) and depletion
(cats). Z Ernahrungswiss. 1995;34(2):137-142.

465. Kano-Sueoka T, Watanabe T, Miya T, Kasai H. Analysis of cytosolic
phosphoethanolamine and ethanolamine and their correlation with
prognostic factors in breast cancer. Jpn J Cancer Res. 1991;82(7):829-834.
466. Whyte MP, Teitelbaum SL, Murphy WA, Bergfeld MA, Avioli LV. Adult
hypophosphatasia. Clinical, laboratory, and genetic investigation of
a large kindred with review of the literature. Medicine (Baltimore).
1979;58(5):329-347.
467. Jaksic T, Wagner DA, Young VR. Plasma proline kinetics and concentrations
in young men in response to dietary proline deprivation. Am J Clin Nutr.
1990;52(2):307-312.
468. Hiramatsu T, Cortiella J, Marchini JS, Chapman TE, Young VR. Plasma
proline and leucine kinetics: response to 4 wk with proline-free diets in
young adults. Am J Clin Nutr. 1994;60(2):207-215.
469. Bates CJ. Vitamin C deficiency in guinea pigs: changes in urinary excretion
of proline, hydroxyproline and total amino nitrogen. Int J Vitam Nutr Res.
1979;49(2):152-159.
470. Nusgens B, Lapiere CM. The relationship between proline and
hydroxyproline urinary excretion in human as an index of collagen
catabolism. Clin Chim Acta. 1973;48(2):203-211.
471. Kitajima H, Shiomoto H, Osada K, Yokogoshi H. Co-administration of
proline and inorganic iron enhance the improvement of behavioral and
hematological function of iron-deficient anemic rats. J Nutr Sci Vitaminol
(Tokyo). Feb 2003;49(1):7-12.
472. Kaddam IM, Iqbal SJ, Holland S, Wong M, Manning D. Comparison of
serum osteocalcin with total and bone specific alkaline phosphatase and
urinary hydroxyproline: creatinine ratio in patients with Paget’s disease of
bone. Ann Clin Biochem. 1994;31(Pt 4):327-330.
473. Hamdy NA, Papapoulos SE, Colwell A, Eastell R, Russell RG. Urinary
collagen crosslink excretion: a better index of bone resorption than
hydroxyproline in Paget’s disease of bone? Bone Miner. 1993;22(1):1-8.
474. Bolzonella S, Paccagnella A, Salvagno L, et al. Urinary hydroxyproline in
multiple myeloma: correlation with clinical stages and bone disease. Tumori.
1984;70(3):249-253.
475. Gilbertson TJ, Brunden MN, Gruszczyk SB, Whyte MP, Burnett MA. Serum
total hydroxyproline assay: effects of age, sex and Paget’s bone disease. J Clin
Chem Clin Biochem. 1983;21(3):129-132.
476. Mahmoodian F, Gosiewska A, Peterkofsky B. Regulation and properties of
bone alkaline phosphatase during vitamin C deficiency in guinea pigs. Arch
Biochem Biophys. 1996;336(1):86-96.
477. Yamada S, Aoto Y, Suou T, Hirayama C. Urinary hydroxyproline and
hydroxylysine excretions in relation to hepatic hydroxyproline content in
chronic liver disease. Clin Biochem. 1989;22(5):389-393.
478. Nagai Y, Sato M, Sasaki M. Effect of cadmium administration upon urinary
excretion of hydroxylysine and hydroxyproline in the rat. Toxicol Appl
Pharmacol. 1982;63(2):188-193.
479. Rauch F, Georg M, Stabrey A, et al. Collagen markers deoxypyridinoline
and hydroxylysine glycosides: pediatric reference data and use for
growth prediction in growth hormone-deficient children. Clin Chem. Feb
2002;48(2):315-322.
480. Moro L, Gazzarrini C, Modricky C, et al. High predictivity of galactosylhydroxylysine in urine as an indicator of bone metastases from breast
cancer. Clin Chem. May 1990;36(5):772-774.
481. Lo Cascio V, Bertoldo F, Gambaro G, et al. Urinary galactosyl-hydroxylysine
in postmenopausal osteoporotic women: A potential marker of bone
fragility. J Bone Miner Res. Aug 1999;14(8):1420-1424.
482. Keskin DS, Tezcaner A, Korkusuz P, Korkusuz F, Hasirci V. Collagenchondroitin sulfate-based PLLA-SAIB-coated rhBMP-2 delivery system for
bone repair. Biomaterials. Jun 2005;26(18):4023-4034.
483. Higgins J, Kabeske C, Bernardini I, Brady R, Barton N. Pyridoxine-resonsive
hyper-beta-alaninemia associated with Cohen’s syndrome. Neurology.
1994;44(9):1728-1732.

444. Kikuchi G. The glycine cleavage system: composition, reaction mechanism,
and physiological significance. Mol Cell Biochem. Jun 27 1973;1(2):169187.
445. Devor EJ, Waziri R. A familial/genetic study of plasma serine and glycine
concentrations. Biol Psychiatry. 1993;34(4):221-225.
446. Dinopoulos A, Kure S, Chuck G, et al. Glycine decarboxylase mutations: a
distinctive phenotype of nonketotic hyperglycinemia in adults. Neurology.
Apr 12 2005;64(7):1255-1257.
447. Siegel GJ. Basic Neurochemistry : Molecular, Cellular, and Medical Aspects.
6th ed. Philadelphia: Lippincott Williams & Wilkins; 1998.
448. Van Hove JL, Kishnani P, Muenzer J, et al. Benzoate therapy and carnitine
deficiency in non-ketotic hyperglycinemia. Am J Med Genet. Dec 4
1995;59(4):444-453.
449. Hamosh A, Maher JF, Bellus GA, Rasmussen SA, Johnston MV. Long-term
use of high-dose benzoate and dextromethorphan for the treatment of
nonketotic hyperglycinemia. J Pediatr. Apr 1998;132(4):709-713.
450. Dudman NP, Tyrrell PA, Wilcken DE. Homocysteinemia: depressed plasma
serine levels. Metabolism. 1987;36(2):198-201.
451. Heady JE, Kerr SJ. Alteration of glycine N-methyltransferase activity in fetal,
adult, and tumor tissues. Cancer Res. Mar 1975;35(3):640-643.
452. Mudd SH, Ebert MH, Scriver CR. Labile methyl group balances in the
human: the role of sarcosine. Metabolism. Aug 1980;29(8):707-720.
453. Scott C. Sarcosinemia. In: Scriver C, ed. The Metabolic and Molecular Bases
of Inherited Disease. Vol 2. 7 ed. New York: McGraw-Hill, Inc.; 2001:20572063.
454. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or D-serine
add-on treatment for acute exacerbation of schizophrenia: a randomized,
double-blind, placebo-controlled study. Arch Gen Psychiatry. Nov
2005;62(11):1196-1204.
455. Heresco-Levy U. Adding sarcosine, but not D-serine, to risperidone
improves symptoms in people with acute phase schizophrenia. Evid Based
Ment Health. May 2006;9(2):48.
456. Bennett S, Gronier B. Modulation of striatal dopamine release in vitro
by agonists of the glycineB site of NMDA receptors; interaction with
antipsychotics. Eur J Pharmacol. Dec 19 2005;527(1-3):52-59.
457. Kurosaki M, Enomoto N, Sato C, et al. Correlation of plasma hepatitis C
virus RNA levels with serum alanine aminotransferase in non-A, non-B
chronic liver disease. J Med Virol. 1993;39(3):246-250.
458. Yang RD, Matthews DE, Bier DM, Wen ZM, Young VR. Response of alanine
metabolism in humans to manipulation of dietary protein and energy
intakes. Am J Physiol. Jan 1986;250(1 Pt 1):E39-46.
459. Evans ML, Hopkins D, Macdonald IA, Amiel SA. Alanine infusion during
hypoglycaemia partly supports cognitive performance in healthy human
subjects. Diabet Med. May 2004;21(5):440-446.
460. Reilmann R, Rolf LH, Lange HW. Decreased plasma alanine and isoleucine
in Huntington’s disease. Acta Neurol Scand. 1995;91(3):222-224.
461. Maeba R, Ueta N. Ethanolamine plasmalogen and cholesterol reduce the
total membrane oxidizability measured by the oxygen uptake method.
Biochem Biophys Res Commun. Mar 7 2003;302(2):265-270.
462. Gerashchenko D, Gorenshtein B, Pyzhik T, Ostrovsky Y. Influence of
pyruvate, threonine and phosphoethanolamine on activities of some
acetaldehyde-producing enzymes. Alcohol Alcohol. 1993;28(4):437-443.
463. Modica-Napolitano JS, Renshaw PF. Ethanolamine and
phosphoethanolamine inhibit mitochondrial function in vitro: implications
for mitochondrial dysfunction hypothesis in depression and bipolar
disorder. Biol Psychiatry. Feb 1 2004;55(3):273-277.
464. Kiss Z, Mukherjee JJ, Crilly KS, Chung T. Ethanolamine, but not
phosphoethanolamine, potentiates the effects of insulin, phosphocholine,
and ATP on DNA synthesis in NIH 3T3 cells—role of mitogen-activated
protein-kinase-dependent and protein-kinase- independent mechanisms.
Eur J Biochem. 1997;250(2):395-402.

503. Willi SM, Zhang Y, Hill JB, Phelan MC, Michaelis RC, Holden KR.
A deletion in the long arm of chromosome 18 in a child with serum
carnosinase deficiency. Pediatr Res. 1997;41(2):210-213.
504. Fleisher LD, Rassin DK, Wisniewski K, Salwen HR. Carnosinase deficiency: a
new variant with high residual activity. Pediatr Res. 1980;14(4 Pt 1):269-271.
505. Murphey WH, Lindmark DG, Patchen LI, Housler ME, Harrod EK,
Mosovich L. Serum carnosinase deficiency concomitant with mental
retardation. Pediatr Res. 1973;7(7):601-606.
506. Wisniewski K, Fleisher L, Rassin D, Lassmann H. Neurological disease in a
child with carnosinase deficiency. Neuropediatrics. 1981;12(2):143-151.
507. Sjolin J, Hjort G, Friman G, Hambraeus L. Urinary excretion of 1methylhistidine: a qualitative indicator of exogenous 3-methylhistidine and
intake of meats from various sources. Metabolism. 1987;36(12):1175-1184.
508. Myint T, Fraser GE, Lindsted KD, Knutsen SF, Hubbard RW, Bennett HW.
Urinary 1-methylhistidine is a marker of meat consumption in Black
and in White California Seventh-day Adventists. Am J Epidemiol. Oct 15
2000;152(8):752-755.
509. Fink K, Williams AD, Fink RM. 1-Methylhistidine excretion by vitamin
E-deficient rabbits. J Biol Chem. May 1959;234(5):1182-1185.
510. Haus JM, Miller BF, Carroll CC, Weinheimer EM, Trappe TA. The effect of
strenuous aerobic exercise on skeletal muscle myofibrillar proteolysis in
humans. Scand J Med Sci Sports. Jun 19 2006.
511. Santidrian S, Moreyra M, Munro HN, Young VR. Effect of testosterone
on the rate of myofibrillar protein breakdown in castrated and
adrenalectomized male rats measured by the urinary excretion of 3methylhistidine. Metabolism. 1982;31(12):1200-1205.
512. Long CL, Birkhahn RH, Geiger JW, Betts JE, Schiller WR, Blakemore WS.
Urinary excretion of 3-methylhistidine: an assessment of muscle protein
catabolism in adult normal subjects and during malnutrition, sepsis, and
skeletal trauma. Metabolism. 1981;30(8):765-776.
513. Marchesini G, Forlani G, Zoli M, Vannini P, Pisi E. Muscle protein
breakdown in uncontrolled diabetes as assessed by urinary 3methylhistidine excretion. Diabetologia. 1982;23(5):456-458.
514. Elia M, Carter A, Bacon S, Winearls CG, Smith R. Clinical usefulness
of urinary 3-methylhistidine excretion in indicating muscle protein
breakdown. Br Med J (Clin Res Ed). 1981;282(6261):351-354.
515. Hillgartner FB, Morin D, Hansen RJ. Effect of excessive vitamin A intake
on muscle protein turnover in the rat. Biochem J. Feb 15 1982;202(2):499508.
516. Sjolin J, Stjernstrom H, Henneberg S, Hambraeus L, Friman G. Evaluation
of urinary 3-methylhistidine excretion in infection by measurements of 1methylhistidine and the creatinine ratios. Am J Clin Nutr. 1989;49(1):62-70.
517. Burini R, Santidrian S, Moreyra M, Brown P, Munro HN, Young VR.
Interaction of thyroid status and diet on muscle protein breakdown in
the rat, as measured by N tau-methylhistidine excretion. Metabolism.
1981;30(7):679-687.
518. Wang Z, Deurenberg P, Matthews DE, Heymsfield SB. Urinary 3methylhistidine excretion: association with total body skeletal muscle
mass by computerized axial tomography. JPEN J Parenter Enteral Nutr.
1998;22(2):82-86.
519. Nunes VA, Gozzo AJ, Juliano MA, et al. Antioxidant dietary deficiency
induces caspase activation in chick skeletal muscle cells. Braz J Med Biol
Res. Aug 2003;36(8):1047-1053.
520. Tang FC. Influence of branched-chain amino acid supplementation on
urinary protein metabolite concentrations after swimming. J Am Coll Nutr.
Jun 2006;25(3):188-194.
521. Goldberg S, Kozlovsky A, Gordon D, Gelernter I, Sintov A, Rosenberg
M. Cadaverine as a putative component of oral malodor. J Dent Res. Jun
1994;73(6):1168-1172.
522. Potoki LV. [Differential reaction of condensed and diffuse chromatin to
polyamines. I. Reaction of interphase nuclei chromatin to putrescine].
Tsitologiia. Apr 1975;17(4):427-431.

484. Mizota C, Fujimoto S, Kikugawa M, Kimura Y, Tamaki N. Effect of
pyridoxine deficiency and prednisolone on beta-alanine- oxoglutarate
aminotransferase and D-3-aminoisobutyrate aminotransferase in rat liver
and kidney. J Nutr Sci Vitaminol (Tokyo). 1988;34(2):223-236.
485. Korang K, Milakofsky L, Hare TA, Hofford JM, Vogel WH. Taurine
administration raises plasma taurine levels and affects certain plasma amino
acids and related compounds in rats. Adv Exp Med Biol. 1996;403:51-53.
486. Bucuvalas JC, Goodrich AL, Suchy FJ. Hepatic taurine transport: a Na+dependent carrier on the basolateral plasma membrane. Am J Physiol.
1987;253(3 Pt 1):G351-358.
487. Schmidt C, Hofmann U, Kohlmuller D, et al. Comprehensive analysis
of pyrimidine metabolism in 450 children with unspecific neurological
symptoms using high-pressure liquid chromatography-electrospray ionization
tandem mass spectrometry. J Inherit Metab Dis. 2005;28(6):1109-1122.
488. Nielsen HR, Killmann SA. Urinary excretion of beta-aminoisobutyrate and
pseudouridine in acute and chronic myeloid leukemia. J Natl Cancer Inst.
1983;71(5):887-891.
489. Zeis PM, Tzaki M, Nakopoulou L, et al. DNA degradation in the
kidney of folic acid-treated guinea pigs [In Process Citation]. Cytobios.
2000;102(400):107-113.
490. Johnson P, Fedyna JS, Schindzielorz A, Smith CM, Kasvinsky PJ. Regulation
of muscle phosphorylase activity by carnosine and anserine. Biochem
Biophys Res Commun. 1982;109(3):769-775.
491. Avena RM, Bowen WJ. Effects of carnosine and anserine on muscle
adenosine triphosphatases. J Biol Chem. 1969;244(6):1600-1604.
492. Penafiel R, Ruzafa C, Monserrat F, Cremades A. Gender-related differences
in carnosine, anserine and lysine content of murine skeletal muscle. Amino
Acids. Feb 2004;26(1):53-58.
493. Tinbergen BJ, Slump P. The detection of chicken meat in meat products
by means of the anserine/carnosine ratio. Z Lebensm Unters Forsch.
1976;161(1):7-11.
494. Furuta S, Toyama S, Sano H. Absorption mechanism of polaprezinc
(zinc L-carnosine complex) by an everted sac method. Xenobiotica.
1994;24(11):1085-1094.
495. Yoshikawa T, Naito Y, Tanigawa T, et al. Effect of zinc-carnosine chelate
compound (Z-103), a novel antioxidant, on acute gastric mucosal injury
induced by ischemia-reperfusion in rats. Free Radic Res Commun.
1991;14(4):289-296.
496. Cho CH, Hui WM, Chen BW, Luk CT, Lam SK. The cytoprotective effect
of zinc L-carnosine on ethanol-induced gastric gland damage in rabbits. J
Pharm Pharmacol. 1992;44(4):364-365.
497. Horning MS, Blakemore LJ, Trombley PQ. Endogenous mechanisms
of neuroprotection: role of zinc, copper, and carnosine. Brain Res.
2000;852(1):56-61.
498. Daniel RL, Osbaldeston NJ, McCormack JG. Activation by anserine and
inhibition by carnosine of Ca(2+)-uptake by mammalian mitochondria
[published erratum appears in Biochem Soc Trans 1992 Nov;20(4):911].
Biochem Soc Trans. 1992;20(2):131S.
499. Tan KM, Candlish JK. Carnosine and anserine as modulators of neutrophil
function. Clin Lab Haematol. 1998;20(4):239-244.
500. Datta AK, Shi X, Kasprzak KS. Effect of carnosine homocarnosine and
anserine on hydroxylation of the guanine moiety in 2’-deoxyguanosine,
DNA and nucleohistone with hydrogen peroxide in the presence of
nickel(II). Carcinogenesis. 1993;14(3):417-422.
501. Preston JE, Hipkiss AR, Himsworth DT, Romero IA, Abbott JN. Toxic
effects of beta-amyloid(25-35) on immortalised rat brain endothelial cell:
protection by carnosine, homocarnosine and beta-alanine. Neurosci Lett.
Feb 13 1998;242(2):105-108.
502. Hipkiss AR, Preston JE, Himswoth DT, Worthington VC, Abbot NJ.
Protective effects of carnosine against malondialdehyde-induced toxicity
towards cultured rat brain endothelial cells. Neurosci Lett. Dec 5
1997;238(3):135-138.

544. Ajayi OB, Odutuga A. Effect of low-zinc status and essential fatty acids
deficiency on the activities of aspartate aminotransferase and alanine
aminotransferase in liver and serum of albino rats. Nahrung. Apr
2004;48(2):88-90.
545. Okada M, Shibuya M, Akazawa T, Muya H, Murakami Y. Dietary protein as
a factor affecting vitamin B6 requirement. J Nutr Sci Vitaminol (Tokyo). Feb
1998;44(1):37-45.
546. Stanley JC, Salter M, Fisher MJ, Pogson CI. The effect of pyridoxine
deficiency on the metabolism of the aromatic amino acids by isolated rat
liver cells. Arch Biochem Biophys. Aug 1 1985;240(2):792-800.
547. Hsu JM, Rubenstein B. Effect of zinc deficiency on histidine metabolism in
rats. J Nutr. Mar 1982;112(3):461-467.
548. Allen RH, Stabler SP, Lindenbaum J. Serum betaine, N,N-dimethylglycine
and N-methylglycine levels in patients with cobalamin and folate
deficiency and related inborn errors of metabolism. Metabolism. Nov
1993;42(11):1448-1460.
549. Lykkelund C, Lou HC, Rasmussen V, Guttler F, Niederwieser A. Biopterin,
neopterin and tyrosine responses to combined oral phenylalanine and
tetrahydrobiopterin loading tests in two normal children and in a girl with
partial biopterin deficiency. J Inherit Metab Dis. 1985;8 Suppl 2:95-96.
550. Unpublished results from Metametrix Clinical Laboratory, 2007, Duluth, GA.

523. Fujita K, Nagatsu T, Maruta K, Ito M, Senba H. Urinary putrescine,
spermidine, and spermine in human blood and solid cancers and in an
experimental gastric tumor of rats. Cancer Res. Apr 1976;36(4):1320-1324.
524. Lodish HF. Molecular Cell Biology. 5th ed. New York: W.H. Freeman and
Company; 2003.
525. Sakagami H, Fujiwara E, Yokote Y, et al. Changes in intracellular
concentrations of amino acids and polyamines during the apoptosis of HL60 cells. Anticancer Res. Jan-Feb 2000;20(1A):265-270.
526. Berdinskikh NK, Lialiushko NM. [Polyamine levels and diamine oxidase
activity in the rat liver and kidneys during hepatocarcinogenesis induced by
N-nitrosodiethylamine]. Eksp Onkol. 1987;9(3):23-27.
527. Wang X, Ikeguchi Y, McCloskey DE, Nelson P, Pegg AE. Spermine synthesis
is required for normal viability, growth, and fertility in the mouse. J Biol
Chem. Dec 3 2004;279(49):51370-51375.
528. Law CL, Wong PC, Fong WF. Effects of polyamines on the uptake
of neurotransmitters by rat brain synaptosomes. J Neurochem. Mar
1984;42(3):870-872.
529. Bonneau MJ, Poulin R. Spermine oxidation leads to necrosis with plasma
membrane phosphatidylserine redistribution in mouse leukemia cells. Exp
Cell Res. Aug 25 2000;259(1):23-34.
530. Allen RD, Roberts TK. Role of spermine in the cytotoxic effects of seminal
plasma. Am J Reprod Immunol Microbiol. Jan 1987;13(1):4-8.
531. Quan CP, Roux C, Pillot J, Bouvet JP. Delineation between T and B
suppressive molecules from human seminal plasma: II. Spermine is the
major suppressor of T-lymphocytes in vitro. Am J Reprod Immunol. Jan-Feb
1990;22(1-2):64-69.
532. Slinchenko NM, Chernysh IH, Kosterin SO. Effect of spermine on activity of
purified Ca2+, Mg2+-ATPase from plasma membranes of myometrium cells.
Ukr Biokhim Zh. Jul-Aug 2003;75(4):51-56.
533. Gilad VH, Halperin R, Chen-Levy Z, Gilad GM. Cyclic changes of plasma
spermine concentrations in women. Life Sci. Nov 29 2002;72(2):135-141.
534. Samartzidou H, Mehrazin M, Xu Z, Benedik MJ, Delcour AH. Cadaverine
inhibition of porin plays a role in cell survival at acidic pH. J Bacteriol. Jan
2003;185(1):13-19.
535. Fernandez IM, Silva M, Schuch R, et al. Cadaverine prevents the escape of
Shigella flexneri from the phagolysosome: a connection between bacterial
dissemination and neutrophil transepithelial signaling. J Infect Dis. Sep 15
2001;184(6):743-753.
536. Cooke M, Leeves N, White C. Time profile of putrescine, cadaverine, indole
and skatole in human saliva. Arch Oral Biol. Apr 2003;48(4):323-327.
537. Sanderson BE, White E, Baldson MJ. Amine content of vaginal fluid from
patients with trichomoniasis and gardnerella associated non-specific
vaginitis. Br J Vener Dis. Oct 1983;59(5):302-305.
538. Clay JC. The odour of non-specific vaginitis: a review. Eur J Clin Microbiol.
Oct 1982;1(5):317-319.
539. Mercer L, Dodds S, Smith D. Dispensable, indispensable, and conditionally
indispensable amino acid ratios in the diet. In: Friedman M, ed. Absorption
and Utilization of Amino Acids. Vol I. Boca Raton: CRC; 1989:1 - 14.
540. Scarabelli TM, Pasini E, Stephanou A, et al. Nutritional supplementation
with mixed essential amino acids enhances myocyte survival, preserving
mitochondrial functional capacity during ischemia-reperfusion injury. Am J
Cardiol. Apr 22 2004;93(8A):35A-40A.
541. Volpi E, Kobayashi H, Sheffield-Moore M, Mittendorfer B, Wolfe RR.
Essential amino acids are primarily responsible for the amino acid
stimulation of muscle protein anabolism in healthy elderly adults. Am J Clin
Nutr. Aug 2003;78(2):250-258.
542. Torricelli P, Fini M, Giavaresi G, Giardino R. Human osteopenic bonederived osteoblasts: essential amino acids treatment effects. Artif Cells Blood
Substit Immobil Biotechnol. Feb 2003;31(1):35-46.
543. Ebara S, Toyoshima S, Matsumura T, et al. Cobalamin deficiency results in
severe metabolic disorder of serine and threonine in rats. Biochim Biophys
Acta. Dec 5 2001;1568(2):111-117.